



EMORY UNIVERSITY AND ITS SUBSIDIARIES

Independent Auditors' Reports as Required by the Uniform
Guidance and State of Georgia and Related Information

Year Ended August 31, 2022

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Table of Contents

	Page
Independent Auditors' Report	1
Consolidated Financial Statements – Years ended August 31, 2022 and 2021	3
Notes to Consolidated Financial Statements	8
Independent Auditors' Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With <i>Government Auditing Standards</i>	38
Supplementary Schedules	
Supplementary Schedule of Expenditures of Federal Awards	40
Supplementary Schedule of Cash Receipts and Expenditures of State of Georgia Awards	68
Notes to Supplementary Schedules of Expenditures of Federal Awards and Cash Receipts and Expenditures of State of Georgia Awards	69
Uniform Guidance Reports	
Independent Auditors' Report on Compliance for Each Major Federal Program; Report on Internal Control Over Compliance; and Report on Supplementary Schedules of Expenditures of Federal Awards Required by the Uniform Guidance and Cash Receipts and Expenditures of State of Georgia Awards	72
Schedule of Findings and Questioned Costs	75



KPMG LLP
Suite 2000
303 Peachtree Street, N.E.
Atlanta, GA 30308-3210

Independent Auditors' Report

The Board of Trustees
Emory University:

Report on the Audit of the Consolidated Financial Statements

Opinion

We have audited the consolidated financial statements of Emory University and its subsidiaries (the University), which comprise the consolidated statements of financial position as of August 31, 2022 and 2021, and the related consolidated statements of activities and cash flows for the years then ended, and the related notes to the consolidated financial statements.

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the financial position of Emory University and its subsidiaries as of August 31, 2022 and 2021, and the changes in their net assets and their cash flows for the years then ended in accordance with U.S. generally accepted accounting principles.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS) and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are required to be independent of the University and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with U.S. generally accepted accounting principles, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the University's ability to continue as a going concern for one year after the date the consolidated financial statements are issued.

Auditors' Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS and *Government Auditing Standards* will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the consolidated financial statements.



In performing an audit in accordance with GAAS and *Government Auditing Standards*, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the University's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the consolidated financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the University's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

Other Reporting Required by *Government Auditing Standards*

In accordance with *Government Auditing Standards*, we have also issued our report dated December 19, 2022 on our consideration of the University's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the University's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the University's internal control over financial reporting and compliance.

KPMG LLP

Atlanta, Georgia
December 19, 2022

EMORY UNIVERSITY
CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

AUGUST 31, 2022 AND 2021 (Dollars in thousands)

	August 31, 2022	August 31, 2021
ASSETS:		
Cash and cash equivalents	\$ 1,421,386	\$ 1,265,377
Patient accounts receivable, net	646,792	607,687
Student accounts receivable, net	14,383	18,616
Loans receivable, net	16,415	18,441
Contributions receivable, net	181,811	180,994
Other receivables, net	283,544	244,847
Prepaid expenses, deferred charges, and other assets	380,662	446,291
Investments	10,605,084	11,630,104
Interests in perpetual funds held by others	1,682,142	1,848,427
Operating lease right-of-use assets	245,976	182,372
Property and equipment, net	4,396,966	4,015,749
Total assets	\$ 19,875,161	\$ 20,458,905
LIABILITIES AND NET ASSETS:		
Accounts payable and accrued liabilities	\$ 1,043,640	\$ 1,001,352
CARES Act accrued liabilities	69,811	345,829
Deferred revenue	420,740	393,435
Interest payable	48,817	40,843
Liability for derivative instruments	87,266	211,164
Bonds and notes payable	2,947,446	2,526,137
Accrued liabilities for benefit obligations and professional liabilities	624,906	693,038
Operating lease liabilities	273,207	186,260
Finance lease liabilities	16,583	17,624
Funds held in trust for others	1,121,578	1,239,045
Annuities payable	13,951	15,843
Government advances for federal loan programs	11,887	16,719
Asset retirement obligations	89,602	85,833
Total liabilities	6,769,434	6,773,122
Net assets without donor restrictions, controlled by Emory	5,464,696	5,495,749
Net assets without donor restrictions related to noncontrolling interests	120,735	139,764
	5,585,431	5,635,513
Net assets with donor restrictions	7,520,296	8,050,270
Total net assets	13,105,727	13,685,783
TOTAL LIABILITIES AND NET ASSETS	\$ 19,875,161	\$ 20,458,905

See accompanying notes to consolidated financial statements.

EMORY UNIVERSITY

CONSOLIDATED STATEMENTS OF ACTIVITIES

YEAR ENDED AUGUST 31, 2022 (WITH SUMMARIZED COMPARATIVE INFORMATION FOR 2021) (Dollars in thousands)

	Net Assets without Donor Restrictions	Net Assets with Donor Restrictions	Total August 31, 2022	Total August 31, 2021
OPERATING REVENUE				
Tuition and fees, net of scholarship allowance	\$ 488,367	-	\$ 488,367	\$ 416,618
Sales and services of auxiliary enterprises, net of scholarship allowance	75,724	-	75,724	37,715
Endowment spending distribution	215,461	-	215,461	206,255
Distribution from perpetual funds	42,407	-	42,407	40,418
Other investment income designated for current operations	63,617	-	63,617	58,316
Gifts and contributions for current use	65,380	13,076	78,456	98,319
Grants and contracts	632,221	-	632,221	590,964
Indirect cost recoveries	189,208	-	189,208	171,885
Net patient service revenue	5,039,219	-	5,039,219	4,803,785
Medical services	310,203	-	310,203	325,027
Independent operations	14,276	-	14,276	12,519
Other revenue	794,280	-	794,280	613,913
Net assets released from restrictions	37,970	(20,609)	17,361	23,428
Total operating revenue	7,968,333	(7,533)	7,960,800	7,399,162
OPERATING EXPENSES				
Salaries	4,138,197	-	4,138,197	3,601,666
Fringe benefits	878,882	-	878,882	799,598
Student financial aid	28,166	-	28,166	28,678
Other operating expenses	2,541,235	-	2,541,235	2,347,090
Interest on indebtedness	76,178	-	76,178	74,959
Depreciation and amortization	319,714	-	319,714	315,406
Total operating expenses	7,982,372	-	7,982,372	7,167,397
NET OPERATING ACTIVITIES	(14,039)	(7,533)	(21,572)	231,765
NONOPERATING ACTIVITIES, NET				
Investment return	(305,342)	(593,427)	(898,769)	2,278,965
Change in undistributed income from perpetual funds held by others	-	(45,452)	(45,452)	250,749
Gifts and contributions for capital and long-term investment	8,499	151,500	159,999	216,527
Other losses	(2,033)	-	(2,033)	(4,359)
Loss on retirement of debt	(441)	-	(441)	-
Change in fair value of derivative instruments	163,122	-	163,122	59,812
Net periodic benefit cost other than service cost	(2,601)	-	(2,601)	(669)
Changes in pension and other postretirement obligations	66,693	-	66,693	65,336
Other nonoperating items, net	8,853	9,506	18,359	(6,792)
Net assets released from restrictions	27,207	(44,568)	(17,361)	(23,428)
Total nonoperating activities, net	(36,043)	(522,441)	(558,484)	2,836,141
CHANGE IN NET ASSETS	(50,082)	(529,974)	(580,056)	3,067,906
Less change in net assets related to noncontrolling interests	(19,029)	-	(19,029)	35,294
CHANGE IN NET ASSETS CONTROLLED BY EMORY	\$ (31,053)	(529,974)	\$ (561,027)	\$ 3,032,612

See accompanying notes to consolidated financial statements.

EMORY UNIVERSITY

CONSOLIDATED STATEMENT OF ACTIVITIES

YEAR ENDED AUGUST 31, 2021 (Dollars in thousands)

	Net Assets without Donor Restrictions	Net Assets with Donor Restrictions	Total August 31, 2021
OPERATING REVENUE			
Tuition and fees, net of scholarship allowance	\$ 416,618	-	\$ 416,618
Sales and services of auxiliary enterprises, net of scholarship allowance	37,715	-	37,715
Endowment spending distribution	206,255	-	206,255
Distribution from perpetual funds	40,418	-	40,418
Other investment income designated for current operations	58,316	-	58,316
Gifts and contributions for current use	57,704	40,615	98,319
Grants and contracts	590,964	-	590,964
Indirect cost recoveries	171,885	-	171,885
Net patient service revenue	4,803,785	-	4,803,785
Medical services	325,027	-	325,027
Independent operations	12,519	-	12,519
Other revenue	613,913	-	613,913
Net assets released from restrictions	41,581	(18,153)	23,428
Total operating revenue	7,376,700	22,462	7,399,162
OPERATING EXPENSES			
Salaries	3,601,666	-	3,601,666
Fringe benefits	799,598	-	799,598
Student financial aid	28,678	-	28,678
Other operating expenses	2,347,090	-	2,347,090
Interest on indebtedness	74,959	-	74,959
Depreciation and amortization	315,406	-	315,406
Total operating expenses	7,167,397	-	7,167,397
NET OPERATING ACTIVITIES	209,303	22,462	231,765
NONOPERATING ACTIVITIES, NET			
Investment return	853,975	1,424,990	2,278,965
Change in undistributed income from perpetual funds held by others	-	250,749	250,749
Gifts and contributions for capital and long-term investment	12,786	203,741	216,527
Other losses	(4,359)	-	(4,359)
Change in fair value of derivative instruments	59,812	-	59,812
Net periodic benefit cost other than service cost	(669)	-	(669)
Changes in pension and other postretirement obligations	65,336	-	65,336
Other nonoperating items, net	(18,546)	11,754	(6,792)
Net assets released from restrictions	(1,627)	(21,801)	(23,428)
Total nonoperating activities, net	966,708	1,869,433	2,836,141
CHANGE IN NET ASSETS	1,176,011	1,891,895	3,067,906
Less change in net assets related to noncontrolling interests	35,294	-	35,294
CHANGE IN NET ASSETS CONTROLLED BY EMORY	\$ 1,140,717	\$ 1,891,895	\$ 3,032,612

See accompanying notes to consolidated financial statements.

EMORY UNIVERSITY
CONSOLIDATED STATEMENTS OF CASH FLOWS

YEARS ENDED AUGUST 31, 2022 AND 2021 (Dollars in thousands)

	August 31, 2022	August 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:		
Change in net assets	\$ (580,056)	\$ 3,067,906
Adjustments to reconcile change in net assets to net cash used in operating activities:		
Contributions and pledge payments restricted for long-term investment and capital projects	(114,858)	(185,734)
Contributions of donated securities	(73,017)	(29,418)
Proceeds from sale of donated securities	14,122	24,664
Equity in net losses of joint ventures	11,684	10,930
Net realized and unrealized losses (gains) on investments	686,070	(2,901,679)
Loss on disposal of property and equipment	2,098	4,406
Change in undistributed income from perpetual funds held by others	45,452	(250,749)
Loss on debt retirement	441	-
Depreciation and amortization	317,609	311,480
Amortization of bond premiums and issuance costs	(17,582)	(19,953)
Amortization of right-of-use assets	44,625	41,749
Change in pension and other postretirement	(66,693)	(64,667)
Change in fair value of derivative instruments	(123,898)	(59,812)
Change in operating assets:		
Accounts and other receivables, net	(73,569)	14,360
Contributions receivable for operations	(14,987)	(39,232)
Prepaid expenses, deferred charges, and other assets	34,319	(53,957)
Change in operating liabilities:		
Accounts payable, accrued liabilities, and interest payable	16,194	183,954
CARES Act accrued liabilities	(276,018)	(229,933)
Asset retirement obligations	3,769	3,218
Accrued liabilities for benefit obligations and professional liabilities	(1,439)	27,250
Lease liabilities, net	(19,788)	(36,467)
Deferred revenue	27,305	67,058
Net cash used in operating activities	(158,217)	(114,626)
CASH FLOWS FROM INVESTING ACTIVITIES:		
Contributions from partnerships	2,000	2,900
Disbursements for loans to students	(2,041)	(1,903)
Repayment of loans from students	4,067	4,245
Proceeds from sales and maturities of investments	4,175,363	3,131,257
Purchases of investments	(3,910,918)	(3,074,681)
Purchases of property, plant, and equipment	(682,034)	(676,349)
(Decrease) increase in funds held in trust for others	(33,934)	327,907
Net cash used in investing activities	\$ (447,497)	\$ (286,624)

(Continued)

EMORY UNIVERSITY
CONSOLIDATED STATEMENTS OF CASH FLOWS

YEARS ENDED AUGUST 31, 2022 AND 2021 (Dollars in thousands)

	August 31, 2022	August 31, 2021
CASH FLOWS FROM FINANCING ACTIVITIES:		
Contributions and pledge payments restricted for long-term investment and capital projects	\$ 109,028	\$ 204,401
Payments received restricted for capital projects from trust held by others	140,833	72,699
Proceeds from sale of donated securities restricted for long-term investment and capital projects	58,895	4,754
Proceeds from bonds payable, including commercial paper	662,981	-
Principal repayments of bonds payable, including commercial paper	(222,077)	(16,769)
Payments on finance lease obligations	(1,041)	(1,591)
Change in annuities payable	(1,892)	1,166
Debt issuance costs	(2,454)	(56)
Change in government advances for federal loan programs	(4,832)	(2,775)
Net cash provided by financing activities	739,441	261,829
Net change in cash, cash equivalents, and restricted cash	133,727	(139,421)
Cash, cash equivalents, and restricted cash at beginning of year	1,327,892	1,467,313
Cash, cash equivalents, and restricted cash at end of year (Note 2a)	\$ 1,461,619	\$ 1,327,892
Supplemental disclosures:		
Cash paid for interest	\$ 103,410	\$ 93,715
Accrued liabilities for property, plant, and equipment purchases	42,807	40,225

See accompanying notes to consolidated financial statements.

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2022 AND 2021

(1) Organization

Emory University (the University or Emory) is a private, coeducational, not-for-profit institution, located in Atlanta, Georgia. Founded in 1836, Emory owns and operates educational, research, and healthcare facilities to support its mission. Emory provides educational services to approximately 8,155 undergraduate students and 7,754 graduate and professional students within its nine schools and colleges. Included within the University is the Emory Healthcare System (Emory Healthcare), Emory Medical Care Foundation, and Emory Innovations, LLC.

Emory Healthcare consists of Emory Healthcare, Inc. (EHC) and its controlled operating companies, including Emory University Hospital Midtown (EUHM), Emory University Hospital (EUH), Emory Saint Joseph's Hospital (ESJH), EHCA Johns Creek Hospital, LLC (EJCH), Emory Rehabilitation Hospital (ERH), DeKalb Medical Center, Inc. (DMC), Decatur Health Resources, Inc. (DHR), DeKalb Medical Center Foundation (DMCF), The Emory Clinic, Inc. (TEC), Emory Specialty Associates, LLC (ESA), Emory Specialty Associates – Joint Operating Company (ESA-JOC), Wesley Woods Center of Emory University, Inc. (WWC), and Clifton Casualty Insurance Company, Ltd. (CCIC). EUH, EUHM, EJCH, ESJH, ERH, DMC, and DHR are sometimes referred to herein, collectively, as “the Hospitals.”

The consolidated financial statements include the University and all other entities in which Emory has a significant financial interest and control. All significant interentity accounts and transactions have been eliminated in consolidation.

(2) Summary of Significant Accounting Policies

The following significant accounting policies are used in the preparation of the accompanying consolidated financial statements:

The consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (GAAP).

Net assets and revenue, gains, and losses are classified based on the existence or absence of externally imposed restrictions.

Accordingly, net assets of the University are classified and reported as follows:

Net assets without donor restrictions – Net assets that are not subject to donor-imposed stipulations.

Noncontrolling interests in net assets are reported in the accompanying consolidated statements of financial position as a separate component of net assets without donor restrictions.

Net assets with donor restrictions – Net assets that are subject to donor-imposed stipulations that will or may be met either by actions of the University and/or the passage of time. These net assets include donor-restricted endowments, unconditional pledges, split-interest agreements, and interests in perpetual trusts held by others. Generally, the donors of these assets permit the University to use all, or part, of the income earned and net appreciation on related investments for general or specific purposes.

Revenue is reported as increases in net assets without donor restrictions unless its use is limited by donor-imposed restrictions. Expenses are reported as decreases in net assets without donor restrictions. Gains and losses on investments and other assets or liabilities are reported as increases or decreases in net assets without donor restrictions unless restricted by explicit donor stipulation or by law. Expirations of restrictions on net assets (i.e., the donor-stipulated purpose has been fulfilled and/or the stipulated time period has elapsed) are reported as net assets released from restrictions and shown as reclassifications among the applicable classes of net assets.

The University considers the following items to be nonoperating activities: gifts and contributions for capital and long-term investment and the related net assets released from restrictions, investment return, change in fair value of derivative instruments, pension- and postretirement-related changes and net periodic benefit cost other than service cost, and other activities, net.

(a) Cash, Cash Equivalents, and Restricted Cash

Cash and cash equivalents consist primarily of bank balances and short-term money market mutual funds and treasury bills with original maturities generally 90 days or less that are not invested as part of the long-term investments. These amounts are carried at cost, which approximates fair value. Cash and cash equivalents that are part of the long-term pool are shown within investments as those funds generally are not used for daily operating purposes. For purposes of the statements of cash flows, activity related to liabilities with original maturities of three months or less is presented net.

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2022 AND 2021

Restricted cash consists of cash on hand that is restricted for a specific purpose under various capital financing arrangements or cash held for others and, therefore, not available to Emory for immediate or general business use. Restricted cash appears separately from the cash and cash equivalents on the University's accompanying consolidated statements of financial position.

The following table is a reconciliation of cash, cash equivalents, and restricted cash reported within the accompanying consolidated statements of financial position to the amounts shown in the accompanying consolidated statements of cash flows as of August 31 (in thousands):

	2022	2021
Cash and cash equivalents	\$ 1,421,386	\$ 1,265,377
Restricted cash included in investments	40,233	31,205
Restricted cash included in prepaid expenses, deferred charges, and other assets	–	31,310
Total cash, cash equivalents, and restricted cash	\$ 1,461,619	\$ 1,327,892

Included within 2022 cash and cash equivalents is \$216.3 million of 2022 bond proceeds (note 12).

(b) Contributions Receivable, Net

Contributions to be received after one year, net of an allowance for uncollectible amounts, are discounted to their present value at credit-adjusted rates. Amortization of discounts is recorded as additional contribution revenue. An allowance for uncollectible contributions receivable is recorded to reduce the contributions receivable balance to the amount reasonably expected to be collected and is based on management's judgment, considering such factors as prior collection history, type of contribution, relationship with donor, and other relevant factors.

(c) Loans Receivable, Net

Loans receivable represents the outstanding loan balance due under Emory-funded and various federal government loan programs offered to graduate and undergraduate students less allowances for bad debt. Loans to students are carried at the estimated net realizable value. Interest earned on these loan programs is recognized as operating revenue in the accompanying consolidated statements of activities. Loans receivable from students under certain government loan programs, carried at cost, can only be assigned to the federal government or its designees. In addition to federal direct loans (which are not reported in the accompanying consolidated financial statements), loans to qualified students are funded

principally with government advances to Emory under the Perkins, Nursing, and Health Professions Student Loan Programs.

(d) Student Accounts and Other Receivables, Net

Student accounts and other receivables are recorded at net realizable value and include receivables from students, sponsors, other organizations, and reinsurers.

(e) Investments

Investments are reported at fair value. Investments in securities and listed funds are valued using quoted prices in active markets if available; otherwise, if the market is inactive, fair value is determined by the University in accordance with its valuation policy.

Investments in alternative investment fund structures are valued using the net asset value (NAV) per share of the investment (or its equivalent), as a practical expedient, if (a) the underlying investment manager's calculation of NAV is fair value based and (b) the University does not currently have plans to sell the investment for an amount different from NAV. Valuations provided by the general partners and investment managers are evaluated by the Emory Investment Management Office at August 31, 2022 and 2021.

Investments are exposed to several risks, which may include (but are not limited to) interest rate, liquidity, currency, market, and credit risks. The University attempts to manage these risks through diversification, ongoing due diligence of fund managers, and monitoring of economic conditions, though it is at least reasonably possible that changes in the values of investments will occur in the near term and that such changes could materially affect the amounts reported in the University's consolidated financial statements.

Investment transactions are accounted for on the trade-date basis. Dividend income is recognized on the ex-dividend date, and interest income is recognized on an accrual basis. Investment return, including realized and unrealized gains and losses, is recognized when earned and reported in the accompanying consolidated statements of activities, net of external and direct internal investment expenses. Investment return, if restricted, is reported in the accompanying consolidated statements of activities as increases or decreases in net assets with donor restrictions until amounts have been appropriated and the donor-imposed or statutory time restrictions have been satisfied.

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2022 AND 2021

(f) Fair Value Measurements

The University uses valuation approaches that maximize the use of observable inputs and minimize the use of unobservable input to the extent possible. The University determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:

Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.

Level 2 – Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.

Level 3 – Unobservable inputs for the asset and liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.

(g) Split-Interest Agreements

The University's split-interest agreements with donors consist primarily of gift annuity agreements and irrevocable charitable remainder trusts for which the University serves as trustee. Assets held in the trusts are included in investments. Contribution revenue is recognized when trusts (or annuity agreements) are established, after recording liabilities for the present value of the estimated future payments to be made to beneficiaries. The liabilities are adjusted annually for changes in the value of assets, accretion of the discount, and other changes in the estimates of future benefits.

(h) Interests in Perpetual Funds Held by Others

The University is also the beneficiary of certain perpetual funds held and administered by others. The value of the funds' net assets (or Emory's share when there are other beneficiaries) is considered a reasonable estimate of the present value of the estimated future cash flows from these funds and is recognized in change in undistributed income from perpetual funds held by others and as contribution revenue at the date such funds are established. The largest fund of this type primarily holds shares of common stock of The Coca-Cola Company. The carrying

value of Emory's interest in such perpetual funds is adjusted monthly for changes in fair value.

(i) Property and Equipment, Net

Land, buildings, and equipment are recorded at cost at the date of acquisition or fair value at the date of gift to the University. Depreciation expense is based on the straight-line method over the estimated useful lives of the assets. Useful lives are as follows: buildings – 10 to 60 years, land improvements and infrastructure – 5 to 40 years, movable equipment – 3 to 20 years, fixed equipment – 3 to 30 years, software and enterprise systems – 3 to 10 years, leasehold improvements – term of the lease, and library books – 10 years. Certain assets totaling \$121.4 million and \$119.2 million, such as art, museum assets, and rare books, are included in property and equipment, net as of August 31, 2022 and 2021, respectively, but are not depreciated.

If circumstances require property and equipment to be tested for impairment, the University compares undiscounted cash flows expected to be generated by the property and equipment to its carrying amount. If the carrying amount exceeds the undiscounted cash flows, an impairment is recognized to the extent that the carrying amount exceeds its fair value. There were no asset impairments for fiscal years 2022 or 2021.

(j) Health Insurance Plan

The University is self-insured for employee and student health insurance costs, with losses insured in excess of a maximum amount on both a per claim and annual aggregate claim amount. The self-insurance liability is based on claims filed and an estimate of claims incurred but not yet reported. Self-insurance claims are reported as net of insurance premiums collected from employees and students.

(k) Patient Accounts Receivable and Concentrations

Patient accounts receivable are reported at the estimated net realizable amounts due from patients, third-party payors, and others for services rendered, including estimated retroactive adjustments due to future audits, reviews, and investigations. Retroactive adjustments are considered in the recognition of revenue on an estimated basis in the period the related services are rendered, and such amounts are adjusted in future periods as adjustments become known or as years are no longer subject to such audits, reviews, and investigations.

Emory Healthcare analyzes contractually due amounts and provides an allowance for implicit price concessions. Accounts

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2022 AND 2021

receivable are written off after collection efforts have been undertaken in accordance with Emory's policies.

The mix of net receivables from patients and third-party payors for the years ended August 31 is as follows:

	2022	2021
Managed care and other third-party payors	61%	58%
Medicare	30	31
Medicaid	4	4
Patients	5	7
	100%	100%

(l) Leases

The University determines whether an arrangement is a lease (operating or finance) at inception by evaluating whether the contract conveys the right to use an identified asset and whether Emory obtains substantially all of the economic benefits from and has the right to control the asset. Right-of-use (ROU) assets represent the University's right to use an underlying asset for the lease term and lease liabilities represent the University's obligation to make lease payments arising from the lease. Operating and finance lease ROU assets and liabilities are recognized at the lease commencement date based on present value of the lease payments over the lease term discounted using the interest rate implicit in the lease agreement or Emory's relevant incremental borrowing rate. The University's current discount rates range from 0.3% to 4.5% depending on the term of the arrangement.

(m) Income Taxes

The University is recognized as a tax-exempt organization as defined in Section 501(c)(3) of the U.S. Internal Revenue Code of 1986, as amended (the Code), and is generally exempt from federal income taxes on related income pursuant to Section 501(a) of the Code. The University is, however, subject to federal and state income tax on unrelated business income.

The Tax Cuts and Job Acts (the Act) imposes an excise tax on net investment income and excess compensation for certain organizations and established rules for calculating unrelated business income. Based on reasonable estimates under the current regulatory guidance on the Act, Emory has recognized current and deferred tax liabilities, net aggregating \$12.7 million as of August 31, 2022 and \$34.6 million as of August 31, 2021. The University also has a net operating loss carryforward related to unrelated business income aggregating \$171.4 million, for which

a valuation allowance of \$144.0 million is recorded as of August 31, 2022. As of August 31, 2021, the University had a net operating loss carryforward of \$133.7 million, with a valuation allowance of \$113.4 million.

The University regularly evaluates its tax positions and as of August 31, 2022 and 2021, there were no material uncertain tax positions.

(n) Derivative Instruments

Certain investment strategies used by the University and its investment managers incorporate various derivative financial instruments in order to reduce volatility, manage market risk, and enhance investment returns. Such instruments are reflected at fair value and included in either investments or liability for derivative instruments within the accompanying consolidated statements of financial position. Changes in the fair value of investment-related derivative instruments are included in investment return on the accompanying consolidated statements of activities. The University also utilizes interest swap agreements to hedge interest rate market exposure of variable rate debt. The difference between amounts paid and received under such agreements is reported in interest expense. Changes in the fair value of these swap agreements are recognized as nonoperating activities in the accompanying consolidated statements of activities.

(o) Pension and Postretirement Benefit Plans

The University recognizes the funded status of its defined-benefit pension and postretirement benefit plans as an asset or liability and recognizes changes in funded status during the year in which the changes occur as changes in net assets without donor restrictions.

(p) COVID-19 Pandemic

In March 2020, the World Health Organization declared the novel coronavirus (COVID-19) a pandemic. The COVID-19 pandemic has resulted in financial loss, stress, and hardship for many.

In 2020 and 2021, the Coronavirus Aid, Relief and Economic Security Act (CARES), the Coronavirus Response and Relief Supplemental Appropriations Act (CRRSAA), and the American Rescue Plan (ARP), (collectively, the Acts) were enacted and signed into law to provide emergency grants to help individuals and businesses affected by the pandemic. Under the provisions of the CARES Act, Emory Healthcare received approximately \$249.7 million in provider relief funds (PRF) from the Department of Health and Human Services (HHS) through August 31, 2022 in both general and targeted distributions.

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2022 AND 2021

Emory Healthcare recognized \$30.6 million and \$219.1 million as other revenue in the accompanying consolidated statements of activities for the years ended August 31, 2022 and 2021, respectively.

During fiscal year 2020, Emory Healthcare also received approximately \$285.2 million in advance payments, that must be repaid, through the Centers for Medicare & Medicaid Services (CMS) COVID-19 Accelerated and Advance Payments (CAAP) Program to provide necessary funds when there is a disruption in claims submissions and processing or in circumstances such as a national emergency or natural disasters in order to accelerate cash flow to impacted healthcare providers. Repayment of outstanding CAAP amounts began in April 2021 and will occur monthly over a 29-month period. Approximately \$15.0 and \$221.2 million, respectively, relating to advanced payments received under the CAAP program is reflected in CARES Act accrued liabilities in the accompanying 2022 and 2021 consolidated statements of financial position.

Through August 31, 2021, the Department of Education awarded \$39.5 million in Higher Education Emergency Relief Funds (HEERF) to the University under the Acts, of which \$33.9 million was approved for payment to Emory and received as of August 31, 2022. The University distributed \$12.2 million and \$9.8 million to students and allocated \$0.2 and \$11.7 million to qualifying COVID-related expenses in fiscal years 2022 and 2021, respectively. Emory recognized \$22.3 million and \$11.6 million, respectively, as grants and contracts revenue in the accompanying 2022 and 2021 consolidated statements of activities.

The CARES Act allows employers to defer deposits and payments of the employer's share of Social Security taxes incurred between March 27, 2020 and December 31, 2020. As of August 31, 2022 and 2021, Emory has deferred payments of \$54.9 million and \$114.7 million, respectively, of employer taxes that are included in CARES Act accrued liabilities in the accompanying consolidated statements of financial position. The remaining amount of the deferred payments is due by December 31, 2022.

(q) New Accounting Pronouncements

In September 2020, the FASB issued ASU No. 2020-07, *Presentation and Disclosures by Not-for-Profit Entities for Contributed Nonfinancial Assets*. The new guidance amends ASC 958-05, requiring not-for-profit (NFP) entities to present contributed nonfinancial assets as a separate line item in the statements of activities, apart from contributions of cash and

other financial assets, and disclose contributed nonfinancial assets. ASU No. 2020-07 is effective for all NFPs for fiscal years beginning after June 15, 2021. Emory adopted ASU No. 2020-07 in fiscal year 2022 with no material impact to the accompanying consolidated financial statements.

(r) Use of Estimates

The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions affecting the reported amounts of assets, liabilities, revenue, and expenses, as well as disclosure of contingent assets and liabilities. Actual results could differ from those estimates.

Significant items in the University's consolidated financial statements subject to such estimates and assumptions include valuations for certain investments without readily determinable fair values, the determination of the allowances for price concessions for medical services, reserves for employee and student healthcare and workers' compensation claims, accrued professional and general liability costs, estimated third-party settlements, and actuarially determined benefit liabilities.

(s) Conflict of Interest Policies (Related Parties)

University trustees, directors, principal officers, and key employees may periodically be directly or indirectly associated with companies doing business with the University. The University requires annual disclosure of significant financial interests in, or employment or board service with, entities doing business with the University. The annual disclosures cover these key officials and their immediate family members.

When such relationships exist, measures are taken to appropriately manage the actual or perceived conflict. The written conflict of interest policy for the University requires, among other things, that no member of a governing board may participate in any decision in which he or she (or an immediate family member) has a material financial interest.

(t) Investments in Joint Ventures

Emory accounts for its investments in joint ventures over which it has significant influence but not a controlling interest, using the equity method. Investments in joint ventures are generally included in investments in the accompanying consolidated statements of financial position and equity income/loss is recorded within nonoperating activities in the accompanying consolidated statements of activities.

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2022 AND 2021

(3) Contributions Receivable

Contributions receivable as of August 31 consist of the following (in thousands):

	2022	2021
UNCONDITIONAL PROMISES		
EXPECTED TO BE COLLECTED IN:		
Less than one year	\$ 87,640	\$ 76,980
One year to five years	94,581	118,402
Over five years	17,816	1,229
Gross contributions receivable	200,037	196,611
Less:		
Allowance for uncollectible amounts	(5,568)	(5,374)
Discount to present value	(12,658)	(10,243)
Contributions receivable, net	\$ 181,811	\$ 180,994

At August 31, 2022 and 2021, the five largest outstanding donor pledge balances represented 74.0% and 70.6%, respectively, of Emory's total contributions receivable, net. Contribution receivables are discounted at rates ranging from 2.04% to 4.2%.

As of August 31, 2022, the University had received bequest intentions and conditional promises of approximately \$59.8 million. These intentions to give are not recognized as assets or revenue and, if received, will generally be restricted for purposes stipulated by the donor.

(4) Revenue Recognition

(a) Net Tuition and Fees

Tuition and fees revenue is derived from degree programs and continuing education programs. Tuition and fees are recognized in the fiscal year in which the academic programs and residential services are provided. Revenue is reflected in the accompanying consolidated statements of activities for the portion that is completed by the end of the fiscal year. The remaining performance obligation that will be completed in the following fiscal year remains a liability on the accompanying consolidated statements of financial position.

Most undergraduate students receive institutional financial aid based upon academic promise and demonstrated financial need. Graduate students often receive tuition support in connection with research assistant, teaching assistant, and fellowship appointments. Student financial aid provided by the University for tuition and fees is reflected as a reduction of tuition and fees revenue from published rates. Institutional resources provided in

excess of amounts owed by the students to Emory are recorded as scholarship expenses.

(b) Sales and Services of Auxiliary Enterprises

An auxiliary enterprise is a nonacademic entity that exists predominantly to furnish goods and services to students, faculty, and staff. Auxiliary enterprises revenue primarily includes residential services, parking, and bookstore. Residential services and parking revenue is recognized over time, as the services are performed. Sales of goods occur as a point-of-sale transaction, and the revenue is recognized as the sale occurs. Any discounts are factored into the selling price at the point of sale.

The following table provides the components of tuition and fees and student-related auxiliary enterprises revenue for the year ended August 31, 2022 (in thousands):

	Tuition and Fees	Auxiliary Enterprises	Total
Undergraduate programs	\$ 458,803	51,536	510,339
Graduate and professional programs	368,358	868	369,226
Total at published rates	827,161	52,404	879,565
Less institutional aid for undergraduate programs	(168,427)	(8,788)	(177,215)
Less institutional aid for graduate and professional programs	(179,234)	(191)	(179,425)
Tuition and fees and auxiliary enterprises, net of institutional aid	479,500	43,425	522,925
Other academic programs	8,867	-	8,867
Total tuition and fees and auxiliary enterprises	\$ 488,367	43,425	531,792

The following table provides the components of tuition and fees and student-related auxiliary enterprises revenue for the year ended August 31, 2021 (in thousands):

	Tuition and Fees	Auxiliary Enterprises	Total
Undergraduate programs	\$ 407,437	17,730	425,167
Graduate and professional programs	327,774	340	328,114
Total at published rates	735,211	18,070	753,281
Less institutional aid for undergraduate programs	(158,755)	(3,984)	(162,739)
Less institutional aid for graduate and professional programs	(167,801)	(103)	(167,904)
Tuition and fees and auxiliary enterprises, net of institutional aid	408,655	13,983	422,638
Other academic programs	7,963	-	7,963
Total tuition and fees and auxiliary enterprises	\$ 416,618	13,983	430,601

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2022 AND 2021

(c) Gifts and Contributions Revenue

Contributions, including unconditional promises to give, are recognized as revenue in the period the promise is received, or in the period in which the unconditional promise was made. Unconditional promises to give, with payments due in future periods, are recorded as increases in net assets with donor restrictions at the estimated present value of future cash flows, net of an allowance for uncollectible pledges. Contributions of assets other than cash are recorded at their estimated fair value at the date of the gift.

Donor-restricted contributions are reported as revenue with donor restrictions, which increases this net asset class. If the donor stipulation is met in the year of the gift, the contribution is reflected in net assets without donor restrictions. Restrictions on gifts to acquire long-lived assets are considered met in the period when the asset is placed in service. Conditional promises to give are not recognized until they become unconditional.

(d) Grants and Contracts Revenue

Emory receives funding from federal, state, corporate, and private foundations (sponsors). The agreement with the sponsor may take the form of a contract, grant, or cooperative agreement. If resource providers do not receive commensurate benefit (only indirect benefit because the research findings serve the general public), such grants and contracts are considered contributions.

Most Emory nonexchange, sponsored research agreements are conditional contributions as the agreements include both a right of return or release of assets and a barrier that Emory must overcome to be entitled to the consideration. The University recognizes revenue associated with these sponsored agreements as qualifying allowable expenses are incurred or a measurable performance-related barrier is achieved in accordance with the terms and conditions of the agreements. Conditional agreements with sponsor-imposed restrictions that expire simultaneously with the satisfaction of the specified conditions are reported as net assets without donor restrictions. Deferred revenue is recognized when cash is received from sponsors in advance of revenue being earned. Amounts recorded in other receivable, net are for services rendered or expenditures incurred in advance of the receipt of funds.

Emory considers revenue from most clinical trial agreements to be exchange transactions where revenue is recognized as services are performed, billed, and the University has contractual right to consideration. Revenue related to clinical trial agreements included in grants and contracts revenue in the accompanying

consolidated statements of activities for the years ended August 31, 2022 and 2021 totaled \$70.1 million and \$57.5 million, respectively.

Indirect cost recoveries are based on negotiated rates with grantor agencies and represent recoveries of facilities and administrative costs incurred under grant and contract agreements.

The following table presents Emory's sources of grants and contracts revenue (including indirect cost recoveries) for the years ended August 31 (in thousands):

	2022		2021	
	Grants	Contracts	Grants	Contracts
Federal government	\$ 631,726	5,757	\$ 582,992	2,454
Other government	2,016	54	1,658	151
Corporate	19,118	56,805	14,634	50,226
Private institutions	98,468	7,485	106,109	4,625
Total	\$ 751,328	70,101	\$ 705,393	57,456

As of August 31, 2022 and 2021, Emory had unexpended grant awards of \$952.5 million and \$834.5 million, respectively, for which revenue will be recognized when conditions have been met or performance obligations have been satisfied.

(e) Royalties Revenue

The University recognizes revenue from nonrefundable, up-front fees allocated to a license at a point in time when the license is transferred to the licensee and the licensee is able to use and benefit from the license. Sales-based royalties revenue, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, is recognized over the licensing agreement.

(f) Medical Services and Other Revenue

Medical services revenue is recognized as services are performed and the customer receives and uses the benefits of the services. The University has contractual agreements with Grady Memorial Hospital where practicing interns and medical residents of the Emory School of Medicine receive clinical training and faculty provide teaching, medical care, and hospitalization services. The School of Medicine is reimbursed for expenses incurred for interns and medical residents based on the costs for labor and reimbursed for the faculty teaching, administrative, and clinical services based on the number of interns and residents trained and time spent performing clinical and administrative services.

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2022 AND 2021

The University also has affiliation and administrative services agreements with Children’s Healthcare of Atlanta and the Emory + Children’s Pediatric Institute, where it provides various administrative services. Revenue is recognized over time and is recorded as other revenue in the accompanying consolidated statements of activities.

Retail pharmaceutical sales are recognized at a point in time when the customer receives the product.

The major components of other sources of operating revenue for the years ended August 31 are as follows (in thousands):

	2022	2021
Retail pharmaceutical sales	\$ 267,409	\$ 198,358
CARES Act provider relief fund	30,616	219,139
Royalties	262,645	11,702
Other	233,610	184,714
Other revenue	\$ 794,280	\$ 613,913

(g) Independent Operations Revenue

Independent operations are activities independent of its mission, including an externally managed conference center, hotel, and a fitness center. Fee charges are based on market rates for the services provided and revenue is recognized at a point in time or over time as the services are rendered.

(h) Net Patient Services Revenue

Emory Healthcare has agreements with government and other third-party payors that provide for reimbursement to Emory Healthcare at amounts different from established rates.

Revenue is recognized as performance obligations are satisfied. Performance obligations are determined based on the nature of the services provided. Revenue for performance obligations satisfied over time is recognized based on actual charges incurred in relation to total expected (or actual) charges. Emory Healthcare believes that this method provides a faithful depiction of the transfer of services over the term of the performance obligation based on the inputs needed to satisfy the obligation. Generally, performance obligations satisfied over time relate to patients in Emory Healthcare’s hospitals receiving inpatient, outpatient, or emergency services. Emory Healthcare measures the performance obligation from admission, or the commencement of an outpatient service, to the point when it is no longer required to provide services to that patient, which is generally at the time of discharge or completion of the outpatient services. Revenue for performance obligations satisfied at a point in time is

generally recognized when goods are provided to Emory Healthcare’s patients and customers in a retail setting (e.g., pharmaceuticals), and Emory Healthcare does not believe it is required to provide additional goods or services related to that sale.

Emory Healthcare determines the transaction price based on standard charges for goods and services provided, reduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients in accordance with Emory Healthcare policy, and implicit price concessions provided to patients. Emory Healthcare determines its estimates of contractual adjustments and discounts based on contractual agreements, its discount policies, and historical experience.

Emory Healthcare provides care to patients regardless of their ability to pay. Emory Healthcare has determined it has provided implicit price concessions to uninsured patients and patients with other uninsured balances (e.g., co-pays and deductibles).

The implicit price concessions included in estimating the transaction price represent the difference between amounts billed to patients and the amounts Emory Healthcare expects to collect based on its collection history with those patients considering business and economic conditions, trends in healthcare coverage, and other collection indicators. Periodically, management assesses the adequacy of the allowance for implicit price concessions based upon historical write-off experience by payor category and adjusts the allowance as appropriate.

Patient service revenue, net of contractual adjustments, implicit price concessions, and other discounts recognized from major payor sources for the years ended August 31 is as follows (in thousands):

	2022	2021
Medicare	\$ 1,526,833	\$ 1,474,617
Medicaid	115,418	178,384
Managed care and other third-party payors	3,336,066	3,092,695
Patients	60,902	58,089
Net patient service revenue	\$ 5,039,219	\$ 4,803,785

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2022 AND 2021

The composition of net patient service revenue based on the Emory Healthcare lines of business for the years ended August 31 is as follows (in thousands):

	2022	2021
Services lines:		
Hospital – inpatient	\$ 2,218,074	\$ 2,141,460
Hospital – outpatient	1,697,647	1,585,008
Physician services	1,123,498	1,077,317
Net patient service revenue	\$ 5,039,219	\$ 4,803,785

Emory Healthcare provides care to patients who meet certain criteria under its financial assistance policy without charge or at amounts less than their established rates and such amounts are not included in net patient service revenue.

Data is maintained to identify and monitor the level of charity care provided, including the amount of charges foregone and actual costs for services furnished under its charity and indigent care policies.

The cost of charity care provided totaled \$148.2 million and \$124.6 million for the years ended August 31, 2022 and 2021, respectively. Emory Healthcare estimated these costs by applying a ratio of cost to gross charges to the gross uncompensated charges associated with providing care to the charity patients.

(5) Liquidity and Availability

Emory regularly monitors liquidity required to meet its operating needs and other contractual commitments, while also maximizing the investment of its available funds.

For purposes of analyzing resources available to meet general expenditures over a 12-month period, the University considers all expenditures related to its ongoing mission-related activities as well as the conduct of services undertaken to support those activities to be general expenditures.

In addition to financial assets available to meet general expenditures over the next 12 months, the University operates with a balanced budget and anticipates collecting sufficient revenue to cover general expenditures not covered by donor-restricted resources.

As of August 31, 2022 and 2021, the following financial assets could readily be made available within one year of the statements of financial position date to meet cash needs for general expenditures (in thousands):

	2022	2021
TOTAL ASSETS	\$ 19,885,028	\$ 20,458,905
Less:		
Property and equipment, net	(4,396,966)	(4,015,749)
Interest in perpetual trusts held by others	(1,682,142)	(1,848,427)
Donor-restricted and board-designated endowment funds	(7,310,837)	(7,974,988)
Other investments	(3,242,498)	(3,589,504)
Prepaid expenses, deferred charges, and other assets	(390,529)	(446,291)
Operating lease right-of-use assets	(245,976)	(182,372)
Contributions receivable, net	(181,811)	(180,994)
Loans receivable, net	(16,415)	(18,441)
Add:		
Endowment payout in following year	223,479	215,002
Contributions receivable due within one year for operations	87,640	76,980
Financial assets available to meet cash needs for general expenditures within one year	\$ 2,728,973	\$ 2,494,121

The University has \$2,729.0 million of financial assets as of August 31, 2022 to meet cash needs for general expenditures, consisting of cash and cash equivalents of \$1,421.4 million, accounts receivable of \$944.7 million, contributions receivable, less than one year of \$87.6 million, payout on with and without donor-restricted endowment funds of \$223.5 million, and other operating investments of \$51.7 million.

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2022 AND 2021

(6) Investments

The following table summarizes investments as of August 31 (in thousands):

	2022	2021
Short-term investments and cash equivalents ^(a)	\$ 498,147	\$ 717,537
Public equity ^(b)	3,741,806	4,689,741
Absolute return/fixed income ^(c)	1,673,726	1,693,687
Private equity/venture capital ^(d)	3,726,232	3,649,517
Real assets ^(e)	953,170	822,990
Derivative instruments ^(f)	11,694	42,034
Total investments at fair value	10,604,775	11,615,506
Joint ventures (equity method)	309	14,598
Total investments	\$ 10,605,084	\$ 11,630,104

a) Includes short-term U.S. and non-U.S. Treasury securities with maturities of less than one year, as well as funds that invest in these types of investments.

b) Includes domestic and international stocks, as well as interests in funds that invest in both long only and long/short equity-based strategies; certain investments in funds may be subject to restrictions that limit the University's ability to withdraw capital until (i) certain "lock-up period" has expired or (ii) until certain underlying investments designated as "illiquid" or "side pockets" are sold. In addition, fund investments in this category may be subject to restrictions limiting the amount the University is able to withdraw as of a given redemption date. Also includes \$0.0 million and \$115.0 million in investment subscriptions paid in advance as well as \$0.0 million and \$220.0 million in investment proceeds receivable as of August 31, 2022 and 2021, respectively.

c) Includes directly-held actively traded global fixed-income securities (such as government bonds and corporate bonds) or commingled funds holding such securities of \$912.9 million and \$851.4 million and investments in multistrategy or credit funds, as well as opportunistic absolute return funds intended to enhance diversification and reduce correlation to public equity of \$760.8 million and \$842.3 million as of August 31, 2022 and 2021, respectively; certain fund investments included in this category may hold marketable securities and be subject to redemption terms governed by the respective fund agreement or may contain illiquid investments and, therefore, offer no liquidity over the fund life. Such funds holding illiquid investments are expected to yield liquidating distributions over the next six years.

d) Includes illiquid investments in private and public companies, both domestically and internationally; the majority of these investments are held through funds and also include buyout, venture capital, private debt, high yield, and subordinated debt strategies. The nature of the investments in this category is such that distributions are received through liquidation of the underlying assets of the funds, which are expected to occur over the next 16 years.

e) Includes investments in oil and gas, commodities, timber, and real estate, the majority of which are held through commingled funds; the nature of the investments in this category is such that distributions are received through liquidation of the underlying assets of the funds, which are expected to occur over the next 10 years.

f) Includes investments in equity options, swaps, and forwards valued at fair value of each underlying investments

As of August 31, 2022, the related unfunded commitments of the University's alternative investments valued using the practical expedient and limitations and restrictions on the University's ability to redeem or sell are summarized as follows (in thousands):

	Unfunded Commitments	Redemption Frequency (if currently eligible)	Redemption Notice Period
Absolute return	\$ 481,854	30 - 90 days or not eligible	31 - 92 days
Private equity/ venture capital	867,461	360 days or not eligible	90 days
Public equity	43,333	30-360 days or not eligible	10-180 days
Real assets	377,602	not eligible	not eligible
	\$ 1,770,250		

Unfunded commitments are generally expected to be called by funds within five years of fund inception.

(7) Endowment Net Assets

The University's endowed assets (the Endowment) consist of 2,318 individual funds established for a variety of purposes, including with donor restriction endowment funds and without donor restrictions funds designated by the Board of Trustees to function as endowments. The Endowment provides stable financial support to a wide variety of programs and activities in perpetuity, playing a critical role in enabling the University to achieve its mission. Net assets associated with these endowment

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2022 AND 2021

funds are classified and reported based on the existence or absence of donor-imposed restrictions.

(a) Interpretation of Relevant Law

The University follows the State of Georgia’s Uniform Prudent Management of Institutional Funds Act (UPMIFA), which provides standards for managing investments of institutional funds and spending from endowments. The University classifies as donor-restricted historical value net assets (a) the original value of gifts donated to the permanent endowment, (b) the original value of subsequent gifts to the permanent endowment, and (c) accumulations to the permanent endowment made in accordance with the direction of the applicable donor gift instrument at the time the accumulation is added to the fund.

The remaining portion of the donor-restricted endowment fund that is classified as restricted appreciation until those amounts are

appropriated for expenditures by the University in a manner consistent with the standard of prudence prescribed by UPMIFA. In accordance with UPMIFA, the University considers several factors in making a determination to appropriate or accumulate donor-restricted endowment funds, including the duration and preservation of the fund, the purposes of the fund, general economic conditions, the possible effect of inflation and deflation, the expected total return from income and the appreciation of investments, other resources of the University, and the investment policies of the University. The endowment funds subject to UPMIFA are true endowments and do not include perpetual funds held by others, long-term investments, annuity funds, funds held in trust for others, and miscellaneous investments. As of August 31, 2022, 68.9% of the investments described in note 6 are classified as endowed net assets.

Endowment funds are categorized in the following net asset classes as of August 31 (in thousands):

	2022			2021		
	Without Donor Restrictions	With Donor Restrictions	Total	Without Donor Restrictions	With Donor Restrictions	Total
Donor-restricted endowment funds						
Appreciation	\$ –	3,878,867	3,878,867	\$ –	4,469,428	4,469,428
Historical value	–	1,226,590	1,226,590	–	1,148,348	1,148,348
Total donor restricted	–	5,105,457	5,105,457	–	5,617,776	5,617,776
Funds functioning as endowments or board-designated	2,205,380	–	2,205,380	2,357,212	–	2,357,212
Total endowment net assets	\$ 2,205,380	5,105,457	7,310,837	\$ 2,357,212	5,617,776	7,974,988

The following table represents endowment net asset composition by purpose as of August 31 (in thousands):

	2022			2021		
	Without Donor Restrictions	With Donor Restrictions	Total	Without Donor Restrictions	With Donor Restrictions	Total
Student financial aid	\$ 214,132	1,030,890	1,245,022	\$ 235,097	1,147,799	1,382,896
Academic, research, and program support	1,216,929	3,903,690	5,120,619	1,258,129	4,148,567	5,406,696
Capital projects, real estate, and infrastructure	774,319	170,877	945,196	863,986	321,410	1,185,396
Total endowment net assets	\$ 2,205,380	5,105,457	7,310,837	\$ 2,357,212	5,617,776	7,974,988

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2022 AND 2021

Changes in endowment funds by net asset classification for the years ended August 31 are summarized as follows (in thousands):

		Without Donor Restrictions	With Donor Restrictions	Total
Balance as of August 31, 2020	\$	1,733,058	4,156,326	5,889,384
Investment return:				
Investment income		4,214	10,062	14,276
Net realized and unrealized gains on investments		660,156	1,597,142	2,257,298
Total investment return		664,370	1,607,204	2,271,574
Cash contributions		7,425	41,693	49,118
Additions of funds for endowments		–	535	535
Transfers of institutional funds for endowments without donor restrictions		32,608	–	32,608
Withdrawal of board-designated funds for strategic initiatives		(8,534)	–	(8,534)
Appropriations for expenditure		(65,091)	(170,612)	(235,703)
Appropriations for capital purposes		(6,624)	(17,370)	(23,994)
Balance as of August 31, 2021	\$	2,357,212	5,617,776	7,974,988
Investment return:				
Investment income		10,952	26,274	37,226
Net realized and unrealized losses on investments		(180,094)	(421,502)	(601,596)
Total investment return		(169,142)	(395,228)	(564,370)
Cash contributions		4,607	78,177	82,784
Additions of funds for endowments		–	65	65
Transfers of institutional funds for endowments without donor restrictions		111,120	–	111,120
Withdrawal of board-designated funds for strategic initiatives		(23,195)	–	(23,195)
Appropriations for expenditure		(68,485)	(177,744)	(246,229)
Appropriations for capital purposes		(6,737)	(17,589)	(24,326)
Balance as of August 31, 2022	\$	2,205,380	5,105,457	7,310,837

(b) Funds with Deficiencies

From time to time, the fair value of assets associated with individual donor-restricted endowment funds may fall below the level of the donor's original contribution. Deficiencies of this nature were \$5.8 million as of August 31, 2022. As of August 31, 2021, there were no endowment funds with significant deficiencies.

(c) Return Objectives and Risk Parameters

The University has adopted investment and spending policies for endowment assets that attempt to provide a predictable stream of funding to programs supported by its endowment and seek to maintain the purchasing power of the endowment assets. Under

this policy, as approved by the Board of Trustees, the endowment assets are invested within risk tolerances of the University to provide an expected total return and inflation over the long term.

(d) Strategies Employed for Achieving Objectives

To satisfy its long-term return objectives, the University relies on a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized) and current yield (interest and dividends). The University employs a diversified asset allocation strategy across public equity, absolute return/fixed income, private equity/venture capital, real assets, and derivative instruments to achieve its long-term return objectives within a prudent risk framework. The Endowment's long-term target asset allocation is approved by the Investment

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2022 AND 2021

Committee of the Board of Trustees. The portfolio is periodically rebalanced to the target weightings for each asset class.

(e) Relationship between Investment Objectives and Spending Policy

The University's Board of Trustees has established a spending policy that determines how endowment distributions are made. The University employs a total return endowment spending policy that establishes the amount of endowment investment return available to support current operating and capital needs. The distribution of endowment investment return in 2022 was

based on 5% of the average fair value of the endowment over the previous 36 months ended on August 31, and 4.8% of the average fair value of the endowment over the previous 12 months in 2021. The University considers the historical average market value in setting the annual appropriation amount. Accordingly, the University expects the current spending policy to allow its endowment to maintain its purchasing power if projected growth rates are achieved. Additional real growth will be provided through new gifts and any excess investment return. The payout rate is approved annually by the Board of Trustees as part of the budget process.

(8) Fair Values of Assets and Liabilities

The following table summarizes the valuation of the University's assets and liabilities according to the fair value hierarchy levels as of August 31, 2022 (in thousands):

	Investments Measured at NAV ⁽²⁾	Fair Value Hierarchy			Total Fair Value
		Level 1	Level 2	Level 3	
FINANCIAL ASSETS:					
Short-term investments and cash equivalents	\$ —	169,462	328,685	—	498,147
Public equity	3,204,693	499,380	37,730	3	3,741,806
Absolute return/fixed income	760,751	550,815	362,160	—	1,673,726
Private equity/venture capital	3,684,239	—	—	41,993	3,726,232
Real assets	950,298	186	1,500	1,186	953,170
Derivative instruments	—	(1)	11,695	—	11,694
Total investments at fair value	8,599,981	1,219,842	741,770	43,182	10,604,775
Interests in perpetual funds held by others ⁽¹⁾	—	—	—	1,682,142	1,682,142
Total assets at fair value	8,599,981	1,219,842	741,770	1,725,324	12,286,917
FINANCIAL LIABILITIES:					
Derivative instruments – interest rate swaps	—	—	(87,266)	—	(87,266)
Funds held in trust for others ⁽³⁾	(1,121,578)	—	—	—	(1,121,578)
Total liabilities at fair value	\$ (1,121,578)	—	(87,266)	—	(1,208,844)

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2022 AND 2021

The following table summarizes the valuation of the University's assets and liabilities according to the fair value hierarchy levels as of August 31, 2021 (in thousands):

	Investments Measured at NAV ⁽²⁾	Fair Value Hierarchy			Total Fair Value
		Level 1	Level 2	Level 3	
FINANCIAL ASSETS:					
Short-term investments and cash equivalents	\$ –	160,664	556,873	–	717,537
Public equity	4,215,093	469,059	5,586	3	4,689,741
Absolute return/fixed income	842,309	192,496	658,882	–	1,693,687
Private equity/venture capital	3,639,503	–	–	10,014	3,649,517
Real assets	820,907	8	1,625	450	822,990
Derivative instruments	–	–	42,034	–	42,034
Total investments at fair value	9,517,812	822,227	1,265,000	10,467	11,615,506
Interests in perpetual funds held by others ⁽¹⁾	–	–	–	1,848,427	1,848,427
Total assets at fair value	9,517,812	822,227	1,265,000	1,858,894	13,463,933
FINANCIAL LIABILITIES:					
Derivative instruments – interest rate swaps	–	–	(211,164)	–	(211,164)
Funds held in trust for others ⁽³⁾	(1,239,045)	–	–	–	(1,239,045)
Total liabilities at fair value	\$ (1,239,045)	–	(211,164)	–	(1,450,209)

⁽¹⁾ Primarily invested in The Coca-Cola Company.

⁽²⁾ Certain investments that are measured at fair value using the net asset value (NAV) per share (or its equivalent) practical expedient have not been categorized in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the accompanying consolidated statements of financial position.

⁽³⁾ Emory uses net asset value of units held as an estimate for fair value.

The following tables present a summary of the University's activity for investments categorized in Level 3 for the years ended August 31, 2022 and 2021 (in thousands):

	2022			2021			
	Purchases	Sales	Transfers out ⁽¹⁾	Purchases	Sales	Transfers out ⁽¹⁾	
Private equity/venture capital	\$ 57,698	(4,290)	–	Private equity/venture capital	\$ 9,411	(749)	(46,148)
Real assets	10	–	–	Real assets	–	(47)	–
Total Investments	57,708	(4,290)	–	Total Investments	9,411	(796)	(46,148)
Interests in perpetual funds held by others	20,000	–	(140,833)	Interests in perpetual funds held by others	105,000	–	(177,699)
Total assets	\$ 77,708	(4,290)	(140,833)	Total assets	\$ 114,411	(796)	(223,847)

⁽¹⁾ Private equity/venture capital transfers out are due to directly held shares of a private company exchanged for shares of a public company as a result of an IPO. Interests in perpetual funds held by others transfer out is due to funds released from operations.

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2022 AND 2021

(9) Derivative Instruments and Hedging Activities

(a) Investments

Investment strategies employed by Emory and investment managers retained by Emory may incorporate futures, options, swaps, and other derivative instruments to adjust elements of investment exposures to various securities, markets, and

currencies without taking a position in the underlying assets. These instruments expose Emory to risk of an unexpected movement in the fair value of the underlying security, a counterparty failing to meet its obligations, and, in certain circumstances, not being able to unwind a position at current fair value due to market illiquidity. Emory has established procedures to monitor and manage these risks.

Emory's investment-related derivative exposures, categorized by primary underlying risk, as of and for the years ended August 31 are as follows (in thousands):

2022	Notional Amount⁽¹⁾	Asset Fair Value	Liability Fair Value	Total Earnings⁽²⁾
Foreign exchange contracts	\$ 935	467	(468)	(69,542)
Equity contracts ⁽³⁾	452,835	29,835	(18,140)	17,980
Total⁽⁴⁾	\$ 453,770	30,302	(18,608)	(51,562)

2021	Notional Amount⁽¹⁾	Asset Fair Value	Liability Fair Value	Total Earnings⁽²⁾
Foreign exchange contracts	\$ 175,251	87,626	(87,625)	5,712
Equity contracts ⁽³⁾	282,228	45,356	(3,323)	76,332
Total⁽⁴⁾	\$ 457,479	132,982	(90,948)	82,044

⁽¹⁾ The notional amount is representative of the absolute value of the open contracts as of August 31, 2022 and 2021, except as otherwise discussed below in (3).

⁽²⁾ Gains on derivative instruments incurred during the fiscal year are included in the accompanying consolidated statements of activities in investment return in nonoperating activities.

⁽³⁾ The notional value for options is presented on a net delta-adjusted basis.

⁽⁴⁾ Derivatives are held primarily with four counterparties. Cash collateral of \$18.4 million and \$0.0 million is pledged as of August 31, 2022 and 2021, respectively.

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2022 AND 2021

(b) Debt

Historically, as a component of the debt portfolio, the University entered into interest rate swap agreements that effectively convert a portion of variable rate debt to fixed rates and are used to manage interest rate risk. Since the inception of the interest rate swap agreements, the debt portfolio has changed to incorporate fixed rate debt not associated with derivatives. The University's exchange arrangements are exposed to credit loss in the event of nonperformance by the counterparty and to interest rate risk driven by any potential basis risk with variable rate debt. Certain of the University's derivative instruments contain provisions requiring long-term, unsecured debt to be maintained at specified credit ratings from Moody's Investors Service and Standard and Poor's Ratings Service. If the ratings of the University's debt were to fall below certain benchmarks, the counterparty could request immediate payment on derivative instruments in net liability positions. As of August 31, 2022, the University's long-term debt ratings exceeded these benchmarks.

At August 31, 2022, Emory had eight interest rate swap agreements expiring on various dates ranging from September 1, 2035 through December 1, 2042. These agreements require Emory to pay fixed interest rates to the counterparties varying from 3.2% to 3.6% in exchange for variable rate payments from the counterparties based on a percentage of the three-month LIBOR.

Net settlement transactions related to the agreements described above resulted in interest expense totaling \$9.7 million and \$10.9 million and, interest expenses related to nonintegrated agreements, reflected as nonoperating loss, of \$8.9 million and \$10.2 million during 2022 and 2021, respectively. During fiscal year 2022 the University entered into and subsequently terminated an interest rate lock agreement which resulted in a favorable termination settlement payment of approximately \$39.0 million. The realized gain on the termination payment received was recorded as a change in the fair value of derivative instruments within non-operating activities, net on the accompanying consolidated statements of activities. The fair value of each exchange agreement is estimated based on pricing models that utilize significant observable inputs, such as relevant current interest rates, that reflect assumptions on the amount the University would receive or pay to terminate the agreement at the reporting date. As such, the University's exchange agreements are categorized as Level 2 in the fair value hierarchy.

The aggregate fair value of all derivative instruments with credit risk-related contingent features that are in a liability position was \$87.3 million and \$211.2 million, collateralized by \$0.0 million and \$31.3 million of cash on August 31, 2022 and 2021, respectively. Collateral postings are reported in prepaid expenses, deferred charges, and other assets in the accompanying consolidated statements of financial position.

The following table summarizes the debt-related derivative instruments as of and for the years ended August 31 (in thousands):

Interest Rate Swaps			2022		2021	
Inception	Maturity	Notional Amount ⁽¹⁾	Liability Fair Value	Unrealized Gain	Liability Fair Value	Unrealized Gain
August 4, 2005	September 1, 2035	\$ 125,000	(13,003)	21,359	\$ (34,362)	10,016
August 25, 2005	September 1, 2035	40,000	(4,467)	7,090	(11,557)	3,473
December 1, 2007	September 1, 2035	75,000	(10,726)	13,906	(24,632)	6,595
May 1, 2008	September 1, 2038	75,000	(13,502)	15,864	(29,366)	7,731
December 1, 2008	December 1, 2042	100,000	(16,724)	23,426	(40,150)	11,957
December 1, 2009	September 1, 2035	75,000	(10,993)	13,964	(24,957)	6,628
June 23, 2015	September 1, 2035	125,000	(13,378)	21,205	(34,583)	9,939
June 23, 2015	September 1, 2035	40,000	(4,473)	7,084	(11,557)	3,473
Total		\$ 655,000	(87,266)	123,898	\$ (211,164)	59,812

⁽¹⁾ The notional amount is the predetermined dollar amount on which the exchanged interest payments are based.

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2022 AND 2021

Emory is exposed to financial loss in the event of nonperformance by a counterparty to any of the financial instruments described above. General market conditions could impact the credit standing of the counterparties and therefore, potentially impact the value of the instruments. Emory management, with consultation from third-party financial advisers, controls this counterparty credit risk by considering the credit rating, business risk, and reputation of any counterparty before entering into a transaction, monitoring for any change in the credit standing of its counterparty during the life of the transaction, and requiring collateral be posted when predetermined thresholds are crossed.

(10) Property and Equipment, Net

Property and equipment, net as of August 31 is summarized as follows (in thousands):

	2022	2021
Land and improvements	\$ 247,868	\$ 242,799
Buildings and improvements	4,203,949	4,097,752
Equipment	3,112,204	2,968,148
Finance lease ROU assets (note 11)	22,190	22,190
Library and museum assets	529,413	507,039
Construction in progress	1,083,361	684,704
	9,198,985	8,522,632
Less: accumulated depreciation	(4,792,917)	(4,499,275)
Less: accumulated amortization of finance leases	(9,102)	(7,608)
Total property, plant, and equipment, net	\$ 4,396,966	\$ 4,015,749

The University has identified asset retirement obligations predominantly from commitments to remove asbestos and lead paint in the University's facilities at the time of major renovation or demolition. The liability was estimated using an inflation rate of 5.0% and discount rate of 4.7%.

The following table summarizes the ARO activity for the year ended August 31 (in thousands):

	2022	2021
ARO liability at beginning of year	\$ 85,833	\$ 82,616
Accretion expense	3,769	3,217
ARO liability at end of year	\$ 89,602	\$ 85,833

(11) Leases

The University has operating and finance leases for office buildings, research and development facilities, hospital and educational buildings, and certain equipment. Leases have remaining lease terms of 1 year to 25 years, some of which include purchase options or options to extend the leases.

Operating leases are included in operating lease right-of-use assets and operating lease liabilities, finance leases are included in property, plant, and equipment, net, and finance lease liabilities in the accompanying consolidated statements of financial position. Operating lease liabilities represent the remaining fixed lease payments discounted to present value, while the right-of-use (ROU) assets include any lease payments made, lease incentives received, and are amortized over the term of the lease. Renewal options are excluded from the calculation of lease liabilities unless it is reasonably assured that the renewal option will be exercised. Lease costs associated with operating lease assets are recognized on a straight-line basis within operating expenses over the term of the lease.

Finance lease ROU assets are amortized within operating expenses on a straight-line basis over the shorter of the estimated useful lives of the assets or the lease term. The interest component of a finance lease is included in interest expense and recognized using the effective interest-method over the lease term. Variable lease costs, such as common area maintenance, property taxes, and insurance are expensed as incurred.

Emory has lease agreements with lease and nonlease components. The University elected a practical expedient, primarily for its copier leases, whereby nonlease components are not separated from the lease component. This results in all of the lease and nonlease components being combined, and accounted for, as a single lease component and included in the measurement of the ROU assets and lease liabilities.

The components of lease expense for the year ended August 31, are as follows (in thousands):

	2022	2021
Finance lease cost	\$ 2,131	\$ 4,569
Amortization of ROU assets	1,493	3,250
Interest on lease liabilities	638	1,319
Operating lease cost	39,835	38,689
Short-term lease cost	22,282	15,194
Total lease expense	\$ 64,248	\$ 58,452

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2022 AND 2021

Aggregate future payments under noncancelable operating and finance leases as of August 31, 2022 are as follows (in thousands):

	Operating Leases	Finance Leases
2023	\$ 43,975	1,721
2024	40,816	1,313
2025	34,525	1,070
2026	28,338	1,044
2027	24,180	1,042
Thereafter	133,724	18,536
Total lease payments	305,558	24,726
Less: amounts representing interest	(32,351)	(8,143)
Total obligation	\$ 273,207	16,583

Supplemental cash flow information related to leases for the year ended August 31 is as follows (in thousands):

	2022	2021
Other information		
Cash paid for amounts included in the measurement of lease liabilities		
Operating cash flows from operating leases	\$ 40,497	\$ 38,499
Operating cash flows from finance leases	1,494	3,250
Financing cash flows from finance leases	1,041	1,591
Right-of-use assets obtained in exchange for new lease obligations		
Operating leases	109,242	16,054
Finance leases	—	1,369
Weighted-average remaining lease term -- finance lease	22 years	22 years
Weighted-average remaining lease term -- operating lease	8 years	8 years
Weighted-average discount rate -- finance lease	3.79%	3.72%
Weighted-average discount rate -- operating lease	2.10%	2.06%

Emory is the lessor in a long-term noncancelable operating sublease for space to serve as an expanded point of entry for imaging and surgical cases for Emory Healthcare at its Executive Park property. The lease agreement's underlying asset will continue to be classified as the original lessor's fixed asset.

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2022 AND 2021

(12) Bonds and Notes Payable

Bonds and notes payable, including unamortized premiums, discounts, and issuance costs, consisted of the following as of August 31 (dollars in thousands):

	Average Interest Rate	Final Maturity	Outstanding Principal	
			2022	2021
Tax-exempt, fixed-rate revenue bonds:				
2022 Series A	5.00%	September 1, 2032	\$ 212,055	\$ –
2020 Series B	4.63	September 1, 2041	486,470	486,470
2019 Series A	4.96	September 1, 2039	201,790	209,665
2019 Series B	5.00	September 1, 2048	39,725	39,725
2016 Series A	4.62	October 1, 2046	130,030	130,030
2016 Series B	4.19	October 1, 2043	192,905	195,750
2013 Series A	5.00	October 1, 2043	178,335	178,460
Total tax-exempt, fixed-rate revenue bonds			1,441,310	1,240,100
Tax-exempt, variable-rate revenue bonds:				
2022 Series B	1.81	September 1, 2052	110,380	–
2013 Series B ⁽¹⁾	0.79	October 1, 2039	–	135,100
Total tax-exempt, variable-rate revenue bonds			110,380	135,100
Taxable, fixed-rate revenue bonds:				
2020 Series A	2.41	September 1, 2050	943,750	943,750
1994 Series C	8.00	October 1, 2024	2,295	2,945
1991 Series	8.85	April 1, 2022	–	41
Total taxable, fixed-rate revenue bonds			946,045	946,736
Taxable, variable-rate revenue bonds:				
2022 Series C-1 ⁽²⁾	2.68	September 1, 2052	110,450	–
2022 Series C-2 ⁽²⁾	2.69	September 1, 2052	110,445	–
Total taxable, variable-rate revenue bonds			220,895	–
Unamortized bond premiums			238,788	212,772
Bond issuance costs			(9,972)	(8,571)
Total bonds and notes payable			\$ 2,947,446	\$ 2,526,137

⁽¹⁾ Average Securities Industry and Financial Markets Association Index (SIFMA) from September 1, 2021 through August 11, 2022 plus a Floating Rate Notes (FRN) spread of 42 basis points

⁽²⁾ Average reset rates taken from Electronic Municipal Market Access (EMMA), plus credit facility and remarketing fees

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2022 AND 2021

The University incurred interest expense of \$76.2 million and \$75.0 million in 2022 and 2021, respectively, net of capitalized interest of \$7.6 million and \$2.8 million in 2022 and 2021, respectively. During 2022, the average interest rate on the University's tax-exempt variable demand bonds was 0.85% and taxable variable bonds was 2.68%. Related indices for this period were 0.44% for tax-exempt debt (SIFMA), and 0.66% for taxable debt.

As of August 31, 2022 the aggregate annual maturities of bonds and notes payable for the next five years and thereafter are as follows (in thousands):

	2022
PAYABLE IN FISCAL YEAR:	
2023	\$ 11,345
2024	11,450
2025	9,990
2026	290,610
2027	11,825
Thereafter	2,383,410
	2,718,630
Unamortized net premium	238,788
Unamortized net bond issuance costs	(9,972)
	\$ 2,947,446

During fiscal year 2022, the University funded \$450.0 million for general corporate purposes with proceeds from the University's issuance of the 2022 Series A, 2022 Series B, 2022 Series C-1 and 2022 C-2 bonds. Additionally, the University refunded its 2013 Series B bonds totaling \$135.1 million with proceeds from the University's issuance of 2022 Series A bonds.

The 2008 taxable Commercial Paper program of \$350.0 million had an outstanding balance of \$0.0 million and \$0.0 million, as of August 31, 2022 and 2021, respectively, under this program. On December 5, 2022, December 6, 2022, and December 12, 2022, the University issued \$75.0 million of 60-day commercial paper, \$75.0 million of 60-day commercial paper, and \$75 million of 30-day commercial paper, respectively, under this program.

The University has three credit facilities to enable the University to purchase tendered variable rate debt in the event of a failed remarketing. It has a direct-pay letter of credit supporting the 2022 C-1 bonds totaling \$110.45 million, a standby bond purchase agreement supporting 2022C-2 bonds totaling \$110.45 million, and a revolving credit agreement supporting any self-liquidity debt totaling \$175.0 million. These credit facilities are committed for the sole purposes of supporting these debt instruments and cannot be used for operating needs of the University. There were no draws against any of these facilities in 2022 or 2021.

The University has a syndicated line of credit of \$750.0 million that expires April 2026. There is no outstanding balance as of August 31, 2022, and 2021.

The University has a letter of credit with a commercial bank totaling \$1.1 million. There were no outstanding balances as of August 31, 2022 or 2021. The letter of credit agreement expires March 2023.

The terms of the University's long-term debt provide for certain financial and nonfinancial covenants, including provisions as to the use of the proceeds, limits as to arbitrage and bond issuance costs, and various other administrative requirements.

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2022 AND 2021

(13) Net Assets

The following is a summary of net assets as of August 31 (in thousands):

	2022			2021		
	Without Donor Restrictions	With Donor Restrictions	Total	Without Donor Restrictions	With Donor Restrictions	Total
Emory undesignated funds	\$ 1,924,345	–	1,924,345	\$ 1,742,921	–	1,742,921
Endowment funds	2,205,380	5,105,457	7,310,837	2,357,212	5,617,776	7,974,988
Investment in plant	1,431,506	–	1,431,506	1,535,380	–	1,535,380
Interest in perpetual funds held by others	–	1,682,142	1,682,142	–	1,848,427	1,848,427
Contributions receivable, net	–	181,811	181,811	–	180,994	180,994
Annuity and other split-interest agreements	–	9,598	9,598	–	12,081	12,081
Capital projects and other donor purposes	–	541,288	541,288	–	390,992	390,992
	\$ 5,561,231	7,520,296	13,081,527	\$ 5,635,513	8,050,270	13,685,783

(14) Retirement and Deferred Compensation Plans

The University has a defined-contribution plan under the Code, Section 403(b), covering eligible employees. The University contributes an amount equal to 6% of each eligible employee's compensation to the plan as well as a supplemental contribution of 3% based on a 1.5 to 1 match of employee contributions of up to 2% of compensation. Employer contributions cliff vest after three years of service.

Emory Healthcare sponsors a retirement plan, covering most full-time employees, under which annuities are purchased with contributions made by Emory Healthcare. Benefits to eligible employees were based on a formula defined in the plan. Benefits are paid as a monthly annuity at age 65 or an eligible employee can elect a reduced benefit as early as age 55. The benefits are vested only to the extent of the annuities purchased. Benefits were frozen as of 12/31/2011. Emory Healthcare also has a defined-contribution plan under the Code, Section 403(b), covering eligible employees. Emory Healthcare contributes an amount equal to 2% of each eligible employee's compensation to the plan as well as a supplemental contribution of up to 5% based on a 1 to 1 match of employee contributions of up to 4% for eligible employees with less than 10 years of service and 5% if 10 or more years of service. Employer contributions cliff vest after three years of service.

TEC sponsors a defined-contribution plan under the Code, Section 403(b), The Emory Clinic, Inc. Retirement Savings Plan covering eligible employees. TEC contributes an amount equal to 6% of each eligible employee's compensation to the plan as well

as a supplemental contribution of 3% based on a 1.5 to 1 match of employee contributions of up to 2% of compensation. Employer contributions cliff vest after three years of service.

Retirement expense totaled \$187.0 million and \$150.5 million during 2022 and 2021, respectively, and is included in fringe benefits expense in the accompanying consolidated statements of activities.

The University sponsors the Code Section 457(b) Deferred Compensation Plan primarily for the purpose of providing deferred compensation for a select group of management or highly compensated employees who are eligible for participation and elect to make salary deferrals under the Deferred Compensation Plan. These assets are fully vested and available to the participating employees at the time of termination of employment from the University. As of August 31, 2022 and 2021, respectively, the University held assets of \$192.7 million and \$215.7 million under the Retirement Plan. These assets are included in other assets, which are designated by the University to pay future salary deferral plan payments. The assets are held in separate investment funds for which the majority are classified as Level 1 in the fair value hierarchy. Associated liabilities for the obligations of \$192.7 million and \$215.7 million as of August 31, 2022 and 2021, respectively, are included in accrued liabilities for benefit obligations and professional liabilities and considered Level 2 in the fair value hierarchy.

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2022 AND 2021

(15) Pension Plans – Emory Healthcare

Emory Healthcare sponsors a defined-benefit pension plan (the Plan). The Plan was curtailed effective December 31, 2011. The terms of the curtailment generally provide that no further benefit accrual under the Plan is provided for service after the effective date nor will new entrants into the Plan be permitted after the effective date.

The Plan’s investment objectives are to protect long-term asset value by applying prudent, low-risk, high-quality investment disciplines and to enhance the values by maximizing investment returns through active security management within the framework of the Plan’s investment policy. Asset allocation strategies and investment management structure are designed to meet the Plan’s investment objectives.

The Plan’s expected long-term rate of return on assets is determined by reviewing the historical return of each asset category comprising the Plan’s target asset allocation.

The Joint Operating Company (JOC) assumed certain defined-benefit pension liabilities covering certain employees of the entities contributed to the JOC by Saint Joseph’s Health System SJHS (the SJHS Pension Plan). The plan was curtailed, effective December 31, 2011, and the JOC has agreed to provide for funding of the plan, generally over 10 years, beginning in fiscal year 2015, subject to certain terms and conditions.

The SJHS Pension Plan’s expected long-term rate of return on assets is determined by reviewing the historical return of each asset category comprising the plan’s target asset allocation.

The accumulated benefit obligations at August 31, 2022 and 2021 are the same as the projected benefit obligations. The changes in the projected benefit obligations as of and for the years ended August 31 are as follows (in thousands):

	2022		2021	
	Emory Healthcare	SJHS	Emory Healthcare	SJHS
Projected benefit obligation, beginning of year	\$ 432,841	176,584	\$ 430,110	180,725
Interest cost	9,884	4,634	9,724	4,803
Actuarial (gain) loss	(102,676)	(39,597)	2,454	(2,175)
Benefits paid	(10,773)	(7,047)	(9,447)	(6,769)
Projected benefit obligation, end of year	\$ 329,276	134,574	\$ 432,841	176,584

The changes in the fair value of plan assets, funded status of the plans, and the status of amounts recognized in the accompanying consolidated statements of financial position as of and for the years ended August 31 are as follows (in thousands):

	2022		2021	
	Emory Healthcare	SJHS	Emory Healthcare	SJHS
Fair Value of plan assets, beginning of year	\$ 369,401	163,431	\$ 319,729	144,088
Actual return on plan assets	(74,676)	(32,086)	51,255	18,727
Employer contributions	–	3,896	7,864	7,385
Benefits paid	(10,773)	(7,047)	(9,447)	(6,769)
Fair value of plan assets, end of year	\$ 283,952	128,194	\$ 369,401	163,431
Funded status - accrued pension cost recognized in the consolidated statements of financial position	\$ (45,324)	(6,381)	\$ (63,440)	(13,153)

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2022 AND 2021

The components of net periodic pension cost for the years ended August 31 are as follows (in thousands):

	2022		2021	
	Emory Healthcare	SJHS	Emory Healthcare	SJHS
Interest cost	\$ 9,884	4,634	\$ 9,724	4,803
Expected return on assets	(13,928)	(6,469)	(15,451)	(9,379)
Amortization of prior service cost	–	(438)	–	(438)
Amortization of net loss	3,342	2,035	3,731	2,487
Net periodic pension cost	\$ (702)	(238)	\$ (1,996)	(2,527)

Net periodic pension costs are recognized as employees render the services necessary to earn the pension benefits.

Weighted average assumptions used to determine benefit obligations in the accompanying consolidated statements of financial position as of August 31 are as follows:

	2022		2021	
	Emory Healthcare	SJHS	Emory Healthcare	SJHS
Discount rate	4.84%	4.84%	2.73%	2.68%
Expected long-term rate of return on plan assets	4.40	4.00	5.20	6.50

Weighted average assumptions used to determine net periodic pension cost for the years ended August 31 are as follows:

	2022		2021	
	Emory Healthcare	SJHS	Emory Healthcare	SJHS
Discount rate	2.73%	2.68%	2.78%	2.71%
Expected long-term rate of return on plan assets	4.40	4.00	5.20	6.50

The following tables summarize the plan assets, which are recorded at fair value as of August 31 as follows (in thousands):

	2022							
	Emory		Total	Fair Value Hierarchy			Total Fair Value	Target ⁽¹⁾ Allocation
	Healthcare	SJHS		Level 1	Level 2	NAV		
INVESTMENTS:								
Short-term investments and cash equivalents	\$ 3,942	6,141	10,083	8,343	–	1,740	10,083	—%
Public equity	89,406	34,298	123,704	10,602	75,510	37,592	123,704	64
Absolute return	15,850	–	15,850	–	–	15,850	15,850	4
Private equity/venture capital	9,829	–	9,829	–	–	9,829	9,829	2
Fixed income	164,925	87,755	252,680	6,180	239,194	7,306	252,680	30
Total investments	\$ 283,952	128,194	412,146	25,125	314,704	72,317	412,146	100%

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2022 AND 2021

	2021								
	Emory			Fair Value Hierarchy			Total	Target ⁽¹⁾	
	Healthcare	SJHS	Total	Level 1	Level 2	NAV	Fair Value	Allocation	
INVESTMENTS:									
Short-term investments and cash equivalents	\$ 1,075	5,780	6,855	4,422	–	2,433	6,855	—%	
Public equity	150,441	57,117	207,558	17,928	133,118	56,512	207,558	64	
Absolute return	31,539	–	31,539	12,825	–	18,714	31,539	4	
Private equity/venture capital	5,106	–	5,106	–	–	5,106	5,106	2	
Fixed income	181,240	100,534	281,774	9,199	269,675	2,900	281,774	30	
Total investments	\$ 369,401	163,431	532,832	44,374	402,793	85,665	532,832	100%	

⁽¹⁾ While each plan has an individual target asset allocation, the percentage represents the averages for all plans assets.

Cash Flows

Emory Healthcare expects to contribute \$0.0 million to the Emory Healthcare Pension Plan, and \$1.8 million to the SJHS Pension Plan during fiscal year 2023.

Other Items

Emory Healthcare uses the straight-line method to amortize prior service cost for both plans.

Expected Future Benefit Payments

Emory Healthcare annual future benefit payments, excluding lump-sum settlements, are expected to range from \$13.1 million to \$18.3 million for the next five years. SJHS Pension Plan annual future benefit payments, excluding lump-sum settlements, are expected to range from \$7.6 million to \$8.7 million for the next five years.

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2022 AND 2021

(16) Postretirement Healthcare and Life Insurance Benefits

The University sponsors a postretirement life insurance and healthcare benefits plan. Participants hired after 2002 pay the full retiree-specific premium equivalent and are therefore assumed to pay the full cost of their coverage. The University and Emory

Healthcare each fund a separate trust (VEBA Trust) for retiree health and life benefits. The assets of the VEBA Trust are invested primarily in equity and fixed-income securities. The University funds these benefits only to the extent of current retiree claims. The University measures its participation in the VEBA Trust at August 31 each fiscal year.

The changes in the accumulated postretirement benefit obligation (APBO) as of August 31 are as follows (in thousands):

	2022			2021	
	Emory University	Emory Healthcare	Total	Total	
APBO, beginning of year	\$ 141,553	73,540	215,093	\$	209,579
Service cost	2,050	490	2,540		2,437
Interest cost	3,229	1,621	4,850		4,651
Actuarial losses (gains)	(44,927)	(19,063)	(63,990)		5,249
Benefits paid	(4,590)	(2,742)	(7,332)		(6,823)
APBO, end of year	\$ 97,315	53,846	151,161	\$	215,093

Discount rate to determine APBO as of August 31, 2022 and 2021 was 4.8% and 2.7%, respectively.

The changes in the fair value of plan assets, funded status of the plan, and the status of the accrued postretirement benefit obligation recognized in the accompanying consolidated statements of financial position as of and for the years ended August 31 are as follows (in thousands):

	2022			2021	
	Emory University	Emory Healthcare	Total	Total	
Fair value of plan assets, beginning of year	\$ 97,662	19,513	117,175	\$	97,783
Actual return on plan assets	(13,225)	(2,816)	(16,041)		19,392
Fair value of plan assets, end of year	\$ 84,437	16,697	101,134	\$	117,175
Funded status – accrued postretirement benefit cost recognized in the consolidated statements of financial position	\$ (12,878)	(37,149)	(50,027)	\$	(97,918)

The components of net periodic postretirement benefit cost for the years ended August 31 are as follows (in thousands):

	2022			2021	
	Emory University	Emory Healthcare	Total	Total	
Service cost of benefits earned	\$ 2,050	490	2,540	\$	2,437
Interest cost on APBO	3,229	1,621	4,850		4,651
Expected return on plan assets	(5,713)	(1,142)	(6,855)		(6,405)
Recognized net actuarial loss	2,670	2,876	5,546		6,946
Net periodic postretirement benefit cost	\$ 2,236	3,845	6,081	\$	7,629

Discount rate and expected return on plan assets used to determine net periodic postretirement benefit cost for the years ended August 31, 2022 and 2021 was 2.7% and 2.8%, respectively, and 5.9% and 6.6%, respectively.

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2022 AND 2021

The amounts accumulated in net assets without donor restrictions follow as of August 31 (in thousands):

	2022			2021	
	Emory University	Emory Healthcare	Total	Total	
Net unrecognized actuarial loss	\$ 27,861	8,064	35,925	\$ 82,595	
Prior service cost	(26)	–	(26)	(56)	
Total	\$ 27,835	8,064	35,899	\$ 82,539	

In fiscal year 2023, net unrecognized actuarial losses of \$1.3 million for Emory University and \$0.4 million for Emory Healthcare are expected to be amortized from net assets without donor restrictions into net periodic postretirement benefit cost.

Plan Assets

The Investment Committee of Emory University’s Board of Trustees approves the investment guidelines and asset allocation targets for the pension benefits and postretirement benefits plans.

The primary objective of the investments is to ensure the solvency of the plans over time to meet plan obligations. The secondary objective is to meet or exceed the plans’ actuarial assumed rate of return over time without taking excess risk. The funds are diversified by asset class in accordance with established allocation targets and rebalanced as needed. Specific investments are apportioned to a combination of institutional pooled funds and mutual funds.

The following table summarizes the VEBA Trust assets for the University and Emory Healthcare as of August 31 (in thousands):

	2022					
	Total Fair Value	Fair Value Hierarchy		NAV	Target Allocation	Total Asset Allocation
		Level 1	Level 2			
Fixed income	\$ 22,602	13,997	7,680	925	15%	22%
Public equity	63,126	6,650	36,597	19,879	70	62
Absolute return	11,658	5,985	–	5,673	10	12
Private equity/venture capital	3,621	–	–	3,621	5	4
Short-term investment and cash equivalent	127	127	–	–	–	–
Total investments	\$ 101,134	26,759	44,277	30,098	100%	100%

	2021					
	Total Fair Value	Fair Value Hierarchy		NAV	Target Allocation	Total Asset Allocation
		Level 1	Level 2			
Fixed income	\$ 19,215	9,784	9,431	–	15%	16%
Public equity	83,615	8,931	49,291	25,393	70	71
Absolute return	12,308	6,694	–	5,614	10	11
Private equity/venture capital	1,824	–	–	1,824	5	2
Short-term investment and cash equivalent	213	213	–	–	–	–
Total investments	\$ 117,175	25,622	58,722	32,831	100%	100%

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2022 AND 2021

Cash Flows

Emory University and Emory Healthcare expect to contribute \$4.8 million and \$0.0 million, respectively, to the postretirement benefit plan during fiscal year 2023.

Expected Future Benefit Payments

Annual future benefit payments are expected to range from \$4.8 million to \$5.4 million for Emory University and from \$2.8 million to \$3.2 million for Emory Healthcare for the next five years.

(17) Functional Expenses

The accompanying consolidated statements of activities present expenses by natural classification. The University also

summarizes expenses by functional classification, in accordance with its mission. The University's primary program services are instruction, research, public service, and the delivery of healthcare and medical services. Expenses for academic support, institutional support, and independent operations/auxiliary enterprises are generally incurred in support of these primary program activities, with academic support being related to student financial aid. Capital and plant expenditures, costs for operation and maintenance of plant, interest on indebtedness, and depreciation and amortization are allocated using a variety of cost allocation techniques, such as square footage and time and effort.

The accompanying consolidated statements of activities include the following functional expenses for the years ended August 31 (in thousands, net of the cost allocations and recharges referenced above):

2022

		Instruction	Research	Academic Support and Scholarship and Fellowship	Institutional Support	Public Service	*Healthcare and Medical Services	Independent Operations and Auxiliary	Total
Salaries	\$	322,298	298,911	101,095	164,625	63,588	3,079,183	108,497	4,138,197
Fringe benefits		81,560	79,711	27,199	50,305	17,212	589,987	32,908	878,882
Student financial aid		–	–	28,166	–	–	–	–	28,166
Other operating expenses		72,688	248,567	66,232	34,326	48,432	2,048,011	22,979	2,541,235
Interest on indebtedness		6,144	9,780	3,907	1,972	1,544	36,146	16,685	76,178
Depreciation and amortization		30,780	51,527	18,582	26,637	8,472	165,349	18,367	319,714
Total expenses	\$	513,470	688,496	245,181	277,865	139,248	5,918,676	199,436	7,982,372

* Healthcare and Medical Services – The portion of patient care services related to Emory Healthcare expense is \$5.7 billion. Healthcare administrative costs are \$549.0 million, included therein.

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2022 AND 2021

2021

		Instruction	Research	Academic Support and Scholarship and Fellowship	Institutional Support	Public Service	*Healthcare and Medical Services	Independent Operations and Auxiliary	Total
Salaries	\$	305,359	265,913	90,250	155,355	58,372	2,628,942	97,475	3,601,666
Fringe benefits		80,373	74,468	25,061	28,524	16,650	539,118	35,404	799,598
Student financial aid		–	–	28,678	–	–	–	–	28,678
Other operating expenses		54,970	210,471	58,698	26,322	45,565	1,921,526	29,538	2,347,090
Interest on indebtedness		6,338	10,089	4,029	2,034	1,594	32,144	18,731	74,959
Depreciation and amortization		30,007	50,238	18,115	25,967	8,259	161,504	21,316	315,406
Total expenses	\$	477,047	611,179	224,831	238,202	130,440	5,283,234	202,464	7,167,397

* Healthcare and Medical Services – The portion of patient care services related to Emory Healthcare expense is \$5.0 billion. Healthcare administrative costs are \$432.1 million, included therein.

Costs related to the University's operation and maintenance of property, including depreciation of property and equipment and interest on related debt, are allocated to program and supporting activities based upon information reported in the space study and debt financing records. Total amounts allocated in 2022 and 2021 were \$205.0 million and \$190.6 million, respectively. Fundraising costs were approximately \$46.7 million and \$41.3 million in 2022 and 2021, respectively.

(18) Medical Professional and General Liability Insurance Coverage

CCIC, Emory Healthcare's wholly owned offshore captive insurer, provides claims-made primary medical professional and general liability coverage for the University, the Hospitals, Emory Clinic, Emory Specialty Associates, and Wesley Woods Center.

As of August 31, 2022 and 2021, the University has recorded an accrual for estimated losses associated with all retained CCIC risks of approximately \$274.4 million (discounted at 2.5%) and \$255.5 million (discounted at 2.5%), respectively.

Emory has purchased layered excess and umbrella insurance and reinsurance coverage beyond the amounts retained by CCIC, through various carriers, for a total of \$110.0 million per claim and in the aggregate.

The estimated liability for professional and general liability claims will be significantly affected if current and future claims differ from historical trends. While the University monitors reported claims closely and considers potential outcomes as estimated by its actuaries when determining its professional and

general liability accruals, the complexity of the claims, the extended period of time to settle the claims, and the wide range of potential outcomes complicate the estimation. The University's management believes adequate provision has been made for the related risk.

(19) Related-Party Transactions

The Carter Center, Inc. (CCI) is a nonprofit organization founded by former U.S. President Jimmy Carter and Rosalynn Carter, which sponsors various domestic and international programs. The Board of Trustees of CCI comprises 16 to 28 members, including its founders, and others as elected half by the University, including the University's president, and half by the Carter Center class trustees. The University's Board of Trustees has the authority to approve amendments to CCI's articles of incorporation and bylaws. Funds held in trust for others include \$1.048 billion and \$1.165 billion, representing CCI's investment in the University's long-term investment portfolio as of August 31, 2022 and 2021, respectively. CCI is permitted partial withdrawals of up to 10% per year (inclusive of regular spending payouts), with 30 days' written notice prior to a calendar quarter or fiscal year end. A full withdrawal request by CCI requires at least one year's written notice and is subject to a multi-year distribution schedule in line with the duration of the long-term investment portfolio, as agreed upon by both CCI and the University.

Emory University and Children's Healthcare of Atlanta, Inc. (Children's), a Georgia nonprofit corporation, established the Emory + Children's Pediatric Institute (the Institute) effective September 1, 2018 under a Master Affiliation Agreement (the

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2022 AND 2021

affiliation agreement). Under the terms of the affiliation agreement, approximately 350 Emory University School of Medicine Department of Pediatrics faculty physicians and PhD researchers transferred to the Institute and became employees thereof. The affiliation agreement restructured previous arrangements between the parties for pediatric teaching, research, and related clinical services. The ownership of the Institute is 50% Emory University and 50% Children's, with equal representation on the governing board. The funding obligations of each party are specified by the affiliation agreement, and each party funds its mission-related expenses. The University reports research and teaching expenses provided by the faculty members in salaries, fringe benefits, professional fees and purchased services, and other operating expenses in the accompanying consolidated statements of activities.

(20) Commitments and Contingencies

Purchase Commitments

Emory University and Emory Healthcare are in the process of constructing, renovating, and equipping certain facilities for which the outstanding commitments at August 31, 2022 and 2021 totaled \$203.9 million and \$217.7 million, respectively.

As part of the terms of the Definitive Agreement to acquire DRHS, Emory Healthcare committed \$239.0 million on capital projects to benefit DRHS and its affiliates over a 7-year period, beginning September 1, 2018. Such period may be extended under certain circumstances to a period of no more than 10 years. The outstanding commitment amount based on the terms of the Definitive Agreement totaled approximately \$69.0 million as of August 31, 2022.

Federal and State Regulatory Matters

Expenditures and indirect costs related to federal and state grants and contracts are subject to adjustment based upon review by the granting agencies. The amounts, if any, of expenditures which may be disallowed by the granting agencies, cannot have a material effect on the University's consolidated financial statements.

The University is subject to many federal and state regulations, and as a result, there may be one or more pending government investigations ongoing at any time. While the outcome of these actions is not presently determinable, it is the opinion of management that any resulting liability from these actions will not have a material adverse effect on the accompanying consolidated statements of financial position.

Other Legal Matters

Lawsuits and claims have been filed against the University in the ordinary course of business. As one of the nation's largest research universities and academic medical centers, the University has active litigation that takes several forms. The University's policy is to accrue for litigation and claims when such amounts are probable and can be reasonably estimated based on consultation with external legal counsel and Emory General Counsel. The University also has a comprehensive program of primary and excess insurance.

Emory Healthcare and SJHS have a JOC under the name of Emory/Saint Joseph's, Inc. to further the respective missions of Emory Healthcare and CHE Trinity Health. Under the JOC Contribution Agreement, Emory Healthcare maintains a 51% controlling ownership interest in the JOC. SJHS has a noncontrolling membership interest in the JOC of 49%. Effective August 31, 2014, CHE Trinity Health has a put right, as defined in the JOC Contribution Agreement, that may be exercised at any time with written notice to Emory Healthcare. Upon the occurrence of such event, Emory Healthcare may be required to purchase from SJHS its noncontrolling interest in the JOC. On March 25, 2022, CHE Trinity Health filed a complaint against Emory Healthcare in the Superior Court of Fulton County, Georgia, alleging breach of contract relating to a potential sale of CHE Trinity Health's 49% membership interest in the JOC. CHE Trinity Health seeks, among other things, a judgment ordering specific performance requiring Emory Healthcare to close the purchase of CHE Trinity Health's membership interest in the JOC and pay a purchase price of \$392.0 million. In the event Emory Healthcare closes the purchase of CHE Trinity's membership interest in the JOC, Emory Healthcare has sufficient sources of available liquidity to consummate the transaction.

The University is a defendant along with sixteen other universities in a putative class action lawsuit, *Carbone, et al. v. Brown University, et al.*, where the plaintiffs allege antitrust violations related to the award of need-based financial aid. The case is in the United States District Court for the Northern District of Illinois. The Court denied defendants' motions to dismiss the case and ordered the case to move forward to discovery.

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2022 AND 2021

(21) Subsequent Events

Emory has evaluated subsequent events after the accompanying consolidated statements of financial position date of August 31, 2022 through December 19, 2022, the date the consolidated financial statements were issued and noted that there are no other items to disclose that would have a material impact on the University's accompanying consolidated statements of financial position.



KPMG LLP
Suite 2000
303 Peachtree Street, N.E.
Atlanta, GA 30308-3210

Independent Auditors' Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With *Government Auditing Standards*

The Board of Trustees
Emory University:

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States, the consolidated financial statements of Emory University and its subsidiaries (the University), which comprise the University's consolidated statement of financial position as of August 31, 2022, and the related consolidated statements of activities and cash flows for the year then ended, and the related notes to the consolidated financial statements, and have issued our report thereon dated December 19, 2022.

Report on Internal Control Over Financial Reporting

In planning and performing our audit of the consolidated financial statements, we considered the University's internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the consolidated financial statements, but not for the purpose of expressing an opinion on the effectiveness of the University's internal control. Accordingly, we do not express an opinion on the effectiveness of the University's internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A material weakness is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected, on a timely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit, we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that were not identified.

Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether the University's consolidated financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.



Purpose of This Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the entity's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

KPMG LLP

Atlanta, Georgia
December 19, 2022

**SUPPLEMENTARY SCHEDULE OF EXPENDITURES OF
FEDERAL AWARDS**

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2022

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Research and Development Cluster:				
U.S. Department of Agriculture:				
Agriculture Research Basic and Applied Research Pass-through CRDF Global	DAA9-19-65373-1	10.001	\$ —	29,323
Total AL No. 10.001			—	29,323
Agriculture and Food Research Initiative (AFRI)	2019-67013-29371	10.310	—	208,683
Agriculture and Food Research Initiative (AFRI)	20196701729642	10.310	—	152,512
Agriculture and Food Research Initiative (AFRI)	20206703431728	10.310	—	48,936
Agriculture and Food Research Initiative (AFRI)	20216703435147	10.310	—	46,472
Agriculture and Food Research Initiative (AFRI)	20226701338133	10.310	12,511	115,615
Pass-through Kansas State University	20206701931157	10.310	—	123,485
Total AL No. 10.310			12,511	695,703
Crop Protection and Pest Management Competitive Grants Program			—	—
Pass-through North Carolina State University	20187000828884	10.329	—	8,836
Total AL No. 10.329			—	8,836
U.S. Department of Agriculture Total			12,511	733,862
U.S. Department of Defense:				
Scientific Research – Combating Weapons of Mass Destruction	HDTRA11810029	12.351	89,312	187,243
Total AL No. 12.351			89,312	187,243
Military Medical Research and Development	W81XWH-12-0255	12.420	—	192
Military Medical Research and Development	W81XWH-15-1-0154	12.420	7,054	7,054
Military Medical Research and Development	W81XWH-17-1-0271	12.420	—	6,121
Military Medical Research and Development	W81XWH1810526	12.420	—	108,886
Military Medical Research and Development	W81XWH1810700	12.420	—	453,819
Military Medical Research and Development	W81XWH-18-KCRP-CA	12.420	—	5,163
Military Medical Research and Development	W81XWH-19-1-0069	12.420	46,308	650,670
Military Medical Research and Development	W81XWH1910498	12.420	228,186	541,714
Military Medical Research and Development	W81XWH1910567	12.420	—	2,229
Military Medical Research and Development	W81XWH1910776	12.420	—	394,747
Military Medical Research and Development	W81XWH1910840	12.420	—	234,613
Military Medical Research and Development	W81XWH2010052	12.420	—	(1,465)
Military Medical Research and Development	W81XWH2010446	12.420	—	38,705
Military Medical Research and Development	W81XWH2010525	12.420	—	205,494
Military Medical Research and Development	W81XWH2010526	12.420	—	152,062
Military Medical Research and Development	W81XWH2010643	12.420	—	2,929
Military Medical Research and Development	W81XWH2110124	12.420	—	226,508
Military Medical Research and Development	W81XWH2110237	12.420	29,715	145,434
Military Medical Research and Development	W81XWH2210073	12.420	—	28,934
Military Medical Research and Development	W81XWH2210338	12.420	—	4,406
Military Medical Research and Development	W81XWH-17-1-0634	12.420	—	(24,725)
Military Medical Research and Development	W81XWH-17-C-0229	12.420	—	271,193
Pass-through Georgia Institute of Technology	W81XWH-18-1-0669	12.420	—	10,170
Pass-through Georgia Institute of Technology	W81XWH-20-1-0649	12.420	—	31,535
Pass-through Public Health Institute	03227-AR04000	12.420	—	139,006
Pass-through University of Arizona	W81XWH-17-1-0443	12.420	—	950,255
Pass-through University of Maryland, Baltimore	066469933	12.420	—	36,470
Pass-through Wayne State University	W81XWH-19-1-0794	12.420	—	90,607
Total AL No. 12.420			311,263	4,712,726
Basic, Applied, and Advanced Research in Science and Engineering			—	—
Pass-through University of Washington	W911NF1910291	12.630	—	4,346
Total AL No. 12.630			—	4,346
Uniformed Services University Medical Research Projects:				
Pass-through Duke University	HT9404-13-0032	12.750	—	(59)
Pass-through Henry M Jackson Foundation	HU00012020018	12.750	—	(572)
Pass-through Henry M Jackson Foundation	HU00012120029	12.750	—	962,667
Total AL No. 12.750			—	962,036
Air Force Defense Research Sciences Program	FA9550-18-1-0189	12.800	—	4,885
Air Force Defense Research Sciences Program	FA9550-18-1-0420	12.800	1,167,226	1,331,765
Air Force Defense Research Sciences Program	FA9550-20-1-0372	12.800	—	132,214
Air Force Defense Research Sciences Program	FA9550-20-1-0411	12.800	—	160,925
Pass-through Georgia State University	FA95501510373	12.800	—	6,105
Total AL No. 12.800			1,167,226	1,635,894
Language Grant Program	H98230-20-1-0232	12.900	—	2,363
Total AL No. 12.900			—	2,363
Research and Technology Development:				
Pass-through Georgia Institute of Technology	HR001117C0124	12.910	—	3,226
Pass-through Georgia Institute of Technology	HR0011-19-2-0008	12.910	—	1,384,241
Pass-through Johns Hopkins University	2019-190516000005	12.910	—	169,579
Pass-through Vanderbilt University Medical Center	066469933	12.910	—	33,039
Total AL No. 12.910			—	1,590,085
Contract	W911NF-16-C-0008	12.RD	8,983	8,906
Contract	0011751760	12.RD	—	3,674
Contract	W81XWH	12.RD	—	71,266
Contract	W81XWH1810505	12.RD	—	47,740
Contract	W81XWH1910281	12.RD	—	168,652
Contract	W81XWH1910353	12.RD	—	165,984
Contract	W81XWH1910420/P00001	12.RD	—	32,739
Contract	W81XWH2110213	12.RD	—	204,732
Pass-through Coalition For National Trauma Research	W81XWH-15-9-001	12.RD	—	36,437
Pass-through Geneva Foundation	W81XWH-17-C-0029	12.RD	—	119,798
Pass-through Henry M Jackson Foundation	W81XWH-15-9-0001	12.RD	—	17,616
Pass-through North Carolina State University	W911NF	12.RD	—	59,752
Pass-through University of Dayton	FA8651-20-F-1024	12.RD	—	114,852
Pass-through University of Michigan	W911QX17D0006	12.RD	—	2,246
Total AL No. 12.RD			8,983	1,054,394
U.S. Department of Defense Total			1,576,784	10,149,087

EMORY UNIVERSITY AND ITS SUBSIDIARIES
Supplementary Schedule of Expenditures of Federal Awards
Year ended August 31, 2022

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
U.S. Department of Justice:				
National Institute of Justice Research, Evaluation, and Development Project Grants:				
Pass-through George Mason University	2019-R2-CX-0005	16.560	\$ —	3,314
Total AL No. 16.560			—	3,314
U.S. Department of Justice Total			—	3,314
U.S. Department of State:				
Academic Exchange Programs – Hubert H. Humphrey Fellowship Program				
Pass-through Institute of International Education	SECAGD21CA3001	19.010	—	45,309
Total AL No. 19.010			—	45,309
Contract				
Pass-through Health Through Walls	SHAPE/HHW09202002	19.RD	—	58,385
Total AL No. 19.RD			—	58,385
U.S. Department of State Total			—	103,694
U.S. Department of Transportation:				
National Priority Safety Programs:				
Pass-through Governors Office of Highway Safety	69A375193000405BGAH	20.616	—	170,814
Total AL No. 20.616			—	170,814
Contract				
DTNH2217F00160	DTNH2217F00160	20.RD	6,716	485,677
Total AL No. 20.RD			6,716	485,677
U.S. Department of Transportation Total			6,716	656,491
National Aeronautics and Space Administration:				
Science	80NSSC19K0191	43.001	126,564	163,713
Science	80NSSC21K0507	43.001	13,940	133,457
Science	80NSSC22K0292	43.001	—	16,848
Science	NNX16AQ28G 000004	43.001	—	(2,857)
Pass-through California Institute of Technology	1588347	43.001	—	184,773
Pass-through University of Georgia	80NSSC20K0360	43.001	—	84,680
Total AL No. 43.001			140,504	580,614
Aeronautics				
Pass-through California Institute of Technology	NMO710860	43.002	—	25,383
Total AL No. 43.002			—	25,383
Exploration	80NSSC188K1116	43.003	—	226,892
Exploration	80NSSC21K0251	43.003	—	30,678
Total AL No. 43.003			—	257,570
National Aeronautics and Space Administration Total			140,504	863,567
National Endowment for the Humanities:				
Promotion of the Humanities Division of Preservation and Access	HAA- 281011-21	45.149	—	55,175
Promotion of the Humanities Division of Preservation and Access	PW- 277494-21	45.149	2,202	61,821
Total AL No. 45.149			2,202	117,096
Promotion of the Humanities Research	RQ-260871-18	45.161	—	45,699
Promotion of the Humanities Research	RZ-271209-20	45.161	—	33,443
Total AL No. 45.161			—	79,142
Promotion of the Humanities Professional Development	AV-279598-21	45.163	—	53,711
Total AL No. 45.163			—	53,711
National Endowment for the Humanities Total			2,202	249,949
National Science Foundation:				
Engineering	1741691	47.041	2,235	97,910
Engineering	1762211	47.041	—	99,723
Engineering	1804198	47.041	—	59,767
Engineering	1807568	47.041	—	55,770
Engineering	1822606	47.041	10,760	(42)
Engineering	184186	47.041	—	59,367
Engineering	1926387	47.041	—	107,862
Engineering	2002815	47.041	—	61,899
Engineering	2005786	47.041	—	77,406
Engineering	2044657	47.041	—	124,984
Pass-through Georgia Institute of Technology	1749677	47.041	—	18,965
Pass-through Georgia Institute of Technology	EEC-1648035	47.041	—	9,678
Pass-through Indiana University	1928481	47.041	—	126,057
Total AL No. 47.041			12,995	899,346
Mathematical and Physical Sciences	1555048	47.049	—	3,668
Mathematical and Physical Sciences	1557960	47.049	—	(14,872)
Mathematical and Physical Sciences	1654485	47.049	—	64,196
Mathematical and Physical Sciences	1700982	47.049	2,295,759	3,553,243
Mathematical and Physical Sciences	1751636	47.049	—	66,683
Mathematical and Physical Sciences	1764385	47.049	—	64,767
Mathematical and Physical Sciences	1801951	47.049	—	15
Mathematical and Physical Sciences	1807865	47.049	—	(10)
Mathematical and Physical Sciences	1808288	47.049	—	70,326
Mathematical and Physical Sciences	1808771	47.049	—	104,529
Mathematical and Physical Sciences	1809566	47.049	—	161,506
Mathematical and Physical Sciences	1819042	47.049	—	114,828
Mathematical and Physical Sciences	1900532	47.049	—	116,395
Mathematical and Physical Sciences	1900555	47.049	—	821
Mathematical and Physical Sciences	1902260	47.049	—	19,120
Mathematical and Physical Sciences	1904805	47.049	—	65,557
Mathematical and Physical Sciences	1905782	47.049	—	132,345
Mathematical and Physical Sciences	1905809	47.049	—	146,746
Mathematical and Physical Sciences	1905947	47.049	—	126,680
Mathematical and Physical Sciences	1951682	47.049	—	60,295
Mathematical and Physical Sciences	1956154	47.049	—	67,261
Mathematical and Physical Sciences	2003157	47.049	—	41,178

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2022

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Mathematical and Physical Sciences	2003692	47.049	\$ —	286,286
Mathematical and Physical Sciences	2003962	47.049	—	126,647
Mathematical and Physical Sciences	2003987	47.049	—	58,980
Mathematical and Physical Sciences	2004080	47.049	—	178,955
Mathematical and Physical Sciences	2004126	47.049	—	130,149
Mathematical and Physical Sciences	2004846	47.049	—	202,526
Mathematical and Physical Sciences	2010524	47.049	—	154,216
Mathematical and Physical Sciences	2012686	47.049	—	52,663
Mathematical and Physical Sciences	2014173	47.049	—	91,566
Mathematical and Physical Sciences	2015540	47.049	—	85,836
Mathematical and Physical Sciences	2038019	47.049	—	118,998
Mathematical and Physical Sciences	2038118	47.049	—	16,875
Mathematical and Physical Sciences	2051019	47.049	—	128,382
Mathematical and Physical Sciences	2055579	47.049	—	100,586
Mathematical and Physical Sciences	2103515	47.049	—	55,697
Mathematical and Physical Sciences	2108290	47.049	—	77,068
Mathematical and Physical Sciences	2108621	47.049	—	196,627
Mathematical and Physical Sciences	2108774	47.049	—	61,990
Mathematical and Physical Sciences	2113350	47.049	—	49,876
Mathematical and Physical Sciences	2143815	47.049	—	23,888
Mathematical and Physical Sciences	2146260	47.049	—	19,925
Mathematical and Physical Sciences	2205266	47.049	—	42,337
Mathematical and Physical Sciences	2206187	47.049	—	19,487
Mathematical and Physical Sciences	2208294	47.049	—	40,566
Pass-through Georgia Institute of Technology	1806833	47.049	—	82,549
Total AL No. 47.049			2,295,759	7,367,952
Geosciences:				
Pass-through Natl Center For Atmospheric Research	1641177	47.050	—	13,716
Pass-through Natl Center For Atmospheric Research	1755088	47.050	—	25,293
Pass-through Rutgers University	2108984	47.050	—	61,446
Total AL No. 47.050			—	100,455
Computer and Information Science and Engineering	1722906	47.070	—	19,296
Computer and Information Science and Engineering	1835364	47.070	—	102,704
Computer and Information Science and Engineering	1838200	47.070	—	220,750
Computer and Information Science and Engineering	1907711	47.070	—	100,787
Computer and Information Science and Engineering	1952192	47.070	—	29,543
Computer and Information Science and Engineering	2003720	47.070	—	102,632
Computer and Information Science and Engineering	2027783	47.070	—	9,891
Computer and Information Science and Engineering	2103592	47.070	—	35,009
Computer and Information Science and Engineering	2103745	47.070	—	120
Computer and Information Science and Engineering	2106359	47.070	—	140,849
Computer and Information Science and Engineering	2106446	47.070	109,510	187,833
Computer and Information Science and Engineering	2110926	47.070	66,323	230,638
Computer and Information Science and Engineering	2124104	47.070	—	88,306
Computer and Information Science and Engineering	2125530	47.070	—	43,561
Computer and Information Science and Engineering	2145411	47.070	—	2,134
Pass-through Georgia Institute of Technology	1915504	47.070	—	73,545
Pass-through University of Arizona	118-1838745	47.070	—	8,253
Pass-through University of Virginia	2041952	47.070	—	9,965
Total AL No. 47.070			175,833	1,405,816
Biological Sciences	1624104	47.074	—	77,766
Biological Sciences	1656247	47.074	2,908	2,370
Biological Sciences	1750553	47.074	—	165,479
Biological Sciences	1754431	47.074	—	328
Biological Sciences	1754595	47.074	—	307,293
Biological Sciences	1755002	47.074	—	69,362
Biological Sciences	1755418	47.074	—	69,438
Biological Sciences	1844803	47.074	34,960	45,983
Biological Sciences	1919953	47.074	—	98,857
Biological Sciences	1922720	47.074	—	160,188
Biological Sciences	1927411	47.074	—	25,709
Biological Sciences	1931697	47.074	—	301,968
Biological Sciences	1943415	47.074	—	3,749
Biological Sciences	2032610	47.074	—	38,466
Biological Sciences	2050009	47.074	—	186,348
Biological Sciences	2106137	47.074	—	84,759
Biological Sciences	2207028	47.074	—	42,675
Pass-through Case Western Reserve University	DBI-2015317	47.074	—	185,507
Pass-through University of California Riverside	2119820	47.074	—	176,722
Total AL No. 47.074			37,868	2,042,967
Social, Behavioral, and Economic Sciences	1533260	47.075	—	24,378
Social, Behavioral, and Economic Sciences	1748293	47.075	—	79
Social, Behavioral, and Economic Sciences	1756853	47.075	—	12,540
Social, Behavioral, and Economic Sciences	1822877	47.075	—	103,947
Social, Behavioral, and Economic Sciences	1830816	47.075	—	10,683
Social, Behavioral, and Economic Sciences	1851501	47.075	—	23,890
Social, Behavioral, and Economic Sciences	1853185	47.075	—	19,611
Social, Behavioral, and Economic Sciences	1926075	47.075	—	31,302
Social, Behavioral, and Economic Sciences	1945046	47.075	—	100,347
Social, Behavioral, and Economic Sciences	1946767	47.075	—	480,875
Social, Behavioral, and Economic Sciences	1946768	47.075	—	59,396
Social, Behavioral, and Economic Sciences	1947845	47.075	—	8,798
Social, Behavioral, and Economic Sciences	1952882	47.075	—	44,178
Social, Behavioral, and Economic Sciences	2017425	47.075	—	79,598
Social, Behavioral, and Economic Sciences	2029678	47.075	—	3,477
Social, Behavioral, and Economic Sciences	2037376	47.075	—	44,049
Social, Behavioral, and Economic Sciences	2049460	47.075	—	8,124
Social, Behavioral, and Economic Sciences	2051553	47.075	—	140,448
Social, Behavioral, and Economic Sciences	2116355	47.075	—	8,005
Social, Behavioral, and Economic Sciences	2120917	47.075	—	6,905
Social, Behavioral, and Economic Sciences	2147325	47.075	—	10,358
Social, Behavioral, and Economic Sciences	2214544	47.075	—	1,490
Pass-through Case Western Reserve University	2129072	47.075	—	41,168
Pass-through Natl Bureau of Economic Research	1919372	47.075	—	12,567
Pass-through University of Colorado	2149191	47.075	—	11,061
Total AL No. 47.075			—	1,287,274

EMORY UNIVERSITY AND ITS SUBSIDIARIES
Supplementary Schedule of Expenditures of Federal Awards
Year ended August 31, 2022

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
STEM Education	1821533	47.076	\$ —	87,454
STEM Education	1937971	47.076	—	1,462,524
STEM Education	2010333	47.076	—	98,159
STEM Education	2142262	47.076	—	17,150
Total AL No. 47.076			—	1,665,287
Polar Programs	1949637	47.078	—	2,546
Polar Programs	2025795	47.078	—	78,908
Total AL No. 47.078			—	81,454
National Science Foundation Total			2,522,455	14,850,551
U.S. Environmental Protection Agency:				
Science to Achieve Results (STAR) Research Program	83479901	66.509	11,144	22,394
Science to Achieve Results (STAR) Research Program	84019801	66.509	10,000	196,039
Science to Achieve Results (STAR) Research Program	84042901	66.509	—	4,058
Pass-through Carleton University	4962-RFA17-2/18-4	66.509	—	6,564
Total AL No. 66.509			21,144	229,055
Solid Waste Management Assistance Grants	02D01621	66.808	—	171,678
Total AL No. 66.808			—	171,678
Environmental Education Grants	01D14720	66.951	5,000	24,314
Total AL No. 66.951			5,000	24,314
Contract				
Pass-through Health Effects Institute	CR-83998101	66.RD	44,003	107,146
Total AL No. 66.RD			44,003	107,146
U.S. Environmental Protection Agency Total			70,147	532,193
U.S. Department of Energy:				
Office of Science Financial Assistance Program	DE-FG02-01ER15153	81.049	—	143,242
Office of Science Financial Assistance Program	DE-FG02-07ER15906	81.049	—	344,087
Office of Science Financial Assistance Program	DE-SC0008798	81.049	—	40,365
Office of Science Financial Assistance Program	DE-SC0016004 MOD 0002	81.049	—	67,341
Office of Science Financial Assistance Program	DE-SC0018976	81.049	—	120,377
Office of Science Financial Assistance Program	DE-SC0019362	81.049	—	2,089
Office of Science Financial Assistance Program	DE-SC0019374	81.049	954,937	1,315,097
Office of Science Financial Assistance Program	DE-SC0020101	81.049	—	161,186
Office of Science Financial Assistance Program	DE-SC0020966/MOD #2	81.049	—	158,783
Office of Science Financial Assistance Program	DE-SC0021290	81.049	—	45,163
Office of Science Financial Assistance Program	DE-SC0022314	81.049	—	95,090
Pass-through University of North Carolina Chapel Hill	DE-SC0021173	81.049	—	225,963
Total AL No. 81.049			954,937	2,718,763
U.S. Department of Energy Total			954,937	2,718,763
U.S. Department of Education:				
Overseas Programs – Doctoral Dissertation Research Abroad	P022A210020	84.022	—	22,689
Total AL No. 84.002			—	22,689
Research in Special Education:				
Pass-through Florida State University	R324A180193	84.324	9,652	78,570
Total AL No. 84.324			9,652	78,570
Contract				
Pass-through Pacific Northwest National Laboratory	DE-AC05-76RL01830	84.RD	—	29,637
Total AL No. 84.RD			—	29,637
U.S. Department of Education Total			9,652	130,896
U.S. Department of Health and Human Services:				
Global AIDS	NU14GH001237	93.067	—	(3,021)
Total AL No. 93.067			—	(3,021)
Chronic Diseases: Research, Control, and Prevention:				
Pass-through American College of Rheumatology	NU58DP006908	93.068	—	13,820
Pass-through Natl Assoc of Chronic Disease Directors	5NU58DP006261-05	93.068	—	11,848
Total AL No. 93.068			—	25,668
Birth Defects and Developmental Disabilities – Prevention and Surveillance	NU50DD000057	93.073	—	519,713
Birth Defects and Developmental Disabilities – Prevention and Surveillance	NU50DD000098	93.073	—	291,649
Pass-through University of Iowa	U01DD001223	93.073	—	9,422
Total AL No. 93.073			—	820,784
Family Smoking Prevention and Tobacco Control Act Regulatory Research:				
Pass-through University of Michigan	U54CA229974	93.077	—	4,235
Total AL No. 93.077			—	4,235
Blood Disorder Program: Prevention, Surveillance, and Research:				
Pass-through Georgia State University	NU58DD0000021	93.080	3,714	5,978
Pass-through Georgia State University	NU58DD0000003	93.080	3,095	7,203
Pass-through Georgia State University	NU58DD0000021	93.080	—	6,999
Pass-through Hemophilia of Georgia	NU27DD0000020	93.080	—	4,552
Pass-through Hemophilia of Georgia	NU27DD0000020-02-00	93.080	—	29,360
Total AL No. 93.080			6,809	54,092
COVID-19 – Prevention of Disease, Disability, and Death by Infectious Diseases	U54CK000601	93.084	—	198,421
Prevention of Disease, Disability, and Death by Infectious Diseases	U54CK000601	93.084	—	351,791
Pass-through Johns Hopkins University	18U01CK000554	93.084	40,879	40,815
Pass-through State University of New York Albany	3-93075	93.084	—	100,358
Pass-through State University of New York Albany	NU38PS004650	93.084	5,550	355,639
Pass-through University of Illinois at Chicago	U01CK000557	93.084	—	731
Pass-through Yale University	U01CK000572	93.084	7,684	130,948
Total AL No. 93.084			54,113	1,178,703
Food and Drug Administration Research	R01FD004814	93.103	—	2,414
Food and Drug Administration Research	R01FD005746	93.103	—	279,994
Pass-through Critical Path Institute (C-Path)	U18FD005320	93.103	—	85,057
Pass-through Health And Environmental Sciences Inst	U01FD006676	93.103	—	8,377
Total AL No. 93.103			—	375,842
Maternal and Child Health Federal Consolidated Programs	T76MC28446	93.110	62,887	377,196
Pass-through Association of Public Health Labs	U22MC24078	93.110	—	15,000
Pass-through Organization of Teratology Information Specialists	UG4MC27861	93.110	—	59,128
Total AL No. 93.110			62,887	451,324

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2022

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Environmental Health	SR01ES023839-04S1	93.113	\$ —	(7,476)
Environmental Health	4P30R0019776-04	93.113	—	(173)
Environmental Health	D43ES030927	93.113	51,787	107,342
Environmental Health	F31ES031845	93.113	—	44,332
Environmental Health	F32ES031827	93.113	—	74,225
Environmental Health	F32ES033908	93.113	—	41,548
Environmental Health	F32ES034241	93.113	—	21,905
Environmental Health	K00ES033033	93.113	—	79,925
Environmental Health	K12ES033593	93.113	—	22,662
Environmental Health	P2CES033430	93.113	12,564	258,083
Environmental Health	P30ES019776	93.113	66,025	1,269,936
Environmental Health	R00ES026648	93.113	—	132,953
Environmental Health	R01ES025775	93.113	—	507,737
Environmental Health	R01ES026082	93.113	216,230	238,078
Environmental Health	R01ES027659	93.113	—	109,976
Environmental Health	R01ES027892	93.113	211,215	552,192
Environmental Health	R01ES028346	93.113	240,703	371,850
Environmental Health	R01ES029212	93.113	434,730	564,969
Environmental Health	R01ES031980	93.113	96,841	460,897
Environmental Health	R01ES032009	93.113	131,414	453,053
Environmental Health	R01ES032140	93.113	133,727	731,031
Environmental Health	R01ES032440	93.113	—	126,106
Environmental Health	R01ES032446	93.113	22,792	189,802
Environmental Health	R01ES033603	93.113	—	332,621
Environmental Health	R21ES028903	93.113	37,358	3,123
Environmental Health	R21ES031824	93.113	—	125,447
Environmental Health	R21ES032117	93.113	—	210,223
Environmental Health	R21ES032344	93.113	71,232	160,501
Environmental Health	R21ES032606	93.113	93,620	258,221
Environmental Health	R21ES034130	93.113	—	25,156
Environmental Health	R21ES034139	93.113	—	6,745
Environmental Health	R24ES028507	93.113	146,417	201,915
Environmental Health	R24ES028528	93.113	35,858	484,482
Environmental Health	R24ES029490	93.113	—	351,257
Environmental Health	R56ES033530	93.113	234,493	438,512
Environmental Health	T32ES012870	93.113	—	458,706
Pass-through Colorado State University	R01ES029965	93.113	—	7,891
Pass-through Johns Hopkins University	R01ES030414	93.113	—	29,141
Pass-through Rutgers University	R01ES032144	93.113	—	61,825
Pass-through University of Alabama Birmingham	U54ES030246	93.113	—	14,192
Pass-through University of Arizona	R01ES032392	93.113	—	38,861
Pass-through University of California Davis	R01ES028089	93.113	—	6,187
Pass-through University of Kentucky	R01ES032176	93.113	—	171,745
Pass-through University of Louisville	R01ES032189	93.113	—	333,156
Pass-through University of Michigan	R01ES032157	93.113	—	30,973
Pass-through University of Nevada	R01ES029528	93.113	—	11,100
Pass-through University of Southern California	R00ES027870	93.113	—	28,659
Pass-through University of Southern California	R01ES029944	93.113	—	18,535
Pass-through University of Southern California	R01ES032247	93.113	—	13,221
Pass-through Wayne State University	R01ES031584	93.113	—	104,448
Total AL No. 93.113			2,237,006	10,277,796
Preventive Medicine Residency	D33HP31663	93.117	—	277,426
Total AL No. 93.117			—	277,426
Oral Diseases and Disorders Research	F31DE030704	93.121	—	11,392
Oral Diseases and Disorders Research	R00DE026910	93.121	—	138,725
Oral Diseases and Disorders Research	R01DE025837	93.121	27,432	6,370
Oral Diseases and Disorders Research	R01DE026333	93.121	93,458	(105,811)
Oral Diseases and Disorders Research	R01DE026941	93.121	53,850	414,127
Oral Diseases and Disorders Research	R01DE028342	93.121	34,490	308,786
Oral Diseases and Disorders Research	R01DE028351	93.121	41,088	264,626
Oral Diseases and Disorders Research	R01DE028905	93.121	112,680	518,813
Oral Diseases and Disorders Research	R01DE030342	93.121	154,750	275,435
Oral Diseases and Disorders Research	R01DE031271	93.121	—	36,071
Oral Diseases and Disorders Research	R03DE027103	93.121	—	3,938
Oral Diseases and Disorders Research	R03DE028387	93.121	—	113,233
Oral Diseases and Disorders Research	R03DE030118	93.121	—	58,350
Oral Diseases and Disorders Research	R03DE032084	93.121	—	1,572
Oral Diseases and Disorders Research	R21DE029592	93.121	—	13,421
Oral Diseases and Disorders Research	R21DE029698	93.121	—	138,421
Oral Diseases and Disorders Research	R21DE030632	93.121	—	146,353
Pass-through Georgia Institute of Technology	1R56DE029703-01	93.121	—	31,750
Pass-through Georgia Institute of Technology	R56DE029703	93.121	—	1,881
Pass-through Indiana University	R03DE030259	93.121	—	25,753
Pass-through Massachusetts General Hospital	R01DE027983	93.121	—	54,711
Pass-through Medical University of South Carolina	R21DE029592	93.121	—	9,587
Pass-through University of Iowa	R01DE027362	93.121	—	21,680
Pass-through University of North Carolina Chapel Hill	R01DE028146	93.121	—	2,106
Pass-through University of Washington	UWSC13900	93.121	—	42,192
Total AL No. 93.121			517,728	2,533,482
Nurse Anesthetist Traineeships	A2231815	93.124	—	15,952
Total AL No. 93.124			—	15,952
COVID-19 – Centers for Research and Demonstration for Health Promotion and Disease Prevention	U48DP006377	93.135	—	413,221
Centers for Research and Demonstration for Health Promotion and Disease Prevention	U48DP006377	93.135	350,295	2,754,316
Total AL No. 93.135			350,295	3,167,537
Injury Prevention and Control Research and State and Community Based Programs	R01CE003104	93.136	—	333,597
Injury Prevention and Control Research and State and Community Based Programs	R49CE003072	93.136	46,982	810,838
Injury Prevention and Control Research and State and Community Based Programs	U01CE002939	93.136	48,751	329,505
Total AL No. 93.136			95,733	1,473,940
NIEHS Hazardous Waste Worker Health and Safety Training: Pass-through Nova Southeastern University	5U45ES019350	93.142	—	19,828
Total AL No. 93.142			—	19,828

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2022

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Health Program for Toxic Substances and Disease Registry: Pass-through American Academy of Pediatrics	NU61TS000296	93.161	\$ —	189,183
Pass-through American Academy of Pediatrics	NU61TS000296	93.161	—	79,203
Total AL No. 93.161			—	268,386
Human Genome Research: Pass-through University of Chicago	RM1HG008935	93.172	—	163,210
Total AL No. 93.172			—	163,210
Research Related to Deafness and Communication Disorders	R01DC008343	93.173	—	440,219
Research Related to Deafness and Communication Disorders	R01DC014021	93.173	—	1,502
Research Related to Deafness and Communication Disorders	R01DC014496	93.173	—	55,955
Research Related to Deafness and Communication Disorders	R21DC017272	93.173	—	112,705
Pass-through University of Memphis	R01DC015108	93.173	—	(1,355)
Total AL No. 93.173			—	609,026
Immunization Research, Demonstration, Public Information and Education Training and Clinical Skills Improvement Projects Pass-through Yale University	U011P001117	93.185	150,253	464,878
	U011P011110	93.185	—	68,193
Total AL No. 93.185			150,253	533,071
Telehealth Programs Pass-through University of Arizona	H2ARH39957	93.211	—	292,083
Pass-through University of Arizona	GA5RH37465	93.211	—	37,121
	U1U42527	93.211	—	101,120
Total AL No. 93.211			—	430,324
Research and Training in Complementary and Integrative Health	F31AT011988	93.213	—	16,314
Research and Training in Complementary and Integrative Health	K01AT010488	93.213	—	139,952
Research and Training in Complementary and Integrative Health	K23AT009713	93.213	—	95,849
Research and Training in Complementary and Integrative Health	K24AT009893	93.213	—	189,900
Research and Training in Complementary and Integrative Health	R01AT011267	93.213	284,359	745,140
Research and Training in Complementary and Integrative Health	R01AT011990	93.213	—	80,528
Research and Training in Complementary and Integrative Health	R21AT010774	93.213	2,931	25,458
Research and Training in Complementary and Integrative Health	R21AT011105	93.213	—	233,782
Research and Training in Complementary and Integrative Health	R61AT010457	93.213	37,138	274,209
Pass-through Veterans Medical Research Foundation	U01AT010332	93.213	—	32,132
Total AL No. 93.213			324,428	1,833,264
National Research Service Awards Health Services Research Training Total AL No. 93.225	F32HS028558	93.225	—	60,448
			—	60,448
Research on Healthcare Costs, Quality and Outcomes	K08HS025240	93.226	—	11,476
Research on Healthcare Costs, Quality and Outcomes	R01HS026081	93.226	238,180	525,872
Research on Healthcare Costs, Quality and Outcomes	R01HS026232	93.226	161,591	307,943
Research on Healthcare Costs, Quality and Outcomes	R03HS027689	93.226	—	10,266
Research on Healthcare Costs, Quality and Outcomes	R18HS026877	93.226	67,335	111,520
Pass-through Clemson University	R01HS025981	93.226	—	80,875
Pass-through University of Iowa	R0HS026724	93.226	—	57,409
Pass-through University of Pittsburgh	U18HS026380	93.226	3,973	11,472
Total AL No. 93.226			471,079	1,116,633
National Center on Sleep Disorders Research	K01HL138211	93.233	—	171,220
National Center on Sleep Disorders Research	R00HL147212	93.233	—	271,715
National Center on Sleep Disorders Research	R01HL157954	93.233	—	27,007
Total AL No. 93.233			—	469,942
Mental Health Research Grants	F30MH117878	93.242	—	26,606
Mental Health Research Grants	R25MH101079	93.242	—	208,340
Mental Health Research Grants	1R21MH118092-01-REVISED	93.242	—	(30)
Mental Health Research Grants	5R01MH100318-05	93.242	—	12,549
Mental Health Research Grants	5R01MH104632-05	93.242	—	13,548
Mental Health Research Grants	5U11MH081988	93.242	—	(27,052)
Mental Health Research Grants	F30MH117873	93.242	—	45,330
Mental Health Research Grants	F31MH114624	93.242	—	9,575
Mental Health Research Grants	F31MH119745	93.242	—	41,913
Mental Health Research Grants	F31MH126623	93.242	—	43,927
Mental Health Research Grants	F31MH127915	93.242	—	42,413
Mental Health Research Grants	F31MH130274	93.242	—	14,490
Mental Health Research Grants	F32 MH115692	93.242	—	19,599
Mental Health Research Grants	F32MH119750	93.242	—	42,361
Mental Health Research Grants	F32MH124273	93.242	—	61,384
Mental Health Research Grants	K01MH121653	93.242	—	166,704
Mental Health Research Grants	K01MH126308	93.242	—	52,772
Mental Health Research Grants	K23MH114037-02	93.242	—	203,957
Mental Health Research Grants	K23MH114771	93.242	45,003	171,957
Mental Health Research Grants	K23MH123816	93.242	—	150,138
Mental Health Research Grants	P50MH100023	93.242	269,996	2,005,368
Mental Health Research Grants	P50MH100029	93.242	629,341	1,642,606
Mental Health Research Grants	R00MH119319	93.242	—	27,233
Mental Health Research Grants	R01MH069852	93.242	—	183,271
Mental Health Research Grants	R01MH072908	93.242	—	214,413
Mental Health Research Grants	R01MH082833	93.242	33,233	163,315
Mental Health Research Grants	R01MH105561	93.242	249,099	496,200
Mental Health Research Grants	R01MH107033	93.242	—	69,360
Mental Health Research Grants	R01MH108605	93.242	—	32,314
Mental Health Research Grants	R01MH108826	93.242	364,754	644,202
Mental Health Research Grants	R01MH109026	93.242	—	184,964
Mental Health Research Grants	R01MH110701	93.242	—	13,039
Mental Health Research Grants	R01MH111416	93.242	—	150,488
Mental Health Research Grants	R01MH112076	93.242	—	105,394
Mental Health Research Grants	R01MH112788	93.242	—	523,671
Mental Health Research Grants	R01MH114692	93.242	605,285	1,374,554
Mental Health Research Grants	R01MH115174	93.242	14,375	789,921
Mental Health Research Grants	R01MH115831	93.242	—	391,127
Mental Health Research Grants	R01MH116995	93.242	—	646,019
Mental Health Research Grants	R01MH117009	93.242	18,975	746,357
Mental Health Research Grants	R01MH117103	93.242	—	367,726
Mental Health Research Grants	R01MH117122	93.242	24,178	366,211
Mental Health Research Grants	R01MH117315	93.242	—	727,843
Mental Health Research Grants	R01MH118285	93.242	—	286,515
Mental Health Research Grants	R01MH118534	93.242	—	288,645
Mental Health Research Grants	R01MH118771	93.242	—	495,736
Mental Health Research Grants	R01MH118982	93.242	400,526	692,780
Mental Health Research Grants	R01MH119251	93.242	—	89,936
Mental Health Research Grants	R01MH120197	93.242	—	10,085
Mental Health Research Grants	R01MH120262	93.242	—	674,687
Mental Health Research Grants	R01MH120299	93.242	—	(2,435)
Mental Health Research Grants	R01MH121363	93.242	6,405	407,102

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2022

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Mental Health Research Grants	R01MH121622	93.242	\$ —	176,879
Mental Health Research Grants	R01MH121962	93.242	—	690,614
Mental Health Research Grants	R01MH122341	93.242	—	972,973
Mental Health Research Grants	R01MH125457	93.242	110,356	985,132
Mental Health Research Grants	R01MH125956	93.242	—	611,954
Mental Health Research Grants	R01MH126083	93.242	—	180,478
Mental Health Research Grants	R01MH126195	93.242	1,038	507,959
Mental Health Research Grants	R01MH126985	93.242	—	79,406
Mental Health Research Grants	R01MH128045	93.242	33,002	393,762
Mental Health Research Grants	R01MH128130	93.242	36,594	139,983
Mental Health Research Grants	R01MH128158	93.242	—	5,959
Mental Health Research Grants	R01MH128244	93.242	—	15,498
Mental Health Research Grants	R01MH128705	93.242	—	68,278
Mental Health Research Grants	R01MH128872	93.242	—	100,579
Mental Health Research Grants	R01MH129655	93.242	—	52,703
Mental Health Research Grants	R21MH114151	93.242	—	2,524
Mental Health Research Grants	R21MH117512	93.242	—	1,242
Mental Health Research Grants	R21MH120414	93.242	—	197,358
Mental Health Research Grants	R21MH121164	93.242	54,509	180,811
Mental Health Research Grants	R21MH121891	93.242	—	198,964
Mental Health Research Grants	R21MH123711	93.242	—	243,108
Mental Health Research Grants	R21MH124200	93.242	18,811	144,275
Mental Health Research Grants	R21MH127404	93.242	—	130,537
Mental Health Research Grants	R25MH101079	93.242	—	(904)
Mental Health Research Grants	R34MH116805	93.242	183,509	274,311
Mental Health Research Grants	R34MH119007	93.242	59,051	237,584
Mental Health Research Grants	R34MH124638	93.242	—	290,121
Mental Health Research Grants	R34MH128048	93.242	4,836	101,471
Mental Health Research Grants	R34MH129187	93.242	13,583	123,079
Mental Health Research Grants	R36MH127827	93.242	—	37,991
Mental Health Research Grants	R56MH119903	93.242	—	25,356
Mental Health Research Grants	R61MH121625	93.242	—	613,990
Mental Health Research Grants	RF1MH119622	93.242	—	69,567
Mental Health Research Grants	U01MH116441	93.242	583,404	1,123,336
Pass-through Brown University	R01MH117960	93.242	—	44,905
Pass-through Carnegie Mellon University	R01MH129725	93.242	—	38,451
Pass-through Childrens Hospital of Los Angeles	R01MH120133	93.242	—	17,617
Pass-through Creighton University	R01MH116003	93.242	—	58,348
Pass-through Duke University	R01MH111671	93.242	—	21,036
Pass-through Georgia Institute of Technology	R01MH119189	93.242	—	27,745
Pass-through Georgia Institute of Technology	R21MH122825	93.242	—	24,943
Pass-through Hartford Hospital	R01MH119815	93.242	—	1,892
Pass-through Johns Hopkins University	R01MH110358	93.242	—	164,011
Pass-through Massachusetts General Hospital	R34MH122362	93.242	—	16,295
Pass-through Mclean Hospital	R01MH117292	93.242	—	225,455
Pass-through Md Anderson	R01MH120299	93.242	—	133,129
Pass-through Research Foundation for Mental Hygiene	R01MH123660	93.242	—	4,456
Pass-through Rhode Island Hospital	R01MH125796	93.242	—	264,486
Pass-through Rutgers University	R01MH126449	93.242	—	16,995
Pass-through St Louis University	R01MH125820	93.242	—	20,141
Pass-through Stanford University	R01MH123486	93.242	—	30,859
Pass-through University of Alabama Birmingham	R34MH128072	93.242	—	45,460
Pass-through University of Arizona	R01MH121706	93.242	—	102,511
Pass-through University of California Los Angeles	R01MH100027	93.242	—	302,999
Pass-through University of California Los Angeles	R01MH118514	93.242	—	199,184
Pass-through University of California Los Angeles	R01MH118973	93.242	—	14,211
Pass-through University of California San Diego	R01MH124590	93.242	—	30,439
Pass-through University of California San Francisco	P30MH062246	93.242	—	96,821
Pass-through University of California San Francisco	R01MH123396	93.242	—	141,298
Pass-through University of Cape Town	U01MH115484	93.242	—	125,259
Pass-through University of Georgia	R01MH116039	93.242	—	59,630
Pass-through University of Georgia	R01MH120092	93.242	—	147,722
Pass-through University of Illinois at Chicago	R01MH116721	93.242	—	198,368
Pass-through University of Louisiana at Lafayette	R01MH125395	93.242	—	141,960
Pass-through University of Maryland, Baltimore	R01MH121102	93.242	—	257,951
Pass-through University of Maryland, Baltimore	R21MH121120	93.242	—	169,205
Pass-through University of Michigan	R01MH123388	93.242	—	49,725
Pass-through University of Michigan	R01MH125857	93.242	—	48,636
Pass-through University of Minnesota	R01MH125377	93.242	—	28,403
Pass-through University of North Carolina Chapel Hill	U01MH110925	93.242	—	5,677
Pass-through University of Pennsylvania	R01MH114847	93.242	—	103,663
Pass-through University of Pittsburgh	R01MH115922	93.242	—	20,262
Pass-through University of Pittsburgh	R01MH116943	93.242	—	30,273
Pass-through University of Pittsburgh	R01MH118270	93.242	—	19,809
Pass-through University of Pittsburgh	R01MH121619	93.242	—	20,307
Pass-through University of Pittsburgh	R01MH125816	93.242	—	38,790
Pass-through University of Pittsburgh	R21MH120511	93.242	—	23,132
Pass-through University of Pittsburgh	R21MH121120	93.242	—	(84)
Pass-through University of Pittsburgh	U01MH111658	93.242	—	24,734
Pass-through University of Rochester	R01MH045573	93.242	—	37,465
Pass-through University of South Carolina	PO 200062637 / USC	93.242	—	4,268
Pass-through University of Washington	R01MH121424	93.242	—	144,029
Pass-through University of Washington Saint Louis	R01MH123723	93.242	—	34,185
Pass-through Vanderbilt University Medical Center	R61MH123029	93.242	—	39,298
Pass-through Washington University	R01MH120194	93.242	—	107,946
Pass-through Wayne State University	R33MH111935	93.242	—	78,542
Pass-through Yale University	R01MH125205	93.242	—	8,004
Pass-through Yale University	U01MH124639	93.242	—	46,962
Total AL No. 93.242			3,759,863	29,073,914
Substance Abuse and Mental Health Services Projects of Regional and National Significance	H79SM081774	93.243	88,710	1,090,298
Pass-through American Psychiatric Association	H79SM080818	93.243	—	191,017
Total AL No. 93.243			88,710	1,281,315

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2022

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Advanced Nursing Education Grant Program	T14HP93112	93.247	\$ 384,315	526,729
Advanced Nursing Education Grant Program	T9642058	93.247	—	348,958
Total AL No. 93.247			384,315	875,687
Occupational Safety and Health Program	5R01OH010745-03	93.262	72,562	581,450
Total AL No. 93.262			72,562	581,450
COVID-19 – Alcohol Research Programs	U01AA029345	93.273	30,175	200,420
Alcohol Research Programs	1R21AA027345-01	93.273	—	14,649
Alcohol Research Programs	F31AA029000	93.273	—	47,543
Alcohol Research Programs	F31AA029938	93.273	—	54,399
Alcohol Research Programs	K08AA024512	93.273	—	129,397
Alcohol Research Programs	R01AA022601	93.273	—	(280)
Alcohol Research Programs	R01AA025854	93.273	20,178	326,624
Alcohol Research Programs	R01AA025857	93.273	—	116,399
Alcohol Research Programs	R01AA026096	93.273	—	430,314
Alcohol Research Programs	R01AA027020	93.273	—	393,931
Alcohol Research Programs	R01AA027396	93.273	—	236,337
Alcohol Research Programs	R01AA028527	93.273	—	348,722
Alcohol Research Programs	R03AA027335	93.273	—	22,377
Alcohol Research Programs	R03AA027662	93.273	—	120,853
Alcohol Research Programs	R21AA028606	93.273	—	163,188
Alcohol Research Programs	U01AA026108	93.273	111,036	281,956
Alcohol Research Programs	U01AA029345	93.273	15,361	335,336
Pass-through Boston Medical Center	P01AA029541	93.273	—	16,508
Pass-through Fdtn for Atlanta Veterans Educ and Res	M20029	93.273	—	(3,105)
Pass-through University of California San Diego	R01AA026579	93.273	—	34,244
Pass-through University of California San Diego	R01AA027785	93.273	—	102,526
Pass-through University of California San Diego	U01AA014835	93.273	—	30,060
Pass-through University of Colorado	R24AA019661	93.273	—	242
Total AL No. 93.273			176,750	3,402,640
Drug Abuse and Addiction Research Programs	R01DA052909	93.279	40,896	830,078
Drug Abuse and Addiction Research Programs	5R01DA038588-04	93.279	—	312
Drug Abuse and Addiction Research Programs	DP1DA042103	93.279	141,862	612,009
Drug Abuse and Addiction Research Programs	F31DA051184	93.279	—	47,631
Drug Abuse and Addiction Research Programs	F31DA053005	93.279	—	59,521
Drug Abuse and Addiction Research Programs	F31DA055447	93.279	—	15,333
Drug Abuse and Addiction Research Programs	K01DA051696	93.279	—	99,695
Drug Abuse and Addiction Research Programs	K01DA053438	93.279	—	14,178
Drug Abuse and Addiction Research Programs	K01DA053985	93.279	—	126,571
Drug Abuse and Addiction Research Programs	R01DA042712	93.279	—	215,964
Drug Abuse and Addiction Research Programs	R01DA042742	93.279	60,259	246,167
Drug Abuse and Addiction Research Programs	R01DA043263	93.279	26,460	299,978
Drug Abuse and Addiction Research Programs	R01DA044297	93.279	—	304,297
Drug Abuse and Addiction Research Programs	R01DA045612	93.279	156,332	578,177
Drug Abuse and Addiction Research Programs	R01DA046197	93.279	102,658	603,339
Drug Abuse and Addiction Research Programs	R01DA046619	93.279	56,292	261,338
Drug Abuse and Addiction Research Programs	R01DA049257	93.279	3,363	515,315
Drug Abuse and Addiction Research Programs	R21DA046738	93.279	—	42
Drug Abuse and Addiction Research Programs	R34DA050340	93.279	—	73,605
Drug Abuse and Addiction Research Programs	RD056235A	93.279	—	41,898
Drug Abuse and Addiction Research Programs	RF1DA055667	93.279	56,702	183,683
Drug Abuse and Addiction Research Programs	T32DA050552	93.279	—	135,944
Drug Abuse and Addiction Research Programs	U01DA055360	93.279	—	475,189
Drug Abuse and Addiction Research Programs	U01DA056000	93.279	—	135,236
Drug Abuse and Addiction Research Programs	UC3DA048502	93.279	141,536	493,940
Drug Abuse and Addiction Research Programs	UC3DA050234	93.279	—	(16,099)
Drug Abuse and Addiction Research Programs	UH3DA050234	93.279	168,589	742,775
Pass-through Case Western Reserve University	R01DA042712	93.279	—	(30,919)
Pass-through Case Western Reserve University	R01DA043263	93.279	—	(44,706)
Pass-through Johns Hopkins University	R61DA047022	93.279	—	37,344
Pass-through Magee-Womens Research Institute and Foundation	R25DA043680	93.279	—	21,111
Pass-through Miriam Hospital	R25DA037190	93.279	—	8,984
Pass-through Oregon Health and Science University	R01DA046229	93.279	—	123,698
Pass-through Pennsylvania State University	R01DA047396	93.279	—	14,083
Pass-through University of California San Diego	U24DA055325	93.279	—	13,258
Pass-through University of California San Francisco	R61DA047024	93.279	—	177,132
Pass-through University of Kentucky	UH3DA044798	93.279	—	183,605
Pass-through University of Miami	UG1DA013720	93.279	—	36,356
Pass-through Wake Forest University	R01DA052214	93.279	—	33,738
Pass-through Yale University	UG1DA015831	93.279	—	166,574
Total AL No. 93.279			954,949	7,827,374
Centers for Disease Control and Prevention Investigations and Technical Assistance	U01DP006488	93.283	2,083	793,996
Pass-through Fdtn for Atlanta Veterans Educ and Res	NU50CK000485	93.283	10,156	4,532,977
Pass-through Georgia Dept of Public Health	40500-036-15110270	93.283	—	31,455
Total AL No. 93.283			12,239	5,358,428
COVID-19 – Discovery and Applied Research for Technological Innovations to Improve Human Health	U54EB027690	93.286	1,707,260	8,428,814
Discovery and Applied Research for Technological Innovations to Improve Human Health	R01EB027147	93.286	—	349,000
Discovery and Applied Research for Technological Innovations to Improve Human Health	R01EB027774	93.286	122,718	284,201
Discovery and Applied Research for Technological Innovations to Improve Human Health	R01EB028350	93.286	193,985	322,626
Discovery and Applied Research for Technological Innovations to Improve Human Health	R01EB029320	93.286	225,880	854,854
Discovery and Applied Research for Technological Innovations to Improve Human Health	R01EB029857	93.286	69,145	283,768
Discovery and Applied Research for Technological Innovations to Improve Human Health	R13EB031602	93.286	—	10,000
Discovery and Applied Research for Technological Innovations to Improve Human Health	R21EB025646	93.286	—	132,252
Discovery and Applied Research for Technological Innovations to Improve Human Health	R21EB026591	93.286	—	23,400
Discovery and Applied Research for Technological Innovations to Improve Human Health	R21EB028519	93.286	30,434	164,150
Discovery and Applied Research for Technological Innovations to Improve Human Health	R21EB029622	93.286	—	198,782
Discovery and Applied Research for Technological Innovations to Improve Human Health	R21EB031545	93.286	—	105,455
Discovery and Applied Research for Technological Innovations to Improve Human Health	U01EB028145	93.286	213,836	213,836
Discovery and Applied Research for Technological Innovations to Improve Human Health	U54EB027690	93.286	932,903	10,138,030
Pass-through Beth Israel Deaconess Medical Center	R01EB030362	93.286	—	41,278
Pass-through Georgia Institute of Technology	R01E029331	93.286	—	20,619
Pass-through Georgia Institute of Technology	R01E023808	93.286	—	82,039
Pass-through Georgia Institute of Technology	R01EB028916	93.286	—	19,167

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2022

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through Georgia Institute of Technology	R01EB031101	93.286	\$ —	59,849
Pass-through Georgia Institute of Technology	R03EB029099	93.286	—	15,886
Pass-through Georgia Institute of Technology	R21EB031535	93.286	—	22,468
Pass-through Georgia Institute of Technology	T32EB021962	93.286	—	43,771
Pass-through Georgia Institute of Technology	T32EB025816	93.286	—	(973)
Pass-through Massachusetts General Hospital	R01EB027122	93.286	—	172,093
Pass-through Univ of Massachusetts Medical School	U54HL143541	93.286	—	(3,776)
Pass-through University of Maryland, Baltimore	REB028324B	93.286	—	64,987
Pass-through University of Pittsburgh	R01EB028248	93.286	—	28,004
Pass-through University of South Florida	R01EB020601	93.286	—	10
Total AL No. 93.286			3,496,161	22,074,590
Minority Health and Health Disparities Research	5U01MD010611	93.307	—	156,122
Minority Health and Health Disparities Research	K01MD016170	93.307	—	25,226
Minority Health and Health Disparities Research	K23MD015098	93.307	—	190,916
Minority Health and Health Disparities Research	R01MD009746	93.307	—	40,638
Minority Health and Health Disparities Research	R01MD010455	93.307	—	83,456
Minority Health and Health Disparities Research	R01MD011682	93.307	—	411,219
Minority Health and Health Disparities Research	R01MD013320	93.307	198,055	1,003,687
Minority Health and Health Disparities Research	R01MD015204	93.307	66,757	230,122
Minority Health and Health Disparities Research	R01MD016031	93.307	—	733,096
Minority Health and Health Disparities Research	R01MD017046	93.307	—	34,298
Minority Health and Health Disparities Research	R03MD013509	93.307	—	32,218
Pass-through Medical University of South Carolina	R01MD015395	93.307	—	1,993
Pass-through Morehouse School of Medicine	U54MD007602	93.307	—	158,528
Pass-through University of Illinois at Chicago	R21MD015813	93.307	—	16,648
Pass-through University of Minnesota	R01MD013801	93.307	—	117,862
Pass-through University of Pennsylvania	R01MD013558	93.307	—	70,742
Pass-through University of Pennsylvania	U01MD011274	93.307	—	96,853
Pass-through University of Puerto Rico	U54MD007600	93.307	—	20,446
Pass-through University of Southern California	R01MD011698	93.307	—	95,161
Pass-through University of Utah	R21MD014281	93.307	—	17,225
Pass-through Yale University	R01MD016386	93.307	—	12,889
Total AL No. 93.307			264,812	3,549,345
COVID-19 – Trans-NIH Research Support	P30DK111024	93.310	613,238	1,703,563
Trans-NIH Research Support	R01CA217304	93.310	—	273,608
Trans-NIH Research Support	R03TR003380	93.310	—	122,853
Trans-NIH Research Support	U01DK132737	93.310	—	90,967
Trans-NIH Research Support	U24DK112341	93.310	450,376	1,089,170
Trans-NIH Research Support	1U2CES026560-01 REVISED	93.310	—	15,716
Trans-NIH Research Support	UZCES030163	93.310	121,163	677,888
Trans-NIH Research Support	5K01OD023039-03	93.310	—	12,858
Trans-NIH Research Support	DPSOD019792-05	93.310	—	10,024
Trans-NIH Research Support	OT2OD030535	93.310	635,196	951,153
Trans-NIH Research Support	UH3OD023318	93.310	32,268	1,328,379
Pass-through Albert Einstein College of Medicine	UH3OD023320	93.310	—	19,517
Pass-through Duke University	U24MD016258	93.310	—	128,399
Pass-through Duke University	UZCOD023375	93.310	—	122,907
Pass-through Georgia Institute of Technology	U53TR02855	93.310	—	147,900
Pass-through Research Foundation for Mental Hygiene	UH3OD023328	93.310	—	22,960
Pass-through Research Triangle Institute	7R03HD106123-02	93.310	—	27,274
Pass-through University of California San Francisco	R61HD105618	93.310	—	159,261
Pass-through University of Illinois Urbana Champaign	R21HD106125	93.310	—	26,465
Pass-through University of Miami	OT2OD26551	93.310	—	3,151,005
Pass-through University of North Carolina	UH3OD023348	93.310	—	19,392
Pass-through Women & Infants Hospital of Rhode Island	UH3OD023347	93.310	—	462,403
Total AL No. 93.310			1,852,241	10,563,462
COVID-19 – Protecting and Improving Health Globally: Building and Strengthening Public Health Impact, Systems, Capacity and Security	NU14GH001238	93.318	179,539	361,243
Protecting and Improving Health Globally: Building and Strengthening Public Health Impact, Systems, Capacity and Security	NU51IP000873	93.318	—	344,735
Pass-through The Center For Global Health Innovation			179,539	705,978
Total AL No. 93.318			—	—
Cooperative Agreement to Support Navigators in Federally-facilitated Exchanges	NU60OE000104	93.332	—	61,760
Pass-through Association of Public Health Labs			—	61,760
Total AL No. 93.332			—	—
National Center for Advancing Translational Sciences	KL2TR002381	93.350	221,528	1,373,910
National Center for Advancing Translational Sciences	R03TR003669	93.350	—	5,362
National Center for Advancing Translational Sciences	R03TR004022	93.350	—	44,506
National Center for Advancing Translational Sciences	TL1TR02382	93.350	108,814	765,116
National Center for Advancing Translational Sciences	UL1TR002378	93.350	3,534,740	9,473,192
Pass-through University of Pittsburgh	UL1TR001857	93.350	17,750	17,750
Total AL No. 93.350			3,882,832	11,679,836
Research Infrastructure Programs	5R24OD020174-04	93.351	3,964	55,098
Research Infrastructure Programs	K01OD031900	93.351	—	200,342
Research Infrastructure Programs	P51OD011132	93.351	48,990	12,043,146
Research Infrastructure Programs	R13OD034052	93.351	—	4,097
Research Infrastructure Programs	R24OD020349	93.351	14,666	17,124
Research Infrastructure Programs	R24OD030035	93.351	—	439,731
Research Infrastructure Programs	R25GM129213	93.351	—	114,618
Research Infrastructure Programs	S10OD028503	93.351	—	810,000
Research Infrastructure Programs	U42OD011023	93.351	—	1,567,207
Pass-through Oregon Health and Science University	R24OD021324	93.351	—	71,492
Total AL No. 93.351			67,620	15,322,855
Construction Support	C06OD030081	93.352	—	1,262,444
Total AL No. 93.352			—	1,262,444
21st Century Cures Act – Beau Biden Cancer Moonshot	U01CA243688	93.353	—	73,726
Pass-through Dana Farber Cancer Institute	U24CA233243	93.353	—	52,099
Pass-through Dana Farber Cancer Institute	U01CA246567	93.353	9,157	138,987
Pass-through University of Alabama Birmingham	U01CA254822	93.353	—	34,187
Pass-through University of Michigan			9,157	298,999
Total AL No. 93.353			—	—

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2022

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
COVID-19 – Nurse Education, Practice and Retention Grants	T1PHP39097	93.359	\$ —	5,260
Nurse Education, Practice and Retention Grants	U4E42423	93.359	—	333,954
Nurse Education, Practice and Retention Grants	UK1HP31697	93.359	37,522	681,506
Total AL No. 93.359			37,522	1,020,720
Biomedical Advanced Research and Development Authority (BARDA), Biodefense Medical Countermeasure Development	IDSEP190055	93.360	—	50,974
Total AL No. 93.360			—	50,974
Nursing Research	1K01NR019651-01A1	93.361	—	37,877
Nursing Research	5R00NR014587-05	93.361	301	269
Nursing Research	K01NR017664	93.361	—	8,534
Nursing Research	K23NR020037	93.361	7,287	131,263
Nursing Research	K23NR020208	93.361	—	85,705
Nursing Research	K24NR018866	93.361	—	117,557
Nursing Research	P30NR018090	93.361	—	588,628
Nursing Research	R00NR017897	93.361	—	221,704
Nursing Research	R01NR014973	93.361	—	750
Nursing Research	R01NR017018	93.361	201,724	518,083
Nursing Research	R01NR017939	93.361	85,409	561,075
Nursing Research	R01NR018666	93.361	147,035	495,465
Nursing Research	R01NR019083	93.361	—	582,890
Nursing Research	R01NR019254	93.361	—	333,197
Nursing Research	R01NR020154	93.361	—	301,403
Nursing Research	R01NR020188	93.361	—	87,833
Nursing Research	R01NR020334	93.361	—	93,051
Nursing Research	R21NR018015	93.361	—	72,848
Nursing Research	R21NR019872	93.361	—	161,395
Nursing Research	R56NR019482	93.361	5,738	139,068
Nursing Research	T32NR012715	93.361	—	449,776
Pass-through Johns Hopkins University	R01NR020437	93.361	—	105,688
Pass-through State University of New York	R01NR018979	93.361	—	3,716
Total AL No. 93.361			447,494	5,077,775
National and State Tobacco Control Program	R01HL155711	93.387	15,129	641,090
Total AL No. 93.387			15,129	641,090
Cancer Cause and Prevention Research	F99CA264407	93.393	—	45,951
Cancer Cause and Prevention Research	R00CA204601	93.393	—	238,765
Cancer Cause and Prevention Research	R01CA095318	93.393	—	18,975
Cancer Cause and Prevention Research	R01CA178999	93.393	—	150,635
Cancer Cause and Prevention Research	R01CA203719	93.393	—	188,112
Cancer Cause and Prevention Research	R01CA207260	93.393	101,909	242,378
Cancer Cause and Prevention Research	R01CA207467	93.393	—	18
Cancer Cause and Prevention Research	R01CA211574	93.393	442,476	562,570
Cancer Cause and Prevention Research	R01CA218155	93.393	44,981	379,898
Cancer Cause and Prevention Research	R01CA218389	93.393	2,765	558,160
Cancer Cause and Prevention Research	R01CA230268	93.393	—	302,209
Cancer Cause and Prevention Research	R01CA234538	93.393	7,186	481,450
Cancer Cause and Prevention Research	R01CA235721	93.393	—	527,904
Cancer Cause and Prevention Research	R01CA237318	93.393	707,318	1,095,168
Cancer Cause and Prevention Research	R01CA245063	93.393	235,996	729,415
Cancer Cause and Prevention Research	R01CA250110	93.393	—	252,869
Cancer Cause and Prevention Research	R01CA254403	93.393	—	295,512
Cancer Cause and Prevention Research	R01CA259192	93.393	—	505,472
Cancer Cause and Prevention Research	R01CA268024	93.393	—	84,649
Cancer Cause and Prevention Research	R03CA259665	93.393	21,492	71,525
Cancer Cause and Prevention Research	R03CA267456	93.393	—	18,741
Cancer Cause and Prevention Research	R21CA238356	93.393	1,320	120,253
Cancer Cause and Prevention Research	R21CA273773	93.393	—	15,802
Cancer Cause and Prevention Research	R37CA234119	93.393	377,336	571,877
Cancer Cause and Prevention Research	U01CA217875	93.393	—	808,970
Cancer Cause and Prevention Research	U01CA240581	93.393	48,047	596,448
Cancer Cause and Prevention Research	R01CA236871	93.393	—	419,224
Pass-through Duke University	R37CA233777	93.393	—	36,547
Pass-through George Washington University	R01CA215155	93.393	—	13,910
Pass-through Georgia State University	R01CA248551	93.393	—	96,414
Pass-through Mayo Clinic	R01CA248288	93.393	—	57,566
Pass-through Mayo Clinic	U01CA195568	93.393	—	105,223
Pass-through Md Anderson	R01CA255322	93.393	—	17,874
Pass-through North Carolina State University	UG3CA265842	93.393	—	160,742
Pass-through Northwestern University	U01CA220401	93.393	—	42,749
Pass-through Public Health Institute	03225-AR04060	93.393	—	147,776
Pass-through Stanford University	61795884-129906	93.393	—	35,437
Pass-through State University of New York Stony Brook	UG3CA22502101	93.393	—	203,000
Pass-through University of Alabama Birmingham	R01CA248439	93.393	500	23,599
Pass-through University of Alabama Birmingham	R01CA262039	93.393	—	44,675
Pass-through University of Iowa	R01CA259048	93.393	—	136,589
Pass-through University of Michigan	R37CA251464	93.393	—	57,159
Pass-through University of Southern California	U19CA214253	93.393	—	489,321
Pass-through University of Utah	R01CA200854	93.393	—	44,424
Pass-through University of Washington Saint Louis	R01CA235773	93.393	—	43,498
Pass-through Vanderbilt University Medical Center	R01CA225005	93.393	—	(3,558)
Pass-through Vanderbilt University Medical Center	R01CA230352	93.393	—	41,380
Pass-through Wayne State University	R01CA240607	93.393	—	57,801
Total AL No. 93.393			1,991,226	11,155,077
COVID-19 – Cancer Detection and Diagnosis Research	U54CA260563	93.394	—	2,665,486
Cancer Detection and Diagnosis Research	R01CA202846	93.394	—	11,527
Cancer Detection and Diagnosis Research	R01CA203388	93.394	5,221	128,426
Cancer Detection and Diagnosis Research	R01CA261251	93.394	31,900	397,225
Cancer Detection and Diagnosis Research	R21CA256280	93.394	8,680	206,478
Cancer Detection and Diagnosis Research	R21CA256375	93.394	—	274,541
Cancer Detection and Diagnosis Research	R21CA256605	93.394	67,559	253,216
Cancer Detection and Diagnosis Research	R21CA259935	93.394	—	171,444
Cancer Detection and Diagnosis Research	U01CA113913	93.394	—	363,229
Cancer Detection and Diagnosis Research	U01CA198913	93.394	—	31,957
Cancer Detection and Diagnosis Research	U01CA264039	93.394	—	72,499
Pass-through Children's Hospital of Philadelphia	R01CA248501	93.394	—	35,014
Pass-through Fred Hutchinson Cancer Center	U01CA224255	93.394	—	9,742
Pass-through Georgia Institute of Technology	R37CA239039	93.394	—	3,587

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2022

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through Georgia State University	U01CA242936	93.394	\$ —	17,000
Pass-through Massachusetts General Hospital	R01CA237133	93.394	—	7,491
Pass-through Northwestern University	R01CA240639	93.394	—	32,274
Pass-through State Univ of New York Downstate Med Ctr	100-1169346-91776	93.394	—	15,340
Pass-through Thomas Jefferson University	R01CA236857	93.394	—	68,467
Pass-through Thomas Jefferson University	UG3CA247605	93.394	—	47,436
Pass-through Univ of Arkansas for Medical Services	U24CA215109	93.394	—	162,082
Pass-through University of Colorado Denver	R01CA236857	93.394	—	(20,172)
Pass-through University of South Florida	R01CA240319	93.394	—	31,019
Total AL No. 93.394			113,360	4,985,308
Cancer Treatment Research	P01CA257906	93.395	—	87,173
Cancer Treatment Research	R01CA193828	93.395	—	(413)
Cancer Treatment Research	R01CA194027	93.395	—	2,196
Cancer Treatment Research	R01CA200905	93.395	—	50,642
Cancer Treatment Research	R01CA202763	93.395	—	7,942
Cancer Treatment Research	R01CA203928	93.395	—	234,028
Cancer Treatment Research	R01CA207768	93.395	—	219,873
Cancer Treatment Research	R01CA208253	93.395	171,002	268,827
Cancer Treatment Research	R01CA208328	93.395	—	293,421
Cancer Treatment Research	R01CA215718	93.395	—	351,900
Cancer Treatment Research	R01CA223220	93.395	—	408,558
Cancer Treatment Research	R01CA226922	93.395	—	640,103
Cancer Treatment Research	R01CA228406	93.395	—	316,342
Cancer Treatment Research	R01CA228414	93.395	175,340	354,195
Cancer Treatment Research	R01CA238471	93.395	—	369,413
Cancer Treatment Research	R01CA245386	93.395	—	307,343
Cancer Treatment Research	R01CA255257	93.395	—	461,521
Cancer Treatment Research	R01CA257961	93.395	—	446,429
Cancer Treatment Research	R01CA267694	93.395	—	41,180
Cancer Treatment Research	R03CA246039	93.395	—	19,307
Cancer Treatment Research	R21CA255831	93.395	—	188,293
Cancer Treatment Research	R21CA256456	93.395	—	114,252
Cancer Treatment Research	R21CA266088	93.395	—	49,453
Cancer Treatment Research	R21CA267365	93.395	—	109,117
Cancer Treatment Research	R21CA267612	93.395	—	16,739
Cancer Treatment Research	R37CA255459	93.395	—	299,282
Cancer Treatment Research	R50CA233168	93.395	—	143,651
Cancer Treatment Research	UG1CA233259	93.395	519,383	659,375
Cancer Treatment Research	R00CA222493	93.395	—	201,626
Cancer Treatment Research	UG1CA233247	93.395	—	719,541
Pass-through Childrens Healthcare of Atlanta	AWD-1000397 /GR-1000	93.395	—	15,065
Pass-through Childrens Healthcare of Atlanta	U10CA180866	93.395	—	104,404
Pass-through Childrens Healthcare of Atlanta	U10CA180896	93.395	—	23,498
Pass-through Childrens Healthcare of Atlanta	UM1CA228823	93.395	—	29,078
Pass-through City of Hope	R01CA194742	93.395	—	29,607
Pass-through Ecog-Acrin Medical Research Foundation	U10CA180820	93.395	—	57,056
Pass-through Georgia Institute of Technology	R01CA207619	93.395	—	42,914
Pass-through Georgia State University	R01CA180519	93.395	—	(2,809)
Pass-through Indiana University	R01CA235632	93.395	13,682	73,917
Pass-through Johns Hopkins University	UM1CA186691	93.395	—	18,674
Pass-through Medical University of South Carolina	P01CA203628	93.395	—	91,637
Pass-through Nrg Oncology Foundation, Inc.	U10CA180868	93.395	—	14,874
Pass-through Ohio State University	R01CA201382	93.395	—	17,870
Pass-through St Jude Childrens Research Hospital	UM1CA081457	93.395	4,053	46,844
Pass-through University of Florida	R01CA200867	93.395	—	963
Pass-through University of North Carolina Chapel Hill	R01CA249190	93.395	—	198,064
Pass-through University of North Carolina Chapel Hill	R01CA259077	93.395	—	158,165
Pass-through University of Pennsylvania	R21CA238108	93.395	—	18,618
Pass-through University of Tennessee Health Sciences nce Ctr	R01CA193609	93.395	—	5,016
Pass-through University of Tennessee Health Sciences nce Ctr	R01CA240447	93.395	—	227,293
Pass-through Vanderbilt University Medical Center	R21CA226562	93.395	—	40,173
Total AL No. 93.395			883,460	8,592,831
Cancer Biology Research	P30CA138292	93.396	—	2,935,657
Cancer Biology Research	R01CA175316	93.396	—	338,044
Cancer Biology Research	R01CA192844	93.396	—	20,545
Cancer Biology Research	R01CA201340	93.396	—	732
Cancer Biology Research	R01CA202948	93.396	—	114,353
Cancer Biology Research	R01CA208514	93.396	—	201,645
Cancer Biology Research	R01CA236369	93.396	—	433,381
Cancer Biology Research	R01CA247367	93.396	—	408,498
Cancer Biology Research	R01CA250422	93.396	—	480,863
Cancer Biology Research	R01CA251393	93.396	87,326	622,326
Cancer Biology Research	R01CA258765	93.396	—	202,738
Cancer Biology Research	R01CA258857	93.396	—	161,096
Cancer Biology Research	R01CA266613	93.396	—	241,159
Cancer Biology Research	R21CA232244	93.396	—	19,317
Cancer Biology Research	R35CA197603	93.396	—	978,834
Cancer Biology Research	R50CA265345	93.396	—	143,985
Pass-through Georgia Institute of Technology	R21CA240214	93.396	—	28,921
Pass-through Georgia Institute of Technology	U01CA214354	93.396	—	5,880
Pass-through Georgia Institute of Technology	U01CA250040	93.396	—	304,293
Pass-through Georgia State University	R33CA235319	93.396	—	56,454
Pass-through Indiana University	R01CA121044	93.396	—	12,289
Pass-through Medical University of South Carolina	R01CA244361	93.396	—	1,459
Pass-through Medical University of South Carolina	R01CA248359	93.396	—	2,203
Pass-through Memorial Sloan Kettering Cancer Center	U24CA220457	93.396	—	21,845
Pass-through Roswell Park Cancer Institute	R01CA121044	93.396	—	(2,238)
Pass-through Univ of Texas Health Sciences Ctr	R01CA239227	93.396	—	32,251
Pass-through University of Alabama Birmingham	U01CA223676	93.396	—	30,410
Pass-through University of Chicago	R01CA174786	93.396	—	6,806
Pass-through University of Rochester	R01CA250531	93.396	—	13,197
Total AL No. 93.396			87,326	7,816,943

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2022

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Cancer Centers Support Grants	P50CA217691	93.397	\$ 11,366	1,773,183
Pass-through Morehouse School of Medicine	U54CA118638	93.397	—	10,019
Total AL No. 93.397			11,366	1,783,202
Cancer Research Manpower	5F32CA199834-02 REVISED	93.398	—	(1,800)
Cancer Research Manpower	F30CA216939	93.398	—	67,959
Cancer Research Manpower	F30CA224968	93.398	—	45,585
Cancer Research Manpower	F30CA236231	93.398	—	24,141
Cancer Research Manpower	F30CA243250	93.398	—	48,038
Cancer Research Manpower	F31CA239563	93.398	—	43,286
Cancer Research Manpower	F31CA243220	93.398	—	35
Cancer Research Manpower	F31CA243472	93.398	—	46,854
Cancer Research Manpower	F31CA243502	93.398	—	44,131
Cancer Research Manpower	F31CA246889	93.398	—	7,094
Cancer Research Manpower	F31CA247564	93.398	—	38,820
Cancer Research Manpower	F31CA254207	93.398	—	45,735
Cancer Research Manpower	F31CA265249	93.398	—	14,118
Cancer Research Manpower	F31CA268737	93.398	—	28,667
Cancer Research Manpower	F32CA257436	93.398	—	88,689
Cancer Research Manpower	K07CA211956	93.398	—	142,440
Cancer Research Manpower	K08CA248962	93.398	—	229,641
Cancer Research Manpower	K12CA237906	93.398	—	528,428
Cancer Research Manpower	K99CA267764	93.398	—	47,446
Cancer Research Manpower	R25CA265964	93.398	—	6,915
Total AL No. 93.398			—	1,496,222
Cancer Control:				
Pass-through Ecog-Acrin Medical Research Foundation	UG1CA189828	93.399	—	38,667
Pass-through Nrg Oncology Foundation, Inc.	UG1CA189867	93.399	—	168,611
Total AL No. 93.399			—	207,278
Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health				
Pass-through CDC Foundation	NU38OT000288-03-01	93.421	—	27,820
Total AL No. 93.421			—	27,820
Every Student Succeeds Act/Preschool Development Grants				
Pass-through Georgia Department of Early Care and Learning	90TP0070	93.434	—	82,839
Total AL No. 93.434			—	82,839
Public Health Training Centers Program				
	UB631680	93.516	327,470	1,028,012
Total AL No. 93.516			327,470	1,028,012
University Centers for Excellence in Developmental Disabilities Education, Research, and Service:				
Pass-through University of Georgia	90DDC10002	93.632	—	97,332
Pass-through University of Georgia	90DDUC0083	93.632	—	1,666
Total AL No. 93.632			—	98,998
COVID-19 – Mental and Behavioral Health Education and Training Grants				
	U3N45397	93.732	—	291,035
Total AL No. 93.732			—	291,035
Hospital Preparedness Program (HPP) Ebola Preparedness and Response Activities				
Pass-through Georgia Dept of Public Health	40500-033-21213660	93.817	—	152,874
Total AL No. 93.817			—	152,874
Health Careers Opportunity Program (HCOP)				
	1D18HP32120-01-00	93.822	51,375	893,667
Total AL No. 93.822			51,375	893,667
COVID-19 – National Ebola Training and Education Center (NETEC)				
COVID-19 – National Ebola Training and Education Center (NETEC)	U3REP150549	93.825	558,249	567,825
National Ebola Training and Education Center (NETEC)	NU38CK000481	93.825	—	16,610
National Ebola Training and Education Center (NETEC)	U3REP150549	93.825	3,089,872	6,605,720
National Ebola Training and Education Center (NETEC)	U3REP170552	93.825	711,622	709,842
Total AL No. 93.825			4,359,743	7,899,997
Planning Grant for Healthcare and Public Health Sector Cybersecurity Information Sharing				
Pass-through University of Florida	R01NS112291	93.835	—	299,275
Total AL No. 93.835			—	299,275
Cardiovascular Diseases Research	5F31HL137367-02	93.837	—	(6,616)
Cardiovascular Diseases Research	5K22HL126922-03	93.837	—	(1,278)
Cardiovascular Diseases Research	F31HL145974	93.837	—	21,011
Cardiovascular Diseases Research	F31HL149272	93.837	—	25,334
Cardiovascular Diseases Research	F31HL149285	93.837	—	42,770
Cardiovascular Diseases Research	F31HL154725	93.837	—	43,597
Cardiovascular Diseases Research	F31HL156426	93.837	—	31,493
Cardiovascular Diseases Research	F31HL156495	93.837	—	45,855
Cardiovascular Diseases Research	F31HL158155	93.837	—	4,392
Cardiovascular Diseases Research	F32HL147547	93.837	—	34,347
Cardiovascular Diseases Research	K01HL133466	93.837	—	1,794
Cardiovascular Diseases Research	K01HL155235	93.837	—	129,286
Cardiovascular Diseases Research	K08HL136873	93.837	—	81,486
Cardiovascular Diseases Research	K23HL128795	93.837	—	57,244
Cardiovascular Diseases Research	K23HL143164	93.837	—	191,750
Cardiovascular Diseases Research	K23HL152903	93.837	—	133,587
Cardiovascular Diseases Research	K24HL148521	93.837	—	160,312
Cardiovascular Diseases Research	K24HL163896	93.837	—	34,472
Cardiovascular Diseases Research	OT2HL155038-02	93.837	—	2,203
Cardiovascular Diseases Research	OT2HL152762	93.837	49,876	189,970
Cardiovascular Diseases Research	P01HL154996	93.837	111,477	319,999
Cardiovascular Diseases Research	R00HL127295	93.837	—	5,114
Cardiovascular Diseases Research	R00HL144824	93.837	—	202,921
Cardiovascular Diseases Research	R01HL109413	93.837	—	718,377
Cardiovascular Diseases Research	R01HL119798	93.837	80,960	536,987
Cardiovascular Diseases Research	R01HL122392	93.837	293,717	1,218,491
Cardiovascular Diseases Research	R01HL125442	93.837	175,242	224,871
Cardiovascular Diseases Research	R01HL125761	93.837	152,845	256,523
Cardiovascular Diseases Research	R01HL127236	93.837	—	(2,900)
Cardiovascular Diseases Research	R01HL130471	93.837	—	48,112
Cardiovascular Diseases Research	R01HL130915	93.837	—	76
Cardiovascular Diseases Research	R01HL133667	93.837	—	690,637
Cardiovascular Diseases Research	R01HL135145	93.837	4,932	255,195
Cardiovascular Diseases Research	R01HL135183	93.837	—	305,032
Cardiovascular Diseases Research	R01HL136205	93.837	42,887	267,060
Cardiovascular Diseases Research	R01HL136345	93.837	—	199,869

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2022

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Cardiovascular Diseases Research	R01HL136915	93.837	\$ —	243,372
Cardiovascular Diseases Research	R01HL137338	93.837	464,408	696,419
Cardiovascular Diseases Research	R01HL139757	93.837	—	277,062
Cardiovascular Diseases Research	R01HL140223	93.837	—	530,414
Cardiovascular Diseases Research	R01HL142762	93.837	—	268,476
Cardiovascular Diseases Research	R01HL143065	93.837	—	174,929
Cardiovascular Diseases Research	R01HL143348	93.837	153,182	939,614
Cardiovascular Diseases Research	R01HL143350	93.837	109,871	563,394
Cardiovascular Diseases Research	R01HL144741	93.837	105,694	391,167
Cardiovascular Diseases Research	R01HL145644	93.837	191,240	610,214
Cardiovascular Diseases Research	R01HL146147	93.837	128,569	478,759
Cardiovascular Diseases Research	R01HL147270	93.837	—	192,879
Cardiovascular Diseases Research	R01HL150005	93.837	—	429,682
Cardiovascular Diseases Research	R01HL150562	93.837	—	100,044
Cardiovascular Diseases Research	R01HL150687	93.837	11,917	344,176
Cardiovascular Diseases Research	R01HL155537	93.837	7,760	173,822
Cardiovascular Diseases Research	R01HL155549	93.837	4,279	277,627
Cardiovascular Diseases Research	R01HL156008	93.837	—	361,754
Cardiovascular Diseases Research	R01HL157242	93.837	—	32,593
Cardiovascular Diseases Research	R01HL157311	93.837	—	287,623
Cardiovascular Diseases Research	R01HL157323	93.837	—	42,585
Cardiovascular Diseases Research	R01HL157363	93.837	—	18,610
Cardiovascular Diseases Research	R01HL158141	93.837	—	831,623
Cardiovascular Diseases Research	R01HL158571	93.837	14,231	622,128
Cardiovascular Diseases Research	R01HL160589	93.837	—	207,526
Cardiovascular Diseases Research	R01HL160693	93.837	—	264,090
Cardiovascular Diseases Research	R01HL166252	93.837	—	21,113
Cardiovascular Diseases Research	R01HL166604	93.837	—	5,487
Cardiovascular Diseases Research	R03HL146874	93.837	—	434,576
Cardiovascular Diseases Research	R03HL146879	93.837	—	(7,743)
Cardiovascular Diseases Research	R03HL155253	93.837	—	74,461
Cardiovascular Diseases Research	R03HL156476	93.837	—	122,565
Cardiovascular Diseases Research	R21HL145486	93.837	—	5,709
Cardiovascular Diseases Research	R21HL156184	93.837	—	44,228
Cardiovascular Diseases Research	R61HL154116	93.837	—	493,709
Cardiovascular Diseases Research	T32HL007745	93.837	—	434,605
Cardiovascular Diseases Research	T32HL130025	93.837	—	583,240
Cardiovascular Diseases Research	U01HL128566	93.837	129,343	144,506
Cardiovascular Diseases Research	U54HL141981	93.837	319,083	1,245,945
Cardiovascular Diseases Research	UG1HL135682	93.837	78,825	176,179
Cardiovascular Diseases Research	U01HL146241	93.837	110,001	2,246,618
Cardiovascular Diseases Research	7K01HL092591-06	93.837	—	(93,149)
Cardiovascular Diseases Research	R01HL159062	93.837	—	38,811
Pass-through Albert Einstein College of Medicine	UH3HL148318	93.837	—	2,408
Pass-through Ann & Robert H. Lurie Children's Hospital	R01HL086741	93.837	—	113,045
Pass-through Beth Israel Deaconess Medical Center	U01HL146382	93.837	—	26,055
Pass-through Boston University	OT2HL152643	93.837	—	6,002
Pass-through Case Western Reserve University	R01HL139420	93.837	—	29,076
Pass-through Children's Hospital of Philadelphia	R34HL142142	93.837	—	286
Pass-through Children's Hospital of Philadelphia	R01HL135505	93.837	—	25,920
Pass-through Georgia Institute of Technology	R01HL140325	93.837	—	92,591
Pass-through Georgia Institute of Technology	R01HL144714	93.837	—	106,558
Pass-through Georgia State University	R01HL14205	93.837	—	14,493
Pass-through Ohio State University	R01HL148581	93.837	—	9,027
Pass-through Research Institute at Nationwide Children's Hospital	R01HL145032	93.837	—	33,163
Pass-through State Univ of New York Downstate Med Ctr	R25HL105446	93.837	—	12,512
Pass-through University of Alabama Birmingham	R01HL131017	93.837	—	70,339
Pass-through University of California Berkeley	R01HL157820	93.837	—	13,360
Pass-through University of California Los Angeles	R01HL118650	93.837	—	20,054
Pass-through University of California Los Angeles	R01HL160850	93.837	—	22,888
Pass-through University of Miami	R25HL105444	93.837	—	6,826
Pass-through University of Minnesota	R01HL141288	93.837	—	11,983
Pass-through University of Texas Houston	K01HL149982	93.837	—	24,107
Pass-through University of Virginia	R01HL130918	93.837	—	2,844
Pass-through University of Virginia	R01HL137112	93.837	—	195,400
Pass-through University of Washington	R01HL153136	93.837	—	13,350
Pass-through Wake Forest University	01HL135853	93.837	—	13,791
Pass-through Washington University	R01HL156991	93.837	—	67,344
Total AL No. 93.837			2,730,339	22,343,245
Lung Diseases Research	F31HL139134	93.838	—	(1,874)
Lung Diseases Research	F31HL149323	93.838	—	35,840
Lung Diseases Research	F31HL156639	93.838	—	43,941
Lung Diseases Research	F32HL151133	93.838	—	320
Lung Diseases Research	K23HL151887	93.838	—	187,984
Lung Diseases Research	K99HL151965	93.838	—	45,747
Lung Diseases Research	R00HL151965	93.838	—	243,896
Lung Diseases Research	R01HL113548	93.838	34,618	265,198
Lung Diseases Research	R01HL136414	93.838	226,247	430,115
Lung Diseases Research	R01HL139876	93.838	258,181	623,725
Lung Diseases Research	R01HL142866	93.838	—	482,148
Lung Diseases Research	R01HL144478	93.838	76,873	323,155
Lung Diseases Research	R01HL152210	93.838	—	572,876
Lung Diseases Research	R01HL158979	93.838	—	174,493
Lung Diseases Research	R01HL159058	93.838	—	59,605
Lung Diseases Research	R35HL150803	93.838	—	653,873
Lung Diseases Research	R56HL150658	93.838	—	154,900
Lung Diseases Research	R56HL152167	93.838	—	98,913
Lung Diseases Research	T32HL116271	93.838	—	496,899
Lung Diseases Research	UM1HL134590	93.838	1,627,088	3,032,082
Lung Diseases Research	R01HL138410	93.838	—	85,725
Pass-through Medical College of Georgia	1OT2HL1568	93.838	—	44,845
Pass-through Morehouse School of Medicine	OT2HL158287	93.838	—	116,789
Pass-through Morehouse School of Medicine	U01HL130045	93.838	—	45,075
Pass-through University of Arizona	UG3HL147016	93.838	—	89,543
Pass-through University of Georgia	R01HL136707	93.838	—	118,583
Pass-through University of Pittsburgh	R01HL138630	93.838	—	76,026
Pass-through University of Washington	723385/AMNDS	93.838	—	(360)
Total AL No. 93.838			2,223,007	8,500,952

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2022

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
COVID-19 – Blood Diseases and Resources Research	R01HL138656	93.839	\$ —	206,387
Blood Diseases and Resources Research	SRO1HL131414-03	93.839	—	(834)
Blood Diseases and Resources Research	F31HL138934	93.839	—	12,404
Blood Diseases and Resources Research	F31HL149357	93.839	—	46,183
Blood Diseases and Resources Research	F31HL154656	93.839	—	33,223
Blood Diseases and Resources Research	F31HL154703	93.839	—	46,721
Blood Diseases and Resources Research	F31HL158223	93.839	—	51,048
Blood Diseases and Resources Research	F31HL160210	93.839	—	20,563
Blood Diseases and Resources Research	K01HL133518	93.839	—	121,452
Blood Diseases and Resources Research	K08HL141635	93.839	—	159,910
Blood Diseases and Resources Research	K08HL151965	93.839	—	102,564
Blood Diseases and Resources Research	K23HL133446	93.839	—	(26)
Blood Diseases and Resources Research	K23HL133457	93.839	10,807	165,552
Blood Diseases and Resources Research	K23HL136900	93.839	—	63,529
Blood Diseases and Resources Research	K23HL140142	93.839	6,247	159,161
Blood Diseases and Resources Research	K23HL146904	93.839	—	156,263
Blood Diseases and Resources Research	K25HL141636	93.839	—	181,107
Blood Diseases and Resources Research	K99HL150595	93.839	—	199,722
Blood Diseases and Resources Research	K99HL150626	93.839	—	245,779
Blood Diseases and Resources Research	R01HL082808	93.839	112,934	408,829
Blood Diseases and Resources Research	R01HL129141	93.839	—	448,197
Blood Diseases and Resources Research	R01HL130995	93.839	—	430,530
Blood Diseases and Resources Research	R01HL135575	93.839	—	(147)
Blood Diseases and Resources Research	R01HL137128	93.839	—	5,664
Blood Diseases and Resources Research	R01HL138423	93.839	—	(33,231)
Blood Diseases and Resources Research	R01HL138656	93.839	328,397	517,930
Blood Diseases and Resources Research	R01HL138714	93.839	604,163	844,040
Blood Diseases and Resources Research	R01HL140589	93.839	469,194	769,123
Blood Diseases and Resources Research	R01HL141335	93.839	—	403,526
Blood Diseases and Resources Research	R01HL143794	93.839	93,857	473,539
Blood Diseases and Resources Research	R01HL146668	93.839	135,979	254,169
Blood Diseases and Resources Research	R01HL152074	93.839	—	405,344
Blood Diseases and Resources Research	R01HL152131	93.839	—	249,519
Blood Diseases and Resources Research	R01HL152322	93.839	29,851	518,222
Blood Diseases and Resources Research	R01HL154034	93.839	—	(19,474)
Blood Diseases and Resources Research	R01HL156024	93.839	—	(75,372)
Blood Diseases and Resources Research	R01HL159213	93.839	8,719	156,621
Blood Diseases and Resources Research	R01HL162725	93.839	—	28,515
Blood Diseases and Resources Research	R01HL164583	93.839	—	4,779
Blood Diseases and Resources Research	R03HL154829	93.839	—	68,690
Blood Diseases and Resources Research	R21HL146299	93.839	34,266	138,673
Blood Diseases and Resources Research	R35HL145000	93.839	—	770,539
Blood Diseases and Resources Research	T32HL069769	93.839	—	81,615
Blood Diseases and Resources Research	T32HL139443	93.839	—	328,528
Blood Diseases and Resources Research	U01HL117721	93.839	—	(116,350)
Blood Diseases and Resources Research	U01HL139483	93.839	—	824,327
Blood Diseases and Resources Research	UG3HL148560	93.839	460,600	506,061
Blood Diseases and Resources Research	UH3HL148560	93.839	244,027	538,622
Blood Diseases and Resources Research	R01HL155330	93.839	1,945	348,055
Blood Diseases and Resources Research	R01HL136480	93.839	—	9,464
Pass-through Ann & Robert H. Lurie Children's Hospital	RHL106365	93.839	1,218	16,226
Pass-through Augusta University Research Institute Inc	P01HL046925	93.839	—	44,558
Pass-through Boston Children's Hospital	P01HL132819	93.839	—	61,102
Pass-through Fred Hutchinson Cancer Center	R34HL142322	93.839	—	25,646
Pass-through Lehigh University	R01HL153986	93.839	—	85,839
Pass-through Rice University	R01HL152314	93.839	—	315,056
Pass-through University of Alabama Birmingham	R01HL133896	93.839	298	11,375
Pass-through University of Florida	UG1HL069301	93.839	—	91,440
Pass-through University of Pittsburgh	UG3HL143192	93.839	—	39,623
Pass-through University of Washington	R01HL141781	93.839	—	729
Pass-through Vanderbilt University	U01HL156620	93.839	—	6,588
Total AL No. 93.839			2,542,502	11,957,637
Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders	K23HL152368	93.840	—	144,928
Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders	R33HL138657	93.840	—	446,219
Pass-through All India Institute of Medical Sciences	U01HL138635	93.840	—	63,347
Pass-through Seattle Biomedical Research Institute	U01HL142103	93.840	—	5,815
Pass-through University of Washington	R01HL137808	93.840	—	92,918
Pass-through University Of Witswatersrand	UG3HL156388	93.840	—	257,210
Total AL No. 93.840			—	1,010,437
Arthritis, Musculoskeletal and Skin Diseases Research	5F31AR069994-02 REVISED	93.846	—	(98)
Arthritis, Musculoskeletal and Skin Diseases Research	F31AR078047	93.846	—	26,062
Arthritis, Musculoskeletal and Skin Diseases Research	F32AR074249	93.846	—	(3,148)
Arthritis, Musculoskeletal and Skin Diseases Research	K23AR075888	93.846	—	146,475
Arthritis, Musculoskeletal and Skin Diseases Research	R01AR048615	93.846	—	257,820
Arthritis, Musculoskeletal and Skin Diseases Research	R01AR051987	93.846	—	231,568
Arthritis, Musculoskeletal and Skin Diseases Research	R01AR068157	93.846	—	11,363
Arthritis, Musculoskeletal and Skin Diseases Research	R01AR070091	93.846	—	170,319
Arthritis, Musculoskeletal and Skin Diseases Research	R01AR070736	93.846	—	250,510
Arthritis, Musculoskeletal and Skin Diseases Research	R01AR070898	93.846	43,880	108,050
Arthritis, Musculoskeletal and Skin Diseases Research	R01AR071397	93.846	—	304,331
Arthritis, Musculoskeletal and Skin Diseases Research	R01AR073874	93.846	52,753	533,517
Arthritis, Musculoskeletal and Skin Diseases Research	R01AR076089	93.846	—	258,539
Arthritis, Musculoskeletal and Skin Diseases Research	R01AR076153	93.846	76,046	309,970
Arthritis, Musculoskeletal and Skin Diseases Research	R01AR076427	93.846	34,818	432,421
Arthritis, Musculoskeletal and Skin Diseases Research	R01AR077926	93.846	—	459,965
Arthritis, Musculoskeletal and Skin Diseases Research	R01AR078908	93.846	—	107,113
Arthritis, Musculoskeletal and Skin Diseases Research	R01AR079298	93.846	—	355,672
Arthritis, Musculoskeletal and Skin Diseases Research	R01AR080750	93.846	—	66,613

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2022

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Arthritis, Musculoskeletal and Skin Diseases Research	R21AR071529	93.846	\$ —	145,336
Arthritis, Musculoskeletal and Skin Diseases Research	R21AR071536	93.846	39,099	38,871
Arthritis, Musculoskeletal and Skin Diseases Research	R21AR072222	93.846	—	498
Arthritis, Musculoskeletal and Skin Diseases Research	R21AR073593	93.846	—	47,540
Arthritis, Musculoskeletal and Skin Diseases Research	R21AR078463	93.846	—	25,350
Arthritis, Musculoskeletal and Skin Diseases Research	U01AR067997	93.846	70,116	440,966
Pass-through Brigham and Womens Hospital	R21AR077768	93.846	—	62,012
Pass-through Cincinnati Childrens Hospital	R01AR070474	93.846	—	36,012
Pass-through Hebrew Rehabilitation Center For Aged	R01AR061445	93.846	—	14,421
Pass-through Louisiana State University	R01AR073277	93.846	—	32,950
Pass-through Mayo Clinic Rochester	R01AR055563	93.846	—	172,832
Pass-through Mount Sinai School of Medicine	R01AR069315	93.846	—	2,269
Pass-through Ohio University	R01AR077248	93.846	—	86,246
Pass-through University of Michigan	U01AR073485	93.846	—	17,190
Total AL No. 93.846			316,712	5,149,655
Diabetes, Digestive, and Kidney Diseases Extramural Research	F30DK117570	93.847	—	25,124
Diabetes, Digestive, and Kidney Diseases Extramural Research	F31DK122745	93.847	—	45,743
Diabetes, Digestive, and Kidney Diseases Extramural Research	F31DK126435	93.847	—	45,932
Diabetes, Digestive, and Kidney Diseases Extramural Research	F31DK126467	93.847	—	75,779
Diabetes, Digestive, and Kidney Diseases Extramural Research	F31DK126501	93.847	—	31,818
Diabetes, Digestive, and Kidney Diseases Extramural Research	F32DK120195	93.847	—	(903)
Diabetes, Digestive, and Kidney Diseases Extramural Research	F32DK127848	93.847	—	69,739
Diabetes, Digestive, and Kidney Diseases Extramural Research	K01DK109025	93.847	—	61,206
Diabetes, Digestive, and Kidney Diseases Extramural Research	K01DK128384	93.847	—	140,858
Diabetes, Digestive, and Kidney Diseases Extramural Research	K08DK111998	93.847	—	109,847
Diabetes, Digestive, and Kidney Diseases Extramural Research	K23DK113241	93.847	—	191,345
Diabetes, Digestive, and Kidney Diseases Extramural Research	K23DK118189	93.847	2,001	242,942
Diabetes, Digestive, and Kidney Diseases Extramural Research	K23DK122115	93.847	—	202,791
Diabetes, Digestive, and Kidney Diseases Extramural Research	K23DK122199	93.847	—	168,718
Diabetes, Digestive, and Kidney Diseases Extramural Research	K23DK123384	93.847	—	207,171
Diabetes, Digestive, and Kidney Diseases Extramural Research	K23DK124647	93.847	—	188,432
Diabetes, Digestive, and Kidney Diseases Extramural Research	K23MH129684	93.847	—	23,130
Diabetes, Digestive, and Kidney Diseases Extramural Research	P30DK111024	93.847	340,091	877,541
Diabetes, Digestive, and Kidney Diseases Extramural Research	P30DK125013	93.847	212,200	667,947
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK044234	93.847	—	258,112
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK047987	93.847	—	492,750
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK054514	93.847	—	(1,872)
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK080684	93.847	85,229	273,125
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK087694	93.847	194,277	924,915
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK107719	93.847	—	110,899
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK108070	93.847	49,708	196,082
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK110409	93.847	—	171,073
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK111678	93.847	—	66,197
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK112946	93.847	—	146,078
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK114891	93.847	75,726	200,198
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK115213	93.847	—	255,756
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK115937	93.847	81,509	230,628
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK116799	93.847	—	392,091
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK119229	93.847	—	412,517
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK120814	93.847	—	95,255
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK122701	93.847	—	559,690
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK124821	93.847	103,523	453,862
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK125187	93.847	158,323	521,285
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK125246	93.847	—	458,648
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK125647	93.847	15,590	469,166
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK125701	93.847	—	282,217
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK125936	93.847	206,759	460,634
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK127083	93.847	214,520	234,027
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK128061	93.847	—	517,317
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK129950	93.847	—	482,746
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK132653	93.847	—	136,889
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK133650	93.847	—	27,630
Diabetes, Digestive, and Kidney Diseases Extramural Research	R03DK122111	93.847	—	5,166
Diabetes, Digestive, and Kidney Diseases Extramural Research	R03DK124736	93.847	—	37,673
Diabetes, Digestive, and Kidney Diseases Extramural Research	R18DK118467	93.847	—	63,793
Diabetes, Digestive, and Kidney Diseases Extramural Research	R21DK119997	93.847	—	18
Diabetes, Digestive, and Kidney Diseases Extramural Research	R21DK122229	93.847	254	23,504
Diabetes, Digestive, and Kidney Diseases Extramural Research	R21DK123616	93.847	2,402	199,228
Diabetes, Digestive, and Kidney Diseases Extramural Research	R25DK101390	93.847	—	89,044
Diabetes, Digestive, and Kidney Diseases Extramural Research	R56DK074731	93.847	—	121,239
Diabetes, Digestive, and Kidney Diseases Extramural Research	T32DK007656	93.847	—	18,947
Diabetes, Digestive, and Kidney Diseases Extramural Research	T32DK108735	93.847	—	11,064
Diabetes, Digestive, and Kidney Diseases Extramural Research	U01DK062470	93.847	603,209	1,927,716
Diabetes, Digestive, and Kidney Diseases Extramural Research	U01DK118099	93.847	23,650	248,205
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK119793	93.847	—	329,067
Pass-through Adventhealth Research Institute	R01DK112700	93.847	—	12,355
Pass-through Ann & Robert H. Lurie Children's Hospital	U01DK127995	93.847	19,688	36,098
Pass-through Augusta University Research Institute Inc	U24DK115255	93.847	—	8,768
Pass-through Baylor College of Medicine	R01DK124395	93.847	—	135,350
Pass-through Children's Hospital of Philadelphia	R01DK110749	93.847	—	28,337
Pass-through Connecticut Childrens Medical Center	U34DK126638	93.847	—	6,345
Pass-through Cornell University	R01DK056628	93.847	—	4,157
Pass-through Cornell University	R01DK103046	93.847	—	35,795
Pass-through Georgia State University	R01DK099071	93.847	—	26,956
Pass-through Georgia State University	R01DK126080	93.847	—	6,432
Pass-through Johns Hopkins University	R01DK110375	93.847	—	203,344
Pass-through Mayo Clinic	RC2DK118619	93.847	—	189,056
Pass-through Mount Sinai School of Medicine	U01DK119200	93.847	—	54,016
Pass-through Northern California Inst of Res and Edu	01DK109823	93.847	—	934

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2022

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through Research Institute at Nationwide Children's Hospital	U01DK100866	93.847	\$ —	36,973
Pass-through Translational Genomics Research Inst	R01 DK107735	93.847	—	1,719
Pass-through University of Alabama Birmingham	R01DK115473	93.847	—	32,656
Pass-through University of Alabama Birmingham	R01DK128457	93.847	—	11,150
Pass-through University of Alabama Birmingham	U01DK106858	93.847	—	72,099
Pass-through University of Kansas Medical Center	R01DK096611	93.847	—	12,492
Pass-through University of Kansas Medical Center	R01DK113111	93.847	—	9,506
Pass-through University of Kentucky	R01DK095662	93.847	—	13,632
Pass-through University of Michigan	R01DK089763	93.847	—	17,660
Pass-through University of South Florida	U01DK106993	93.847	—	145,329
Pass-through Vanderbilt University Medical Center	R01DK120814	93.847	—	8,256
Pass-through Virginia Commonwealth University	U01DK061731	93.847	—	88,016
Pass-through Wright State University	R21DK119879	93.847	—	(44,008)
Total AL No. 93.847			2,388,659	16,431,362
Extramural Research Programs in the Neurosciences and Neurological Disorders	F31NS110312	93.853	—	29,846
Extramural Research Programs in the Neurosciences and Neurological Disorders	F32HD105458	93.853	—	64,905
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS119831	93.853	130,388	154,426
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS120182	93.853	5,825	646,908
Extramural Research Programs in the Neurosciences and Neurological Disorders	R03HD104276	93.853	—	210,350
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS112740	93.853	—	125,216
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS112948	93.853	—	171,267
Extramural Research Programs in the Neurosciences and Neurological Disorders	1R21NS106346-01	93.853	—	48
Extramural Research Programs in the Neurosciences and Neurological Disorders	1R21NS123882-01	93.853	—	49,147
Extramural Research Programs in the Neurosciences and Neurological Disorders	5K23NS083748-05	93.853	—	(22)
Extramural Research Programs in the Neurosciences and Neurological Disorders	5P30NS055077-09	93.853	—	(586)
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS095064-03 REVISED	93.853	—	(4,000)
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS095279-04	93.853	—	1,879
Extramural Research Programs in the Neurosciences and Neurological Disorders	DP2NS127291	93.853	1,821	348,795
Extramural Research Programs in the Neurosciences and Neurological Disorders	DP2NS127704	93.853	—	121,449
Extramural Research Programs in the Neurosciences and Neurological Disorders	F31NS113530	93.853	—	44,083
Extramural Research Programs in the Neurosciences and Neurological Disorders	F31NS113572	93.853	—	16,944
Extramural Research Programs in the Neurosciences and Neurological Disorders	F31NS115479	93.853	—	44,256
Extramural Research Programs in the Neurosciences and Neurological Disorders	F31NS117086	93.853	—	42,565
Extramural Research Programs in the Neurosciences and Neurological Disorders	F31NS117129	93.853	—	44,036
Extramural Research Programs in the Neurosciences and Neurological Disorders	F31NS118667	93.853	—	43,619
Extramural Research Programs in the Neurosciences and Neurological Disorders	F31NS124269	93.853	—	43,286
Extramural Research Programs in the Neurosciences and Neurological Disorders	F31NS127419	93.853	—	18,335
Extramural Research Programs in the Neurosciences and Neurological Disorders	F31NS127530	93.853	—	16,140
Extramural Research Programs in the Neurosciences and Neurological Disorders	F31NS127545	93.853	—	8,986
Extramural Research Programs in the Neurosciences and Neurological Disorders	F99NS129168	93.853	—	4,392
Extramural Research Programs in the Neurosciences and Neurological Disorders	K00NS108539	93.853	—	93,545
Extramural Research Programs in the Neurosciences and Neurological Disorders	K01NS124912	93.853	—	183,019
Extramural Research Programs in the Neurosciences and Neurological Disorders	K08NS099474	93.853	—	270
Extramural Research Programs in the Neurosciences and Neurological Disorders	K08NS105929	93.853	—	148,659
Extramural Research Programs in the Neurosciences and Neurological Disorders	K23NS097576	93.853	—	187,799
Extramural Research Programs in the Neurosciences and Neurological Disorders	K23NS105944	93.853	—	220,274
Extramural Research Programs in the Neurosciences and Neurological Disorders	K23NS119964	93.853	—	46,329
Extramural Research Programs in the Neurosciences and Neurological Disorders	P50NS096865	93.853	—	74,363
Extramural Research Programs in the Neurosciences and Neurological Disorders	P50NS123103	93.853	89,230	1,824,507
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS036232	93.853	—	170,242
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS037112	93.853	—	366,957
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS045962	93.853	52,656	546,371
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS047357	93.853	—	514,189
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS065992	93.853	—	432,748
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS078095	93.853	—	312,160
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS083654	93.853	—	227,621
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS084844	93.853	—	372,264
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS085387	93.853	—	36
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS088748	93.853	192,794	653,434
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS089694	93.853	—	49,845
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS090677	93.853	—	81,024
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS091201	93.853	—	376,997
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS091585	93.853	—	107,846
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS092343	93.853	—	87,502
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS093016	93.853	—	372,960
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS093362	93.853	—	155,718
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS095181	93.853	—	1,144
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS095269	93.853	—	212,911
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS097549	93.853	302,047	518,293
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS097776	93.853	—	189,446
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS098441	93.853	—	222,797
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS099375	93.853	—	191,477
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS100908	93.853	—	262,468
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS100967	93.853	—	169,551
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS101701	93.853	—	515,452
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS102306	93.853	209,254	349,739
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS102850	93.853	—	339,051
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS102871	93.853	—	264,684
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS105971	93.853	—	343,947
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS105982	93.853	—	254,676
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS107505	93.853	174,556	649,239
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS109237	93.853	—	419,054
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS109242	93.853	—	379,487
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS110110	93.853	61,403	432,591
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS110347	93.853	—	18,283
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS110386	93.853	—	419,823
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS111280	93.853	—	385,776
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS111470	93.853	46,385	450,238
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS111969	93.853	—	479,537
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS112308	93.853	—	505,698
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS112350	93.853	—	221,580
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS113746	93.853	382,145	719,285

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2022

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS114130	93.853	\$ 51,179	553,193
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS114221	93.853	—	373,883
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS114253	93.853	158,825	390,460
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS118819	93.853	—	465,877
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS119683	93.853	33,742	190,304
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS119758	93.853	—	347,829
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS120676	93.853	130,566	434,949
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS123447	93.853	74,796	536,384
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS123562	93.853	—	367,010
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS125143	93.853	70,328	231,834
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS125317	93.853	—	1,707
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS125768	93.853	—	381,930
Extramural Research Programs in the Neurosciences and Neurological Disorders	R01NS126924	93.853	—	83,957
Extramural Research Programs in the Neurosciences and Neurological Disorders	R03NS114791	93.853	—	37,737
Extramural Research Programs in the Neurosciences and Neurological Disorders	R03NS127079	93.853	—	59,166
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS108758	93.853	—	78,412
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS108760	93.853	—	6,294
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS110416	93.853	—	124,508
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS111765	93.853	—	57,034
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS113019	93.853	—	139,922
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS114603	93.853	—	67,157
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS114795	93.853	—	129,145
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS114839	93.853	—	24,515
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS114882	93.853	—	87,045
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS114908	93.853	—	37,384
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS115758	93.853	—	164,623
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS116311	93.853	—	57,312
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS116318	93.853	—	20,574
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS116438	93.853	36,868	145,604
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS116639	93.853	—	38,735
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS116665	93.853	—	174,083
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS116724	93.853	—	60,600
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS117113	93.853	—	111,332
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS119985	93.853	—	195,468
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS121850	93.853	—	226,387
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS122011	93.853	—	224,936
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS122013	93.853	—	62,706
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS123487	93.853	—	21,326
Extramural Research Programs in the Neurosciences and Neurological Disorders	R21NS125502	93.853	—	80,664
Extramural Research Programs in the Neurosciences and Neurological Disorders	R3NS106120	93.853	—	295,226
Extramural Research Programs in the Neurosciences and Neurological Disorders	R3NS111602	93.853	—	834,202
Extramural Research Programs in the Neurosciences and Neurological Disorders	R3NS111619	93.853	—	722,716
Extramural Research Programs in the Neurosciences and Neurological Disorders	R5NS122964	93.853	—	106,930
Extramural Research Programs in the Neurosciences and Neurological Disorders	R5NS124764	93.853	—	357,296
Extramural Research Programs in the Neurosciences and Neurological Disorders	T32NS007480	93.853	—	23
Extramural Research Programs in the Neurosciences and Neurological Disorders	T32NS096050	93.853	—	344,095
Extramural Research Programs in the Neurosciences and Neurological Disorders	U24NS100673	93.853	56,036	122,442
Extramural Research Programs in the Neurosciences and Neurological Disorders	U24NS107234	93.853	—	264,191
Extramural Research Programs in the Neurosciences and Neurological Disorders	U54NS116025	93.853	366,172	665,149
Extramural Research Programs in the Neurosciences and Neurological Disorders	UG3NS100559	93.853	83,245	147,369
Extramural Research Programs in the Neurosciences and Neurological Disorders	UG3NS113879	93.853	—	202
Extramural Research Programs in the Neurosciences and Neurological Disorders	UG3NS127386	93.853	—	111,435
Pass-through Albert Einstein College of Medicine	K12NS080223	93.853	—	70,092
Pass-through Baylor College of Medicine	U01NS114042	93.853	—	108,043
Pass-through Brigham and Womens Hospital	R21NS119660	93.853	—	137,320
Pass-through Cedars Sinai Medical Center	R01NS121544	93.853	—	101,198
Pass-through Childrens Healthcare of Atlanta	R21NS103507	93.853	—	(127)
Pass-through Children's Hospital of Philadelphia	U01NS106845	93.853	2,721	16,215
Pass-through Children's Hospital of Philadelphia	U54NS115052	93.853	—	12,723
Pass-through Columbia University	R01NS110826	93.853	—	56,666
Pass-through Creighton University	R01NS118731	93.853	—	98,152
Pass-through George Washington University	R01NS124477	93.853	—	73,809
Pass-through George Washington University	R01NS126090	93.853	—	156,597
Pass-through Georgia Institute of Technology	R01NS115994	93.853	—	234,993
Pass-through Georgia Institute of Technology	R21NS117067	93.853	—	6,651
Pass-through Georgia State University	R21NS111355	93.853	—	7,948
Pass-through Johns Hopkins University	R01NS111283	93.853	—	16,214
Pass-through Mayo Clinic	P01NS084974	93.853	—	414,776
Pass-through Mayo Clinic	U54NS115198	93.853	—	34,034
Pass-through Medical University of South Carolina	R01NS110347	93.853	—	48,527
Pass-through Morehouse School of Medicine	R01NS112422	93.853	—	166,912
Pass-through Morehouse School of Medicine	R21 NS116726	93.853	42,194	79,643
Pass-through Mount Sinai School of Medicine	UH3NS103550	93.853	—	133,625
Pass-through Pennsylvania State University	EMUNS113912	93.853	—	17,319
Pass-through Stanford University	U01NS038455	93.853	—	154,824
Pass-through Univ of Texas Health Sciences Ctr	R61NS113329-01	93.853	—	6,623
Pass-through University of Akron	R15NS109957	93.853	—	44,076
Pass-through University of California Los Angeles	R01NS112799	93.853	—	24,224
Pass-through University of Georgia	R01NS099596	93.853	—	53,272
Pass-through University of Miami	R01NS084288	93.853	—	536
Pass-through University of Pennsylvania	U01NS113198	93.853	—	70,284
Pass-through University of Pittsburgh	R21NS111063	93.853	—	9,893
Pass-through University of South Carolina	R01NS117821	93.853	—	145,718
Pass-through University of Southern California	R01NS115845	93.853	—	16,431
Pass-through University of Utah	R01NS097819	93.853	—	14,122
Pass-through University of Wisconsin-Madison	R01NS099158	93.853	—	5,283
Pass-through University of Wisconsin-Madison	R01NS108756	93.853	—	197,845
Pass-through Weill Cornell Medical College	R01NS093002	93.853	—	40,705
Pass-through Weill Cornell Medical College	R01NS115963	93.853	—	66,030
Pass-through Wright State University	R01NS107398	93.853	—	3,357
Total AL No. 93.853			2,755,176	32,376,451

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2022

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
COVID-19 – Allergy and Infectious Diseases Research	P01A1125180	93.855	\$ —	182,329
COVID-19 – Allergy and Infectious Diseases Research	R01A1123126	93.855	—	(105)
COVID-19 – Allergy and Infectious Diseases Research	R01A1141327	93.855	—	1,213
COVID-19 – Allergy and Infectious Diseases Research	R01A1143875	93.855	35,742	908,773
COVID-19 – Allergy and Infectious Diseases Research	R01A1148378	93.855	—	106,824
COVID-19 – Allergy and Infectious Diseases Research	R01A1161570	93.855	176,568	607,113
COVID-19 – Allergy and Infectious Diseases Research	U01A1141993	93.855	81,840	390,276
COVID-19 – Allergy and Infectious Diseases Research	U19A1057266	93.855	779,152	1,964,525
COVID-19 – Allergy and Infectious Diseases Research	U19A090023	93.855	—	2,151,763
COVID-19 – Allergy and Infectious Diseases Research	U19A1110483	93.855	4,371,487	7,708,279
COVID-19 – Allergy and Infectious Diseases Research	UM1A1069418	93.855	—	106,073
COVID-19 – Allergy and Infectious Diseases Research	UM1A1148576	93.855	—	8,222,606
COVID-19 – Allergy and Infectious Diseases Research	UM1A1148684	93.855	9,497,219	10,992,148
COVID-19 – Allergy and Infectious Diseases Research	P51OD011132	93.855	58,351	1,095,851
COVID-19 – Allergy and Infectious Diseases Research	P51OD011132	93.855	11,671	31,633
Allergy and Infectious Diseases Research	1R03A1139675-01	93.855	—	(933)
Allergy and Infectious Diseases Research	1R03A1139871-01	93.855	—	4,425
Allergy and Infectious Diseases Research	1R21A1141094-01	93.855	—	6,247
Allergy and Infectious Diseases Research	5011649 / 8470038	93.855	—	85,550
Allergy and Infectious Diseases Research	5R21A1135711-02	93.855	—	(1,933)
Allergy and Infectious Diseases Research	SU19A057266-15	93.855	—	(117)
Allergy and Infectious Diseases Research	5JUN1A1069418-13	93.855	—	(10)
Allergy and Infectious Diseases Research	F30A1152342	93.855	—	41,360
Allergy and Infectious Diseases Research	F31A1145178	93.855	—	(725)
Allergy and Infectious Diseases Research	F31A1147589	93.855	—	46,995
Allergy and Infectious Diseases Research	F31A1147611	93.855	—	49,296
Allergy and Infectious Diseases Research	F31A1150114	93.855	—	46,871
Allergy and Infectious Diseases Research	F31A1152459	93.855	—	28,628
Allergy and Infectious Diseases Research	F31A1154738	93.855	—	41,524
Allergy and Infectious Diseases Research	F31A1154792	93.855	—	45,932
Allergy and Infectious Diseases Research	F31A1155158	93.855	—	45,572
Allergy and Infectious Diseases Research	F31A1157884	93.855	—	45,964
Allergy and Infectious Diseases Research	F31A1161911	93.855	—	13,624
Allergy and Infectious Diseases Research	F32A1145150	93.855	—	(4,615)
Allergy and Infectious Diseases Research	F32A1161857	93.855	—	62,353
Allergy and Infectious Diseases Research	K01A1130326	93.855	—	107,536
Allergy and Infectious Diseases Research	K01A1166093	93.855	—	5,271
Allergy and Infectious Diseases Research	K08A1132747	93.855	—	175,855
Allergy and Infectious Diseases Research	K08A1139348	93.855	—	205,581
Allergy and Infectious Diseases Research	K23A1124913	93.855	—	119,946
Allergy and Infectious Diseases Research	K23A1134192	93.855	—	186,583
Allergy and Infectious Diseases Research	K23A1143479	93.855	8,910	169,267
Allergy and Infectious Diseases Research	K23A1144036	93.855	12,880	160,350
Allergy and Infectious Diseases Research	K23A1144040	93.855	—	175,990
Allergy and Infectious Diseases Research	K24A1114444	93.855	—	187,605
Allergy and Infectious Diseases Research	K99A1146271	93.855	—	(378)
Allergy and Infectious Diseases Research	K99A1153736	93.855	—	108,280
Allergy and Infectious Diseases Research	P01A1125180	93.855	21,666	894,670
Allergy and Infectious Diseases Research	P30A050409	93.855	599,414	3,323,857
Allergy and Infectious Diseases Research	P30A1168396	93.855	—	81,596
Allergy and Infectious Diseases Research	R00A1138860	93.855	—	188,305
Allergy and Infectious Diseases Research	R01A1021150	93.855	186,016	413,406
Allergy and Infectious Diseases Research	R01A1030048	93.855	—	497,142
Allergy and Infectious Diseases Research	R01A1051231	93.855	195,348	898,170
Allergy and Infectious Diseases Research	R01A1053668	93.855	151,503	467,500
Allergy and Infectious Diseases Research	R01A1064060	93.855	—	81,270
Allergy and Infectious Diseases Research	R01A1076119	93.855	—	22,255
Allergy and Infectious Diseases Research	R01A1088025	93.855	12,089	557,392
Allergy and Infectious Diseases Research	R01A1072435	93.855	—	516,067
Allergy and Infectious Diseases Research	R01A1107960	93.855	38,871	806,437
Allergy and Infectious Diseases Research	R01A1113021	93.855	59,848	549,557
Allergy and Infectious Diseases Research	R01A1116933	93.855	—	434,225
Allergy and Infectious Diseases Research	R01A1120880	93.855	193,120	645,469
Allergy and Infectious Diseases Research	R01A1121252	93.855	—	8,584
Allergy and Infectious Diseases Research	R01A1121315	93.855	40,089	(4,162)
Allergy and Infectious Diseases Research	R01A1123126	93.855	—	(1,254)
Allergy and Infectious Diseases Research	R01A1123733	93.855	—	185,337
Allergy and Infectious Diseases Research	R01A1124680	93.855	69,484	142,506
Allergy and Infectious Diseases Research	R01A1125064	93.855	—	496,389
Allergy and Infectious Diseases Research	R01A1125202	93.855	148,125	556,287
Allergy and Infectious Diseases Research	R01A1125268	93.855	—	6,170
Allergy and Infectious Diseases Research	R01A1127799	93.855	405,226	709,565
Allergy and Infectious Diseases Research	R01A1128799	93.855	—	131,012
Allergy and Infectious Diseases Research	R01A1128837	93.855	54,650	748,426
Allergy and Infectious Diseases Research	R01A1129862	93.855	120,417	373,985
Allergy and Infectious Diseases Research	R01A1130163	93.855	973,178	1,438,707
Allergy and Infectious Diseases Research	R01A1132766	93.855	28,983	893,997
Allergy and Infectious Diseases Research	R01A1132833	93.855	168,519	446,149
Allergy and Infectious Diseases Research	R01A1133706	93.855	—	490,169
Allergy and Infectious Diseases Research	R01A1134244	93.855	—	356,384
Allergy and Infectious Diseases Research	R01A1135806	93.855	26,563	498,390
Allergy and Infectious Diseases Research	R01A1136533	93.855	117,763	345,042
Allergy and Infectious Diseases Research	R01A1136581	93.855	—	355,272
Allergy and Infectious Diseases Research	R01A1137127	93.855	—	184,481
Allergy and Infectious Diseases Research	R01A1138646	93.855	399,126	716,203
Allergy and Infectious Diseases Research	R01A1138783	93.855	386,337	720,128
Allergy and Infectious Diseases Research	R01A1139406	93.855	216,391	620,707
Allergy and Infectious Diseases Research	R01A1139761	93.855	274,846	581,393

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2022

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Allergy and Infectious Diseases Research	R01AI141327	93.855	\$ 52,644	385,767
Allergy and Infectious Diseases Research	R01AI141833	93.855	—	440,449
Allergy and Infectious Diseases Research	R01AI143414	93.855	—	204,557
Allergy and Infectious Diseases Research	R01AI143875	93.855	84,407	366,783
Allergy and Infectious Diseases Research	R01AI144067	93.855	—	518,207
Allergy and Infectious Diseases Research	R01AI145231	93.855	—	586,733
Allergy and Infectious Diseases Research	R01AI145640	93.855	58,153	1,206,687
Allergy and Infectious Diseases Research	R01AI146017	93.855	142,303	438,273
Allergy and Infectious Diseases Research	R01AI146260	93.855	—	209,224
Allergy and Infectious Diseases Research	R01AI147609	93.855	61,790	348,292
Allergy and Infectious Diseases Research	R01AI148377	93.855	—	1,245,950
Allergy and Infectious Diseases Research	R01AI148382	93.855	616,419	1,303,799
Allergy and Infectious Diseases Research	R01AI148471	93.855	56,017	488,678
Allergy and Infectious Diseases Research	R01AI148661	93.855	79,670	640,831
Allergy and Infectious Diseases Research	R01AI149297	93.855	78,177	556,836
Allergy and Infectious Diseases Research	R01AI149466	93.855	—	805,385
Allergy and Infectious Diseases Research	R01AI149527	93.855	—	117,966
Allergy and Infectious Diseases Research	R01AI149724	93.855	—	400,792
Allergy and Infectious Diseases Research	R01AI150453	93.855	—	521,851
Allergy and Infectious Diseases Research	R01AI150774	93.855	115,000	367,173
Allergy and Infectious Diseases Research	R01AI152516	93.855	—	725,591
Allergy and Infectious Diseases Research	R01AI153071	93.855	—	370,464
Allergy and Infectious Diseases Research	R01AI153102	93.855	—	444,220
Allergy and Infectious Diseases Research	R01AI153152	93.855	143,770	675,655
Allergy and Infectious Diseases Research	R01AI154894	93.855	191,548	622,188
Allergy and Infectious Diseases Research	R01AI155007	93.855	74,899	347,924
Allergy and Infectious Diseases Research	R01AI155023	93.855	161,508	660,570
Allergy and Infectious Diseases Research	R01AI156052	93.855	—	425,723
Allergy and Infectious Diseases Research	R01AI156267	93.855	22,650	861,739
Allergy and Infectious Diseases Research	R01AI162633	93.855	—	334,957
Allergy and Infectious Diseases Research	R01AI164716	93.855	—	24,824
Allergy and Infectious Diseases Research	R01AI165644	93.855	—	114,231
Allergy and Infectious Diseases Research	R01AI166305	93.855	205,980	363,411
Allergy and Infectious Diseases Research	R01AI166988	93.855	—	4,368
Allergy and Infectious Diseases Research	R01AI167356	93.855	—	11,471
Allergy and Infectious Diseases Research	R01AI167724	93.855	—	85,108
Allergy and Infectious Diseases Research	R01AI172740	93.855	—	32,023
Allergy and Infectious Diseases Research	R01AI47839	93.855	121,989	615,949
Allergy and Infectious Diseases Research	R13AI143393	93.855	—	20,002
Allergy and Infectious Diseases Research	R13AI157254	93.855	—	5,000
Allergy and Infectious Diseases Research	R21AI142489	93.855	—	9,738
Allergy and Infectious Diseases Research	R21AI142507	93.855	—	23,516
Allergy and Infectious Diseases Research	R21AI145650	93.855	—	138,621
Allergy and Infectious Diseases Research	R21AI146443	93.855	—	49,049
Allergy and Infectious Diseases Research	R21AI146503	93.855	—	209,099
Allergy and Infectious Diseases Research	R21AI148847	93.855	—	160,579
Allergy and Infectious Diseases Research	R21AI149252	93.855	—	197,620
Allergy and Infectious Diseases Research	R21AI150292	93.855	—	141,123
Allergy and Infectious Diseases Research	R21AI152031	93.855	—	78,624
Allergy and Infectious Diseases Research	R21AI154232	93.855	—	205,907
Allergy and Infectious Diseases Research	R21AI154352	93.855	—	140,609
Allergy and Infectious Diseases Research	R21AI155142	93.855	—	185,052
Allergy and Infectious Diseases Research	R21AI155221	93.855	—	99,112
Allergy and Infectious Diseases Research	R21AI156161	93.855	21,604	94,006
Allergy and Infectious Diseases Research	R21AI156376	93.855	306	138,938
Allergy and Infectious Diseases Research	R21AI157730	93.855	—	276,327
Allergy and Infectious Diseases Research	R21AI157911	93.855	—	218,570
Allergy and Infectious Diseases Research	R21AI159765	93.855	—	105,679
Allergy and Infectious Diseases Research	R21AI161521	93.855	—	13,760
Allergy and Infectious Diseases Research	R21AI163427	93.855	—	248,734
Allergy and Infectious Diseases Research	R21AI164733	93.855	39,487	164,208
Allergy and Infectious Diseases Research	R21AI167032	93.855	—	228,868
Allergy and Infectious Diseases Research	R21AI171501	93.855	—	11,597
Allergy and Infectious Diseases Research	R21AI38079	93.855	77,903	92,870
Allergy and Infectious Diseases Research	R24AI162317	93.855	155,581	648,105
Allergy and Infectious Diseases Research	R37AI066998	93.855	—	409,743
Allergy and Infectious Diseases Research	R37AI076119	93.855	90,076	455,122
Allergy and Infectious Diseases Research	R37AI11278	93.855	181,179	1,651,426
Allergy and Infectious Diseases Research	R37AI141258	93.855	21,259	998,693
Allergy and Infectious Diseases Research	R37AI157862	93.855	—	1,343,379
Allergy and Infectious Diseases Research	R38AI140299	93.855	—	335,463
Allergy and Infectious Diseases Research	R56AI132833	93.855	—	342,858
Allergy and Infectious Diseases Research	R56AI145231	93.855	—	(26)
Allergy and Infectious Diseases Research	R56AI150401	93.855	2,120	37,857
Allergy and Infectious Diseases Research	R56AI154895	93.855	—	369,216
Allergy and Infectious Diseases Research	R56AI165149	93.855	—	351,956
Allergy and Infectious Diseases Research	T32 AI138952	93.855	—	183,989
Allergy and Infectious Diseases Research	T32AI070081	93.855	—	191,563
Allergy and Infectious Diseases Research	T32AI074492	93.855	—	416,143
Allergy and Infectious Diseases Research	T32AI06699	93.855	—	248,023
Allergy and Infectious Diseases Research	T32AI157855	93.855	—	60,518
Allergy and Infectious Diseases Research	U01AI131295	93.855	1,075,311	1,368,674
Allergy and Infectious Diseases Research	U01AI131566	93.855	157,090	269,621
Allergy and Infectious Diseases Research	U01AI138909	93.855	—	901,467
Allergy and Infectious Diseases Research	U01AI141993	93.855	61,320	583,357
Allergy and Infectious Diseases Research	U01AI148069	93.855	469,061	1,329,700
Allergy and Infectious Diseases Research	U01AI150747	93.855	501,250	1,142,171
Allergy and Infectious Diseases Research	U19 AI051731	93.855	—	10,147
Allergy and Infectious Diseases Research	U19AI051731	93.855	1,789,495	2,052,459
Allergy and Infectious Diseases Research	U19AI057266	93.855	1,129,695	2,211,764

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2022

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Allergy and Infectious Diseases Research	U19AI090023	93.855	\$ 2,980,969	3,902,621
Allergy and Infectious Diseases Research	U19AI110483	93.855	2,407,905	3,795,903
Allergy and Infectious Diseases Research	U19AI11121	93.855	755,541	1,571,532
Allergy and Infectious Diseases Research	U19AI117891	93.855	—	(14,386)
Allergy and Infectious Diseases Research	U19AI158080	93.855	385,430	2,271,748
Allergy and Infectious Diseases Research	U19AI159819	93.855	299,862	1,265,476
Allergy and Infectious Diseases Research	U19AI171403	93.855	—	273,548
Allergy and Infectious Diseases Research	U24AI120134	93.855	41,036	812,569
Allergy and Infectious Diseases Research	UH3AI122320	93.855	85,045	1,272,261
Allergy and Infectious Diseases Research	UM1AI069418	93.855	1,097,990	3,194,098
Allergy and Infectious Diseases Research	UM1AI124436	93.855	1,041,372	6,859,855
Allergy and Infectious Diseases Research	UM1AI148576	93.855	8,062	1,149,210
Allergy and Infectious Diseases Research	UM1AI148684	93.855	2,855,378	3,817,328
Allergy and Infectious Diseases Research	UM1AI164562	93.855	1,259,653	5,789,763
Allergy and Infectious Diseases Research	UM1AI169662	93.855	—	56,949
Allergy and Infectious Diseases Research	SR33AI121684-04	93.855	—	114,678
Allergy and Infectious Diseases Research	R01AI064462	93.855	—	220,466
Allergy and Infectious Diseases Research	R01AI148378	93.855	—	1,025,575
Pass-through Albert Einstein College of Medicine	R01HL149921	93.855	—	84,459
Pass-through Benaroya Research Institute at Virginia	UM1AI109565	93.855	—	301,135
Pass-through Beth Israel Deaconess Medical Center	UM1AI124377	93.855	—	184,921
Pass-through Beth Israel Deaconess Medical Center	UM1AI124377	93.855	—	6,502
Pass-through Boston Children's Hospital	U24AI152179	93.855	—	2,108
Pass-through Boston University	R01AI133486	93.855	—	19,605
Pass-through Brigham and Womens Hospital	R01AI138801	93.855	—	63,145
Pass-through Case Western Reserve University	1R37AI141258-01	93.855	—	(258)
Pass-through Case Western Reserve University	AI072219-11	93.855	—	132,428
Pass-through Cincinnati Childrens Hospital	R01AI146276	93.855	—	36,354
Pass-through Cincinnati Childrens Hospital	UM1AI144673	93.855	—	360,965
Pass-through Dana Farber Cancer Institute	R33AI129017	93.855	—	39,890
Pass-through Drexel University	U19AI128910	93.855	—	461,144
Pass-through Duke University	PO1AI131276	93.855	—	(41,946)
Pass-through Duke University	R01AI143457	93.855	—	71,575
Pass-through Duke University	U19AI131471	93.855	—	17,176
Pass-through Duke University	UM1AI104981	93.855	—	17,886
Pass-through Family Health International	PO15004277	93.855	7,268	7,491
Pass-through FHI 360 LLC	HPTN 083-02- PO19002009	93.855	—	40,498
Pass-through FHI 360 LLC	PO17001870	93.855	—	237,637
Pass-through FHI 360 LLC	UM1 AI068619	93.855	—	(273)
Pass-through FHI 360 LLC	UM1AI068619	93.855	234,168	284,486
Pass-through Fred Hutchinson Cancer Center	UM1AI068614	93.855	—	840,353
Pass-through Fred Hutchinson Cancer Center	UM1AI068635	93.855	—	5,131
Pass-through Fred Hutchinson Cancer Center	UM1AI1068635	93.855	—	50,355
Pass-through George Washington University	P30AI117970	93.855	—	6,435
Pass-through Georgia Institute of Technology	R01AI153116	93.855	—	73,065
Pass-through Georgia Institute of Technology	R01AI155007	93.855	—	(2,685)
Pass-through Georgia Institute of Technology	R21AI166639	93.855	—	19,278
Pass-through Georgia Institute of Technology	UH2AI153028	93.855	—	19,431
Pass-through Georgia State University	R01AI071002	93.855	—	104,737
Pass-through Georgia State University	R01AI141222	93.855	—	351,925
Pass-through Georgia State University	R01AI153400	93.855	—	162,340
Pass-through Georgia State University	R01AI154656	93.855	—	71,581
Pass-through Georgia State University	SP00013950-01/AMND 1	93.855	—	3,606
Pass-through Harvard University	PO1AI056299	93.855	—	331,382
Pass-through Harvard University	P30AI060354	93.855	—	4,419
Pass-through Henry M. Jackson Foundation	U19AI144190	93.855	—	78,465
Pass-through Immune Tolerance Network	UM1AI109565	93.855	—	148,347
Pass-through Johns Hopkins University	U01AI069918	93.855	—	123,200
Pass-through Johns Hopkins University	U01AI134591	93.855	—	67,933
Pass-through Johns Hopkins University	U01AI138897	93.855	—	61,525
Pass-through Johns Hopkins University	UH3AI133669	93.855	—	147,071
Pass-through Johns Hopkins University	UM1 AI068632	93.855	—	30,666
Pass-through Johns Hopkins University	UM1AI068632	93.855	—	24,157
Pass-through Johns Hopkins University	UM1AI164566	93.855	—	1,035,713
Pass-through Johns Hopkins University	UM2AI130836	93.855	165,385	212,881
Pass-through La Jolla Institute for Allergy	R37AI125068	93.855	—	429,588
Pass-through La Jolla Institute for Allergy	U19AI142742	93.855	—	(864)
Pass-through La Jolla Institute For Immunology	U19AI142790	93.855	—	155,617
Pass-through Massachusetts General Hospital	R01AI042006	93.855	—	42,818
Pass-through Massachusetts General Hospital	R01AI124718	93.855	—	10,256
Pass-through Mayo Clinic Rochester	R01AI121054	93.855	—	449,907
Pass-through Medical University of South Carolina	U01AI125159	93.855	—	210,069
Pass-through Mount Sinai School of Medicine	PO1AI097092	93.855	—	249,941
Pass-through Mount Sinai School of Medicine	U19AI135972	93.855	—	284,106
Pass-through Northwestern University	R01AI131346	93.855	—	84,983
Pass-through Ohio State University	R01AI127863	93.855	—	92,882
Pass-through Pennsylvania State University	R01AI158706	93.855	—	25,587
Pass-through Population Council	R01AI150360	93.855	—	55,358
Pass-through Regents of the University of California	9862SC Amendment #1	93.855	—	63,624
Pass-through Regents of the University of California	R01AI125842	93.855	—	134,371
Pass-through Regents of the University of California	UM1AI068636	93.855	—	42,691
Pass-through Research Institute at Nationwide Children's Hospital	R01AI096892	93.855	—	99,991
Pass-through Research Institute at Nationwide Children's Hospital	R01AI126890	93.855	—	543,705
Pass-through Research Institute at Nationwide Children's Hospital	R01AI151175	93.855	—	63,890
Pass-through Sanford Burnham Prebys Med Disc Inst	UM1AI164561	93.855	—	233,230
Pass-through Scripps Research Institute	PO1AI157299	93.855	—	245,238
Pass-through Scripps Research Institute	R01AI145629	93.855	—	90,618
Pass-through Scripps Research Institute	UM1 AI144462	93.855	—	695,806
Pass-through Scripps Research Institute	UM1AI144462	93.855	—	2,324,610
Pass-through Scripps Research Institute	UM1AI164561	93.855	—	289,584

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2022

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through Seattle Childrens Hospital	R01A1165351	93.855	\$ —	3,533
Pass-through Seattle Children's Research Institute	125573UB	93.855	—	28,258
Pass-through Seattle Children's Research Institute	R01A1134419	93.855	—	151,640
Pass-through St Jude Childrens Research Hospital	R56A1114442	93.855	—	19,145
Pass-through St Jude Childrens Research Hospital	U01A1144616	93.855	—	244,613
Pass-through Stanford University	U19A1159840	93.855	—	225,563
Pass-through Temple University	R01A1143653	93.855	—	19,184
Pass-through Texas Biomedical Research Institute	R01A1111943	93.855	—	(192)
Pass-through Texas Biomedical Research Institute	R01A1123047	93.855	—	281,457
Pass-through Tufts University	R01A1137424	93.855	—	179,440
Pass-through University of Alabama Birmingham	R01A1153365	93.855	—	36,625
Pass-through University of Alabama Birmingham	U19A1142737	93.855	—	28,499
Pass-through University of Alabama Birmingham	U19A1142759	93.855	—	357,125
Pass-through University of Alabama Birmingham	U54A1150225	93.855	—	9,627
Pass-through University of Calgary	R01A1165327	93.855	—	6,803
Pass-through University of California Berkeley	R01A1148127	93.855	—	11,803
Pass-through University of California Berkeley	U01A1151788	93.855	—	42,484
Pass-through University of California Los Angeles	UM1A1068636	93.855	—	194,446
Pass-through University of California Los Angeles	UM1A1106701	93.855	—	95,610
Pass-through University of California San Francisco	R01A1143464	93.855	—	(3,872)
Pass-through University of California San Francisco	R01A1151075	93.855	—	367,081
Pass-through University of California San Francisco	R01A1152161	93.855	—	218,264
Pass-through University of California San Francisco	U01A1131296	93.855	—	145,806
Pass-through University of California San Francisco	U011118594	93.855	—	56,425
Pass-through University of Georgia	1R01A114866701A1	93.855	—	32,176
Pass-through University of Georgia	R01A1125738	93.855	—	14,960
Pass-through University of Georgia	R21A1154343	93.855	—	68,436
Pass-through University of Houston	R01A1125362	93.855	—	46,854
Pass-through University of Kentucky	R01A1141899	93.855	—	96,124
Pass-through University of Louisiana at Lafayette	R01A1139288	93.855	—	109,091
Pass-through University of Louisiana at Lafayette	U19A1142636	93.855	—	295
Pass-through University of Maryland, Baltimore	P01A1124912	93.855	—	76,178
Pass-through University of Maryland, Baltimore	R01A1138797	93.855	—	1,183,519
Pass-through University of Miami	P01A1094420	93.855	—	(1,411)
Pass-through University of Minnesota	U01A1132904	93.855	—	26,722
Pass-through University of Nevada	R01A1122266	93.855	—	1,146
Pass-through University of North Carolina	K23A1159073	93.855	—	916
Pass-through University of North Carolina	UM1A1126619	93.855	—	(16,618)
Pass-through University of North Carolina Chapel Hill	R01A1136990	93.855	—	(140,759)
Pass-through University of North Carolina Chapel Hill	R01A1153007	93.855	—	69,828
Pass-through University of North Carolina Chapel Hill	UAI100625C	93.855	—	27,361
Pass-through University of North Carolina Chapel Hill	UM1A1154567	93.855	—	1,240,343
Pass-through University of Pennsylvania	P01A1131338	93.855	—	483,604
Pass-through University of Pennsylvania	R01A1139188	93.855	—	147,663
Pass-through University of Pennsylvania	R01A1147487	93.855	—	14,816
Pass-through University of Pennsylvania	U19A1131130	93.855	—	121,892
Pass-through University of South Florida	R01A1153830	93.855	—	21,671
Pass-through University of Texas Medical Branch	R01A1143653	93.855	—	32,648
Pass-through University of Texas Southwestern	R01A1141101	93.855	—	105,755
Pass-through University of Utah	R01A1147641	93.855	—	32,958
Pass-through University of Virginia	R01A1154242	93.855	—	15,019
Pass-through University of Washington	R01A1137679	93.855	—	92,255
Pass-through University of Washington	R01A1142647	93.855	—	606,751
Pass-through University of Washington	R61A1149665	93.855	—	3,449
Pass-through University of Wisconsin-Madison	R01A1148707	93.855	—	104,941
Pass-through Vanderbilt University	U19A1095227	93.855	—	(6,489)
Pass-through Vanderbilt University Medical Center	P30A1110527	93.855	—	10,083
Pass-through Vanderbilt University Medical Center	U19A1095227	93.855	—	24,515
Pass-through Washington State University	U01A1151799	93.855	—	161,270
Pass-through Washington University	R56A1147623	93.855	—	154,472
Pass-through Wayne State University	R21A1140033	93.855	—	70,332
Pass-through Weill Cornell Medical College	P01A1131276	93.855	—	761,138
Pass-through Wistar Institute	U19A1109646	93.855	—	83,014
Pass-through Yale University	R01A1112970	93.855	—	33,834
Pass-through Yale University	R01A1161399	93.855	—	23,791
Total AL No. 93.855			41,586,117	156,296,686
Microbiology and Infectious Diseases Research	R01GM099142	93.856	—	386,628
Total AL No. 93.856			—	386,628
Biomedical Research and Research Training	2R01GM100151-05	93.859	—	132
Biomedical Research and Research Training	5R35GM122549	93.859	—	477,166
Biomedical Research and Research Training	F31GM134649	93.859	—	44,129
Biomedical Research and Research Training	F31GM143891	93.859	—	45,734
Biomedical Research and Research Training	F32GM1140778	93.859	—	10,476
Biomedical Research and Research Training	K12GM000680	93.859	26,907	903,560
Biomedical Research and Research Training	K23GM137182	93.859	—	129,289
Biomedical Research and Research Training	K23GM144867	93.859	—	128,270
Biomedical Research and Research Training	K99GM143517	93.859	—	13,156
Biomedical Research and Research Training	R00GM129460	93.859	—	317,576
Biomedical Research and Research Training	R01GM035463	93.859	—	(50)
Biomedical Research and Research Training	R01GM051173	93.859	—	4,753
Biomedical Research and Research Training	R01GM053640	93.859	—	358,504
Biomedical Research and Research Training	R01GM083889	93.859	—	216,411
Biomedical Research and Research Training	R01GM084070	93.859	—	210,073
Biomedical Research and Research Training	R01GM093278	93.859	29,988	276,921
Biomedical Research and Research Training	R01GM104323	93.859	—	236,422
Biomedical Research and Research Training	R01GM113243	93.859	122,016	238,128
Biomedical Research and Research Training	R01GM116065	93.859	—	126,635
Biomedical Research and Research Training	R01GM116991	93.859	—	43,510
Biomedical Research and Research Training	R01GM121967	93.859	—	105,700
Biomedical Research and Research Training	R01GM122083	93.859	88,628	212,729
Biomedical Research and Research Training	R01GM123136-	93.859	107,172	202,384
Biomedical Research and Research Training	R01GM124061	93.859	—	(112)

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2022

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Biomedical Research and Research Training	R01GM124280	93.859	\$ 150,473	507,902
Biomedical Research and Research Training	R01GM124472	93.859	—	3,471
Biomedical Research and Research Training	R01GM129495	93.859	—	202,931
Biomedical Research and Research Training	R01GM131099	93.859	—	340,857
Biomedical Research and Research Training	R01GM132598	93.859	—	246,035
Biomedical Research and Research Training	R01GM136880	93.859	—	319,367
Biomedical Research and Research Training	R01GM137011	93.859	—	213,499
Biomedical Research and Research Training	R01GM138544	93.859	—	451,436
Biomedical Research and Research Training	R01GM139967	93.859	74,347	336,963
Biomedical Research and Research Training	R01GM140632	93.859	219,513	454,784
Biomedical Research and Research Training	R01GM140657	93.859	—	290,524
Biomedical Research and Research Training	R01GM142113	93.859	—	222,722
Biomedical Research and Research Training	R01GM144729	93.859	—	160,286
Biomedical Research and Research Training	R21GM127971	93.859	—	38,298
Biomedical Research and Research Training	R35GM119426	93.859	—	531,683
Biomedical Research and Research Training	R35GM122568	93.859	—	449,505
Biomedical Research and Research Training	R35GM122591	93.859	—	282,830
Biomedical Research and Research Training	R35GM133509	93.859	—	452,462
Biomedical Research and Research Training	R35GM136407	93.859	—	269,857
Biomedical Research and Research Training	R35GM138123	93.859	—	322,522
Biomedical Research and Research Training	R35GM138313	93.859	24,766	440,775
Biomedical Research and Research Training	R35GM142503	93.859	—	368,292
Biomedical Research and Research Training	R35GM142724	93.859	—	288,988
Biomedical Research and Research Training	R35GM143050	93.859	—	377,080
Biomedical Research and Research Training	R35GM147558	93.859	—	2,213
Biomedical Research and Research Training	T32GM008169	93.859	—	1,157,490
Biomedical Research and Research Training	T32GM008602	93.859	—	264,515
Biomedical Research and Research Training	T32GM142617	93.859	—	7,475
Biomedical Research and Research Training	K23GM128221	93.859	—	203,391
Biomedical Research and Research Training	R01GM072808	93.859	—	132,668
Biomedical Research and Research Training	R01GM130950	93.859	—	519,058
Biomedical Research and Research Training	R01GM141074	93.859	—	162,721
Biomedical Research and Research Training	R01GM141392	93.859	58,941	206,849
Biomedical Research and Research Training	R21GM134664	93.859	100,523	105,762
Biomedical Research and Research Training	R25GM125598	93.859	—	512,842
Biomedical Research and Research Training	R35GM133719	93.859	—	612,721
Biomedical Research and Research Training	R35GM139408	93.859	—	300,572
Biomedical Research and Research Training	T32GM008490	93.859	—	483,657
Biomedical Research and Research Training	T32GM095442	93.859	—	310,048
Biomedical Research and Research Training	T32GM135060	93.859	—	376,065
Biomedical Research and Research Training	R01GM134245	93.859	—	335,670
Pass-through George Mason University	R01GM140476	93.859	—	2,110
Pass-through Georgia Institute of Technology	R01A1148740	93.859	—	136,019
Pass-through North Carolina State University	R25GM130528	93.859	—	12,816
Pass-through Ohio State University	R01GM30135	93.859	—	65,533
Pass-through Pennsylvania State University	R01GM121650	93.859	—	36,591
Pass-through Seattle Children's Research Institute	U54AI150472	93.859	—	544,807
Pass-through Univ of Texas Health Sciences Ctr	R01GM130147	93.859	—	150,152
Pass-through University of Michigan	R01GM124061	93.859	—	27,237
Pass-through University of Wisconsin-Madison	R01GM127687	93.859	—	30,857
Total AL No. 93.859			1,003,274	18,574,404
Emerging Infectious Sentinel Networks				
Pass-through International Society of Travel Medicine	1U01CK000632-01-00	93.860	—	25
Total AL No. 93.860			—	25
Child Health and Human Development Extramural Research	5K25HD086276-03	93.865	—	(106)
Child Health and Human Development Extramural Research	5R01HD075784-05	93.865	6,975	1,107
Child Health and Human Development Extramural Research	F31HD096815	93.865	—	29,937
Child Health and Human Development Extramural Research	F31HD098816	93.865	—	21,893
Child Health and Human Development Extramural Research	F31HD100145	93.865	—	44,964
Child Health and Human Development Extramural Research	F31HD100265	93.865	—	20,728
Child Health and Human Development Extramural Research	F31HD105452	93.865	—	43,286
Child Health and Human Development Extramural Research	F31HD107968	93.865	—	6,588
Child Health and Human Development Extramural Research	F32HD096816	93.865	—	35,258
Child Health and Human Development Extramural Research	F32HD097920	93.865	—	9,068
Child Health and Human Development Extramural Research	F32HD100176	93.865	—	55,492
Child Health and Human Development Extramural Research	K01HD100588	93.865	—	130,498
Child Health and Human Development Extramural Research	K12HD072245	93.865	—	396,789
Child Health and Human Development Extramural Research	K12HD085850	93.865	—	440,585
Child Health and Human Development Extramural Research	K99HD104991	93.865	—	87,138
Child Health and Human Development Extramural Research	P50HD104458	93.865	627,237	1,450,960
Child Health and Human Development Extramural Research	R00HD092625	93.865	—	142,682
Child Health and Human Development Extramural Research	R00HD093858	93.865	—	267,169
Child Health and Human Development Extramural Research	R00HD096322	93.865	—	81,332
Child Health and Human Development Extramural Research	R00HD097290	93.865	—	237,322
Child Health and Human Development Extramural Research	R01HD046922	93.865	—	534,874
Child Health and Human Development Extramural Research	R01HD081120	93.865	138,841	478,884
Child Health and Human Development Extramural Research	R01HD082373	93.865	—	312,639
Child Health and Human Development Extramural Research	R01HD090642	93.865	245,207	488,979
Child Health and Human Development Extramural Research	R01HD090925	93.865	—	408,951
Child Health and Human Development Extramural Research	R01HD092033	93.865	—	148,779
Child Health and Human Development Extramural Research	R01HD092580	93.865	327,619	481,502
Child Health and Human Development Extramural Research	R01HD092595	93.865	393,442	541,195
Child Health and Human Development Extramural Research	R01HD093602	93.865	36,016	158,698
Child Health and Human Development Extramural Research	R01HD093706	93.865	75,330	453,469
Child Health and Human Development Extramural Research	R01HD094716	93.865	—	384,295
Child Health and Human Development Extramural Research	R01HD095741	93.865	58,272	822,785
Child Health and Human Development Extramural Research	R01HD097175	93.865	289,855	439,322
Child Health and Human Development Extramural Research	R01HD099224	93.865	—	275,196
Child Health and Human Development Extramural Research	R01HD099480	93.865	241,837	551,410
Child Health and Human Development Extramural Research	R01HD101600	93.865	320,555	597,914

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2022

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Child Health and Human Development Extramural Research	R01HD102534	93.865	\$ 262,048	572,619
Child Health and Human Development Extramural Research	R03HD102513	93.865	—	46,710
Child Health and Human Development Extramural Research	R21HD100820	93.865	—	139,573
Child Health and Human Development Extramural Research	R21HD103030	93.865	—	149,300
Child Health and Human Development Extramural Research	R25HD079102	93.865	—	13,143
Child Health and Human Development Extramural Research	T32HD071845	93.865	—	189,373
Child Health and Human Development Extramural Research	UG1HD027851	93.865	—	197,462
Child Health and Human Development Extramural Research	F31HD106748	93.865	—	15,035
Child Health and Human Development Extramural Research	R01HD095975	93.865	—	654,600
Child Health and Human Development Extramural Research	R33HD099745	93.865	135,052	294,999
Child Health and Human Development Extramural Research	R21HD097491	93.865	26,743	116,234
Pass-through Baylor College of Medicine	P5DH104463	93.865	—	664,332
Pass-through Bradley Hospital	7127549	93.865	—	31,875
Pass-through Case Western Reserve University	R01HD092351	93.865	—	84,032
Pass-through Childrens Hospital of Los Angeles	R21HD107963	93.865	—	19,854
Pass-through Children's Hospital of Philadelphia	R01HD101528	93.865	—	51,599
Pass-through Cincinnati Childrens Hospital	PL1HD101059	93.865	—	17,733
Pass-through City University of New York	R01HD102429	93.865	—	158,841
Pass-through Global Health Uganda Ltd	R01HD096559	93.865	—	10,608
Pass-through Harvard University	P01HD103133	93.865	—	14,218
Pass-through Harvard University	R01HD102342	93.865	—	30,857
Pass-through Michigan State University	R01HD096033	93.865	—	16,405
Pass-through Morehouse School of Medicine	R01HD097843	93.865	—	44,739
Pass-through Mount Sinai School of Medicine	R01HD099231	93.865	—	378,559
Pass-through Northwestern University	5K12HD073945-08	93.865	—	(272)
Pass-through Northwestern University	R01HD099344	93.865	—	14,124
Pass-through Ohio State University	R01HD091274	93.865	—	60,381
Pass-through Phoenix Children's Hospital	R01HD088528	93.865	—	72,342
Pass-through Research Institute at Nationwide Children's Hospital	R01HD091347	93.865	—	13,739
Pass-through Rutgers The State University	R21HD104558	93.865	—	26,058
Pass-through Seattle Children's Research Institute	R01HD086978	93.865	9,143	63,806
Pass-through Shepherd Center	F31HD101151	93.865	—	34,900
Pass-through University of California San Francisco	R61HD105618	93.865	—	16,298
Pass-through University of Connecticut	R01HD106617	93.865	—	15,602
Pass-through University of Georgia	R01HD090126	93.865	6,552	13,667
Pass-through University of Miami	R01HD101352	93.865	—	503,133
Pass-through University of Minnesota	R01HD103634	93.865	—	12,920
Pass-through University of North Carolina	U19HD89881	93.865	—	1,106,970
Pass-through University of North Carolina Chapel Hill	R01HD094009	93.865	—	60,325
Pass-through University of North Carolina Chapel Hill	U19HD089881	93.865	—	455,702
Pass-through University of North Carolina Chapel Hill	U24HD089880	93.865	—	453,382
Pass-through University of Pennsylvania	U24HD089880	93.865	—	21,014
Pass-through University of Pittsburgh	R01HD102313	93.865	—	95,184
Pass-through University of Washington	R01HD089831	93.865	—	101,918
Pass-through University of Washington	R21HD102825	93.865	—	5,303
Pass-through Wayne State University	R01HD099178	93.865	—	91,499
Pass-through Women & Infants Hospital of Rhode Island	R01HD084515	93.865	—	127,611
Total AL No. 93.865			3,200,724	17,859,888
Aging Research	P30AG064200	93.866	137,323	803,123
Aging Research	R01AG070704	93.866	18,490	841,342
Aging Research	R21AG065977	93.866	—	112,999
Aging Research	1RF1AG060285-01A1 REVISED	93.866	56,934	655,045
Aging Research	3U01AG052460-03S1	93.866	—	307,065
Aging Research	F31AG067623	93.866	—	45,386
Aging Research	F31AG069502	93.866	—	46,218
Aging Research	F31AG071319	93.866	—	43,512
Aging Research	F31AG072907	93.866	—	44,109
Aging Research	F31AG074665	93.866	—	45,166
Aging Research	F32AG064862	93.866	—	37,010
Aging Research	K08AG068604	93.866	—	139,172
Aging Research	K23AG065452	93.866	—	171,437
Aging Research	K23AG065505	93.866	—	124,614
Aging Research	K23AG066931	93.866	—	124,108
Aging Research	K23AG070378	93.866	—	178,620
Aging Research	K23AG073516	93.866	—	128,082
Aging Research	K24AG062786	93.866	—	104,914
Aging Research	P30AG066511	93.866	—	2,618,454
Aging Research	P50AG025688	93.866	—	226
Aging Research	R01AG049752	93.866	—	500,155
Aging Research	R01AG054046	93.866	—	(103,254)
Aging Research	R01AG054991	93.866	—	(46,389)
Aging Research	R01AG055634	93.866	—	290,012
Aging Research	R01AG056533	93.866	118,284	644,576
Aging Research	R01AG057714	93.866	53,526	430,657
Aging Research	R01AG058704	93.866	206,722	429,580
Aging Research	R01AG061175	93.866	—	459,915
Aging Research	R01AG061179	93.866	7,781	333,052
Aging Research	R01AG061971	93.866	116,102	412,290
Aging Research	R01AG062577	93.866	12,577	538,720
Aging Research	R01AG062581	93.866	—	678,216
Aging Research	R01AG062691	93.866	—	630,007
Aging Research	R01AG064464	93.866	—	345,888
Aging Research	R01AG065177	93.866	—	464,866
Aging Research	R01AG065611	93.866	244,196	812,842
Aging Research	R01AG066203	93.866	107,528	531,409
Aging Research	R01AG066956	93.866	80,456	400,576
Aging Research	R01AG067736	93.866	—	406,056
Aging Research	R01AG068247	93.866	—	449,634
Aging Research	R01AG070060	93.866	—	421,757
Aging Research	R01AG070861	93.866	—	63,616

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2022

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Aging Research	R01AG070937	93.866	\$ —	4,366,570
Aging Research	R01AG071174	93.866	—	(42)
Aging Research	R01AG072120	93.866	—	71,800
Aging Research	R01AG072603	93.866	—	120,094
Aging Research	R01AG072756	93.866	—	16,481
Aging Research	R01AG074019	93.866	—	31,282
Aging Research	R01AG074357	93.866	103,061	628,833
Aging Research	R01AG075444	93.866	—	49,693
Aging Research	R01AG075820	93.866	67,925	601,469
Aging Research	R01AG075827	93.866	—	83,194
Aging Research	R03AG066559	93.866	—	37,106
Aging Research	R03AG067207	93.866	—	73,029
Aging Research	R13AG047064	93.866	—	22,546
Aging Research	R21AG062386	93.866	—	116,253
Aging Research	R21AG064405	93.866	—	94,001
Aging Research	R21AG065815	93.866	48,108	121,107
Aging Research	R21AG067473	93.866	—	168,476
Aging Research	R21AG072142	93.866	—	153,255
Aging Research	R21AG072767	93.866	—	100,509
Aging Research	R21AG074218	93.866	—	18,904
Aging Research	R24AG066599	93.866	74,955	295,071
Aging Research	R34AG058835	93.866	102,093	136,680
Aging Research	R36AG075455	93.866	—	7,115
Aging Research	R56AG059714	93.866	147,836	423,440
Aging Research	R56AG062633	93.866	99,076	108,246
Aging Research	R56AG070861	93.866	—	82,643
Aging Research	R56AG072473	93.866	—	284,351
Aging Research	RF1AG051633	93.866	—	953
Aging Research	RF1AG057470	93.866	—	6
Aging Research	RF1AG057965	93.866	146,936	1,489,899
Aging Research	RF1AG065282	93.866	84,402	267,840
Aging Research	RF1AG069114	93.866	43,232	507,579
Aging Research	RF1AG069253	93.866	—	288,792
Aging Research	RF1AG071170	93.866	—	519,612
Aging Research	RF1AG071587	93.866	—	529,535
Aging Research	RF1AG079199	93.866	—	9,079
Aging Research	U01AG061357	93.866	275,571	1,402,064
Aging Research	U54AG062334	93.866	(3,140)	1,551,742
Aging Research	U54AG065187	93.866	7,062,483	10,196,271
Pass-through Baylor College of Medicine	R01AG057339	93.866	—	118,406
Pass-through Baylor College of Medicine	R01AG53960	93.866	—	8,000
Pass-through Beth Israel Deaconess Medical Center	1RF2AG062161-01	93.866	—	328,037
Pass-through Beth Israel Deaconess Medical Center	R01AG068141	93.866	—	47,139
Pass-through Brown University	U54AG063546	93.866	—	46,809
Pass-through Columbia University	R01AG062624	93.866	—	9,939
Pass-through Columbia University	U01AG061356	93.866	—	53,296
Pass-through Duke University	R01AG057235	93.866	—	32,075
Pass-through Georgia Institute of Technology	R01AG072309	93.866	—	19,185
Pass-through Georgia Institute of Technology	R21AG061687	93.866	—	150
Pass-through Georgia Institute of Technology	R21AG064309	93.866	—	(787)
Pass-through Georgia State University	R01AG062310	93.866	—	67,711
Pass-through Georgia State University	SP00013539-01.R56AG0	93.866	—	(618)
Pass-through Harvard University	R21AG073744	93.866	—	58,887
Pass-through Indiana University	U54AG054345	93.866	—	280,269
Pass-through Jackson Laboratory	R01AG075818	93.866	—	62,780
Pass-through M D Anderson Cancer Center	R01AG068719	93.866	—	104,600
Pass-through M D Anderson Cancer Center	R01AG071174	93.866	—	38,737
Pass-through Northwestern University	U19AG073153	93.866	—	8,829
Pass-through Northwestern University	U2CAG057441	93.866	—	27,190
Pass-through Northwestern University	U2CAG060426	93.866	—	17,729
Pass-through Ohio State University	R21AG068831	93.866	—	13,572
Pass-through Oregon Health and Science University	R01AG067546	93.866	—	32,161
Pass-through Rush University Medical Center	R01AG015819	93.866	—	48,092
Pass-through Univ of Texas Health Sciences Ctr	R01AG059993	93.866	—	13,259
Pass-through University of Alabama Birmingham	R01AG061800	93.866	—	353,100
Pass-through University of Arizona	U19AG065169	93.866	—	125,253
Pass-through University of California San Diego	R01AG062387	93.866	—	334,967
Pass-through University of Connecticut	U54AG063546	93.866	—	61,561
Pass-through University of Florida	R01AG064796	93.866	—	264,405
Pass-through University of Florida	RF1AG057247	93.866	—	69,233
Pass-through University of Florida	SUB00002834	93.866	—	83,704
Pass-through University of Louisville	RAG070659A	93.866	—	48,027
Pass-through University of Nebraska Medical Center	R01AG069609	93.866	—	21,521
Pass-through University of New Mexico	R01AG049395	93.866	—	31,829
Pass-through University of North Carolina Greensboro	R01AG058919	93.866	—	41,681
Pass-through University of Pittsburgh	R21AG060732	93.866	—	16,700
Pass-through University of Pittsburgh	R21AG074094	93.866	—	38,823
Pass-through University of Rochester	R21AG066970	93.866	—	29,930
Pass-through University of Southern California	R01AG053798	93.866	—	5,133
Pass-through University of Southern California	R21AG071790	93.866	—	25,252
Pass-through University of Southern California	U19AG024904	93.866	—	8,037
Pass-through University of Southern California	U24AG057437	93.866	—	93,794
Pass-through University of Washington	U01AG016976	93.866	—	68,004
Pass-through University of Washington	U24AG072122	93.866	—	26,780
Pass-through University of Washington Saint Louis	U19AG032438	93.866	—	39,133
Pass-through University of Wisconsin-Madison	R01AG058680	93.866	—	16,272
Pass-through University of Wisconsin-Madison	R01AG070883	93.866	—	136,232
Pass-through Vanderbilt University	R01AG068606	93.866	—	7,062
Pass-through Vanderbilt University	R01AG069900	93.866	—	356,072
Pass-through Washington University	R01AG067505	93.866	—	123,950
Pass-through Washington University	U19AG032438	93.866	—	109,435
Pass-through Washington University	U19AG071754	93.866	—	2,542
Pass-through Yale University	R33AG058926	93.866	—	189,481
Total AL No. 93.866			9,412,457	44,803,481

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2022

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Vision Research	F31EY033691	93.867	\$ —	18,252
Vision Research	K23EY030158	93.867	—	(556)
Vision Research	P30EY006360	93.867	—	566,827
Vision Research	R01EY014852	93.867	—	154,685
Vision Research	R01EY021592	93.867	—	438,832
Vision Research	R01EY027711	93.867	—	11,195
Vision Research	R01EY028450	93.867	50,902	464,968
Vision Research	R01EY028859	93.867	62,852	219,380
Vision Research	R01EY029594	93.867	—	(251)
Vision Research	R01EY029724	93.867	—	441,516
Vision Research	R01EY030871	93.867	—	22,265
Vision Research	R01EY031042	93.867	—	360,140
Vision Research	R21EY028320	93.867	—	96,867
Vision Research	T32EY007092	93.867	133,407	247,565
Pass-through Georgia Institute of Technology	R01EY016435	93.867	—	40,437
Pass-through Jaeb Center For Health Research	UG1EY011751	93.867	—	15,349
Pass-through Johns Hopkins University	U10EY024527	93.867	—	(26,985)
Pass-through Johns Hopkins University	UG1EY028091	93.867	—	35,135
Pass-through Morehouse School of Medicine	R01EY026291	93.867	—	14,522
Pass-through New England College of Optometry	R01EY025307	93.867	—	34,467
Pass-through University of Alabama Birmingham	R01EY028578	93.867	—	32,242
Pass-through University of California San Francisco	R01EY023939	93.867	—	15,644
Pass-through University of Nebraska Medical Center	R01EY029594	93.867	—	135,796
Pass-through University of North Texas	R01EY030967	93.867	—	31,640
Total AL No. 93.867			247,161	3,369,932
Medical Library Assistance	G13LM013010	93.879	—	50,259
Medical Library Assistance	K01LM012924	93.879	—	40,989
Medical Library Assistance	R01LM013049	93.879	158,309	241,574
Medical Library Assistance	R01LM013323	93.879	—	216,051
Total AL No. 93.879			158,309	548,873
Cancer Prevention and Control Programs for State, Territorial, and Tribal Organizations				
Pass-through Georgia Dept of Public Health	NU58DP006352	93.898	—	730,394
Total AL No. 93.898			—	730,394
HIV Demonstration, Research, Public and Professional Education Projects				
U01PS005181	93.941	—	59,166	302,389
Total AL No. 93.941			59,166	302,389
Block Grants for Prevention and Treatment of Substance Abuse				
Pass-through Georgia Department of Behavioral Health	MSACD 44100-906-0000	93.959	—	1,100
Total AL No. 93.959			—	1,100
PPHF Geriatric Education Centers				
Pass-through University Of New Mexico	U1Q33070	93.969	213,598	657,543
Pass-through University Of New Mexico	3RJUK7	93.969	205,789	229,303
Total AL No. 93.969			419,387	886,846
Sexually Transmitted Diseases (STD) Provider Education Grants				
Pass-through University of Washington	NU62PS924588	93.978	—	63,122
Total AL No. 93.978			—	63,122
International Research and Research Training				
International Research and Research Training	5D43TW007124	93.989	21,191	73,713
International Research and Research Training	D43TW007124	93.989	—	115,670
International Research and Research Training	D43TW009127	93.989	(26,566)	197,667
International Research and Research Training	D43TW010934	93.989	28,636	327,297
International Research and Research Training	D43TW011404	93.989	46,741	221,985
International Research and Research Training	D43TW012188	93.989	—	89,148
International Research and Research Training	R01TW010664	93.989	243,799	303,865
International Research and Research Training	UZRTW010114	93.989	25,778	95,162
Pass-through Addis Ababa University	R25TW011214	93.989	—	23,015
Pass-through Aga Khan University	D43TW010905	93.989	—	6,620
Pass-through Aga Khan University	G11TW010936	93.989	—	13,544
Pass-through Natl Ctr for Tuberculosis and Lung Diseases	R21TW011157	93.989	—	38,822
Pass-through University of Virginia	R01TW012183	93.989	—	11,245
Pass-through Vanderbilt University	D43TW009337	93.989	—	1,746
Pass-through Vanderbilt University Medical Center	D43TW009337	93.989	83,305	228,771
Total AL No. 93.989			422,884	1,748,270
Contract	00HCVGDB-2021-58627	93.RD	—	359,307
Contract	00HCVJCG-2018-25346	93.RD	—	98,910
Contract	200-2011-41278	93.RD	—	47,473
Contract	200-2017-95890	93.RD	—	(60)
Contract	75D30118C02645	93.RD	23,185	167,206
Contract	75D30118P01681	93.RD	—	62,592
Contract	75D30119C06635	93.RD	—	100,082
Contract	75D30119C06765	93.RD	—	101,432
Contract	75D30119C06772	93.RD	—	49,234
Contract	75D30119P06734	93.RD	—	115,400
Contract	75D30120C09509	93.RD	131,671	239,889
Contract	75D30120C09611	93.RD	—	51,473
Contract	75D30120P07242	93.RD	—	187,253
Contract	75D30120P08338	93.RD	—	129,734
Contract	75D30121C10084	93.RD	—	302,256
Contract	75D30121D10817	93.RD	—	28,063
Contract	75D30121P11776	93.RD	—	233,103
Contract	75D30122C14631	93.RD	—	7,312
Contract	75D30122P13467	93.RD	—	28,889
Contract	75D30122P13545	93.RD	—	6,618
Contract	HHS258201800013C	93.RD	—	18,357
Contract	HHS0100201900015C	93.RD	20,000	17,995
Contract	DTNH2217D00068	93.RD	97,674	161,801
Contract	ISN 2020	93.RD	—	12,411
Contract	NFC-2020	93.RD	—	5,996
Contract	75N91021P00843	93.RD	—	51,535
Contract	75N91021P00955	93.RD	—	226,955
Contract	HHSN612018000031	93.RD	—	3,008,614
Contract	HHSN612018000031	93.RD	—	91,211

EMORY UNIVERSITY AND ITS SUBSIDIARIES
Supplementary Schedule of Expenditures of Federal Awards
Year ended August 31, 2022

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Contract	HHSN268201700205A	93.RD	\$ —	2,444
Contract	75N94020D00009	93.RD	—	10,237
Contract	HHSN2752015000011	93.RD	—	231,373
Contract	75N93020D00005	93.RD	—	2,663,363
Contract	75N93021C00017	93.RD	214,283	2,846,711
Contract	HHNS272201300006C	93.RD	—	58,343
Contract	HHNS272201300018I	93.RD	901,331	1,757,512
Contract	HHNS272201300018I/HHNSN272	93.RD	—	103,860
Contract	HHNS272201400004C	93.RD	1,417,422	2,852,807
Contract	20FED2000031PSE	93.RD	—	16,528
Pass-through American Assoc. of Colleges of Nursing	6NU36OE000009-05-01	93.RD	—	45,964
Pass-through Ann & Robert H. Lurie Children's Hospital	75D30119C06841	93.RD	—	3,560
Pass-through Cincinnati Childrens Hospital	200-2012-53661	93.RD	—	9,015
Pass-through Georgia Institute of Technology	75D30120C09782	93.RD	—	5,056
Pass-through Georgia Institute of Technology	75F40120C00207	93.RD	—	67,529
Pass-through Hennepin Healthcare Research Institute	75R80220C00011	93.RD	—	8,899
Pass-through Infectious Disease Research Institute	75N93019C00059	93.RD	—	504,299
Pass-through Mayo Clinic	D30119C06088	93.RD	—	398
Pass-through Mount Sinai School of Medicine	75N93019C00046	93.RD	—	276,012
Pass-through Mount Sinai School of Medicine	75N93019C00051	93.RD	—	1,978,478
Pass-through NORC at the University of Chicago	8421.EMORY.01/MOD.0	93.RD	—	6,001
Pass-through NORC at the University of Chicago	HHSD2020213MS4955B	93.RD	—	371,497
Pass-through Rice University	OT2HL154977	93.RD	—	119,927
Pass-through Univ of Arkansas for Medical Services	75N91019D00024	93.RD	—	20,752
Pass-through University of Alabama Birmingham	HHNS272201300012I/75N93019F00131	93.RD	—	32,592
Pass-through University of Chicago	75N92020D00018/75N92020F00001	93.RD	—	150,788
Pass-through University of Florida	PO 1900686132	93.RD	—	43,773
Pass-through University of Georgia	N93019C00052	93.RD	—	49,304
Pass-through University of North Carolina Chapel Hill	2538	93.RD	—	44,466
Pass-through University of Washington	HHNS272201800008C	93.RD	—	86,130
Total AL No. 93.RD			2,805,566	20,078,659
U.S. Department of Health and Human Services Total			100,068,992	557,100,342
U.S. Agency for International Development:				
USAID Foreign Assistance for Programs Overseas	AID114A1700003	98.001	89,565	149,971
Pass-through FHI 360 LLC	7200AA20CA00016	98.001	—	41,478
Pass-through Intl Aids Vaccine Initiative	AID-OAA-A-16-00032	98.001	—	293,934
Pass-through University of Prishtina	2000012308	98.001	—	8,732
Total AL No. 98.001			89,565	494,115
U.S. Agency for International Development Total			89,565	494,115
Total Research and Development Cluster			105,454,465	588,586,824
Student Financial Assistance Cluster (notes 2 through 5):				
U.S. Department of Education:				
Federal Work Study		84.033	—	1,757,559
Federal Supplemental Education Opportunity Grant Program		84.007	—	1,715,044
Federal Pell Grant		84.063	—	8,323,144
Federal Direct Loan Program		84.268	—	91,859,453
Federal Direct PLUS Loan Program		84.268	—	73,990,885
Federal Perkins Loan Program		84.038	—	4,788,817
Total U.S. Department of Education			—	182,434,902
U.S. Department of Health and Human Services:				
Nursing Faculty Loan Program		93.264	—	1,011,781
Health Profession Student Loan Program		93.342	—	3,198,555
Nursing Student Loans		93.364	—	4,549,821
Total U.S. Department of Health and Human Services			—	8,760,157
Total Student Financial Assistance Cluster			—	191,195,059
U.S. Department of Commerce:				
Cluster Grants	ED20HDO0200045	11.020	110,915	115,476
Total AL No. 11.020			110,915	115,476
U.S. Department of Commerce Total			110,915	115,476
U.S. Department Of Defense:				
Contract	N62645-11-C-4008	12.CTR	—	(14,600)
Total AL No. 12.CTR			—	(14,600)
U.S. Department of Defense Total			—	(14,600)
National Endowment for Humanities:				
Promotion of the Arts Grants to Organizations and Individuals	1886761-42-21	45.024	—	13,718
Total AL No. 45.024			—	13,718
Promotion of the Arts Partnership Agreements				
Pass-through Georgia Council for the Arts	FY22 P 16	45.025	—	5,999
Total AL No. 45.025			—	5,999
National Endowment for Humanities Total			—	19,717
U.S. Department of Veterans Affairs:				
Contract	36C24721C0077	64.CTR	—	340,413
Contract	36C24722C0090	64.CTR	—	336,772
Contract	36C24E21D0032	64.CTR	—	5,000
Total AL No. 64.CTR			—	682,185
U.S. Department of Veterans Affairs Total			—	682,185

EMORY UNIVERSITY AND ITS SUBSIDIARIES
Supplementary Schedule of Expenditures of Federal Awards
Year ended August 31, 2022

<u>Program title/federal grantor/pass-through entity</u>	<u>Award number</u>	<u>AL number</u>	<u>Passed through to subrecipients</u>	<u>Federal expenditures</u>
U.S. Department of Education: COVID-19 – Education Stabilization Fund – Higher Education Emergency Relief Fund Student Aid Portion Total AL No. 84.425E		84.425E	\$ —	12,141,474
			—	12,141,474
COVID-19 – Education Stabilization Fund – Higher Education Emergency Relief Fund Institutional Portion Total AL No. 84.425F		84.425F	—	206,527
			—	206,527
Total AL No. 84.425			—	12,348,001
U.S. Department of Education Total			—	12,348,001
U.S. Department of Health and Human Services: National Family Caregiver Support, Title III, Part E Pass-through Atlanta Regional Commission Total AL No. 93.052	2001GAO AFC	93.052	—	13,956
			—	13,956
Global AIDS Total AL No. 93.067	NU2GGH001815	93.067	72,003	74,542
			72,003	74,542
Maternal and Child Health Federal Consolidated Programs Pass-through Hemophilia of Georgia Total AL No. 93.110	UH7MC30772 H3024046	93.110 93.110	95,508 —	670,843 39,668
			95,508	710,511
Emergency Medical Services for Children: Pass-through Rhode Island Hospital Total AL No. 93.127	U03MC33155	93.127	—	288,965
			—	288,965
Community Programs to Improve Minority Health Grant Program Pass-through American College of Rheumatology Total AL No. 93.137	CPIMP201213	93.137	—	1,139
			—	1,139
AIDS Education and Training Centers: Pass-through University of Washington Total AL No. 93.145	6 U1OHA33252-01-01	93.145	—	55,437
			—	55,437
Scaling the National Diabetes Prevention Program to Priority Populations: Pass-through Amer Assoc of Diabetes Educators Pass-through American Diabetes Association Total AL No. 93.261	NU58DP006361 NU58DP006364	93.261 93.261	— —	10,613 176
			—	10,789
Protecting and Improving Health Globally: Building and Strengthening Public Health Impact, Systems, Capacity and Security Total AL No. 93.318	NU14GH001238	93.318	340,320	1,517,695
			340,320	1,517,695
Epidemiology and Laboratory Capacity for Infectious Diseases (ELC): Pass-through Georgia Dept of Public Health Pass-through Public Health Foundation Enterprises Total AL No. 93.323	NU50CK000529 NU50CK000539	93.323 93.323	— —	109,184 80,803
			—	189,987
The Healthy Brain Initiative: Technical Assistance to Implement Public Health Actions related to Cognitive Health, Cognitive Impairment, and Caregiving at the State and Local Levels: Pass-through Alzheimers Association Pass-through Alzheimers Association Total AL No. 93.334	NU58DP006744 NU58DP006912	93.334 93.334	— —	308,007 3,980
			—	311,987
Sickle Cell Treatment Demonstration Program: Pass-through Carolinas Healthcare System Pass-through University of Alabama Birmingham Total AL No. 93.365	U1EMC31108 U1EMCA42461	93.365 93.365	17,027 —	35,501 22,326
			17,027	57,827
National and State Tobacco Control Program: Pass-through Georgia Dept of Public Health Pass-through Kansas Department of Health & Environment Total AL No. 93.387	NU58DP006828-01-00 NU58DP006823	93.387 93.387	— —	42,805 38,512
			—	81,317
COVID-19 – Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health: Pass-through Amer College of Preventive Medicine Pass-through Natl Assoc of Chronic Disease Directors Pass-through Natl Assoc of Chronic Disease Directors Total AL No. 93.421	1 NU50CK000617-01-00 NU38OT000289 6-NU38OT000286-01 NU38OT000286	93.421 93.421 93.421 93.421	— — — —	9,087 89,308 4,976 20,900
			—	124,271
Improving the Health of Americans through Prevention and Management of Diabetes and Heart Disease and Stroke: Pass-through Alabama Department of Public Health Pass-through Georgia Dept of Public Health Pass-through Kentucky Department for Public Health Pass-through Maine Dept of Health And Human Services Pass-through Minnesota Department of Health Pass-through Nebraska Department of Health and Human Pass-through South Dakota Department of Health Pass-through South Dakota Department of Health Pass-through Tennessee Department of Health Total AL No. 93.426	NU58DP006527 NU58DP006463 NU58DP006612 NU58DP006545 NU58DP006522 5 NU58DP006548 23SC09 0802 NU58DP006526 NU58DP006552	93.426 93.426 93.426 93.426 93.426 93.426 93.426 93.426 93.426	— — — — — — — — —	45,000 25,196 38,403 667 5,622 12,000 10,119 294,514 70,881
			—	502,402
Networking2Save*: CDC's National Network Approach to Preventing and Controlling Tobacco-related Cancers in Special Populations Pass-through Patient Advocate Foundation Total AL No. 93.431	NU58DP006468	93.431	—	123,630
			—	123,630
Innovative State and Local Public Health Strategies to prevent and Manage Diabetes and Heart Disease and Stroke: Pass-through Georgia Dept of Public Health Pass-through Kentucky Department for Public Health Pass-through Utah Department of Health Pass-through Wisconsin Department of Health and Family Total AL No. 93.435	NU58DP006623 NU58DP006612 NU58DP006609 NU58DP006607	93.435 93.435 93.435 93.435	— — — —	26,678 117,454 19,019 23,558
			—	186,709
Coalition for a Healthier Community Pass-through Georgia Dept of Public Health Total AL No. 93.453	NU58DP006623	93.453	—	6,621
			—	6,621

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2022

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
COVID-19 – HRSA COVID-19 Claims Reimbursement to the Uninsured Program and the COVID-19 Coverage Assistance Fund		93.461	\$ —	9,866,856
Total AL No. 93.461			—	9,866,856
COVID-19 – Provider Relief Fund and American Rescue Plan Rural Distribution		93.498	—	75,736,689
Total AL No. 93.498			—	75,736,689
Children’s Justice Grants to States:				
Pass-through Georgia Department of Human Services	42700-040-0000098036	93.643	—	48
Pass-through Georgia Department of Human Services	42700-040-0000103366	93.643	—	84,128
Total AL No. 93.643			—	84,176
Emergency Grants to Address Mental and Substance Use Disorders During COVID-19				
Pass-through Georgia Department of Behavioral Health	H79FG000262	93.665	—	2,000
Total AL No. 93.665			—	2,000
PPHF: Racial and Ethnic Approaches to Community Health Program financed solely by Public Prevention and Health Funds Pass-through Georgia Dept of Public Health				
Pass-through Georgia Dept of Public Health	NU58DP006580	93.738	—	52,123
Total AL No. 93.738			—	52,123
Medical Assistance Program:				
Pass-through Georgia Department of Behavioral Health	2205GA5MAP	93.778	—	337,126
Pass-through Georgia Department of Behavioral Health	H79TI081726	93.778	—	48,259
Total AL No. 93.778 (Medicaid Cluster)			—	385,385
Opioid STR				
Pass-through Atlanta Harm Reduction Coalition	H79TI083292	93.788	—	11,142
Total AL No. 93.788			—	11,142
Hospital Preparedness Program (HPP) Ebola Preparedness and Response Activities				
Pass-through Georgia Dept of Public Health	HITEP210054	93.817	—	441,015
Pass-through Georgia Dept of Public Health	40500-033-16161809	93.817	—	(116)
Pass-through Georgia Dept of Public Health	U3REP150546	93.817	—	19,700
Total AL No. 93.817			—	460,599
COVID-19 – National Ebola Training and Education Center				
National Ebola Training and Education Center	NU38CK000481	93.825	—	1,431,635
National Ebola Training and Education Center	NU38CK000481	93.825	—	297,304
Total AL No. 93.825			—	1,728,939
HIV Emergency Relief Project Grants:				
Pass-through Fulton County	2 HA89HA00007-29-00	93.914	—	(1,000)
Pass-through Fulton County	HA89HA00007-32	93.914	—	385,366
Total AL No. 93.914			—	384,366
Grants to Provide Outpatient Early Intervention Services with Respect to HIV Disease				
Grants to Provide Outpatient Early Intervention Services with Respect to HIV Disease	H7607848	93.918	—	385,339
Grants to Provide Outpatient Early Intervention Services with Respect to HIV Disease	H76HA07848	93.918	—	222,401
Pass-through Fulton County	2 HA89HA00007-31-00	93.918	—	523,336
Total AL No. 93.918			—	1,131,076
Assistance Programs for Chronic Disease Prevention and Control:				
Pass-through Natl Assoc of Chronic Disease Directors	NU58DP006979	93.945	—	10,744
Pass-through Ohio Department of Health	NU58DP006544	93.945	—	3,600
Total AL No. 93.945			—	14,344
Block Grants for Prevention and Treatment of Substance Abuse				
Pass-through Georgia Department of Behavioral Health	B08TI083442	93.959	—	261,467
Total AL No. 93.959			—	261,467
Special Minority Initiatives				
Special Minority Initiatives	IDSEP190055	93.960	4,583	4,493
Total AL No. 93.960			4,583	4,493
Contract	75D30120C07672	93.CTR	—	1,161,117
Contract	75D30120P09249	93.CTR	—	3,645
Contract	HHS02002017M95146B	93.CTR	—	16,360
Contract	Task Order 2191618	93.CTR	—	4,999
Contract	TRAINING ORDER	93.CTR	—	6,980
Pass-through Adcare Educational Institute	INTF4000M04502123189	93.CTR	—	(12)
Pass-through Assoc of State & Territorial Denta	ASTDD072215/AMND 6	93.CTR	—	14,498
Pass-through CDC Foundation	NU38OT000288	93.CTR	—	33,747
Pass-through Fdtn for Atlanta Veterans Educ and Res	M21021	93.CTR	—	15,959
Pass-through Georgia Department of Community Health	2017001	93.CTR	—	258,697
Total AL No. 93.CTR			—	1,515,990
U.S. Department of Health and Human Services Total			529,441	95,897,430
Total Expenditures of Federal Awards			\$ 106,094,821	888,830,092

See accompanying notes to Supplementary Schedule of Expenditures of Federal Awards and Schedule of Cash Receipts and Expenditures of State of Georgia Awards.

**SUPPLEMENTARY SCHEDULE OF CASH RECEIPTS AND
EXPENDITURES OF STATE OF GEORGIA AWARDS**

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Supplementary Schedule of Cash Receipts and Expenditures of State of Georgia Awards

Year ended August 31, 2022

State of Georgia contract number	State of Georgia Agency	Program title	Cash receipts	Expenditures
2 HA89HA00007-29-00	FULTON COUNTY	17RW2018A-MH, FY 18 Ryan White Part A	\$ (117,114)	(1,000)
2017001	GEORGIA DEPARTMENT OF COMMUNITY HEALTH	Evaluation Services for the Planning for Healthy Babies Family Planning Waiver Pro	2,125,499	220,745
21RW0119C-MH	FULTON COUNTY	Ryan White HIV/AIDS Treatment Extension Act of 2009	778,211	908,702
40500-032-21213892	GEORGIA DEPT OF PUBLIC HEALTH	BreatheEasy Recognition Program	60,024	42,805
40500-033-21213660	GEORGIA DEPT OF PUBLIC HEALTH	Hospital Preparedness Program (HPP) Ebola Preparedness and Response Activities	149,072	152,874
40500-036-21161799	GEORGIA DEPT OF PUBLIC HEALTH	Operation of the Statewide Georgia Comprehensive Cancer Registry	931,377	31,455
40500-036-22223686	GEORGIA DEPT OF PUBLIC HEALTH	Operation of the Statewide Georgia Comprehensive Cancer Registry	470,200	627,546
40500-036-22223938	GEORGIA DEPT OF PUBLIC HEALTH	GA DPH NWSS Training	32,349	109,184
40500-CVD19-32	GEORGIA DEPT OF PUBLIC HEALTH	Hospital Preparedness Program (HPP) Ebola Preparedness and Response Activities	22,658	19,700
42700-040-0000098036	GEORGIA DEPARTMENT OF HUMAN SERVICES	Summer Child Advocacy Program 2021	64,895	48
42700-040-0000103366	GEORGIA DEPARTMENT OF HUMAN SERVICES	Summer Child Advocacy Program 2021	24,987	84,128
44100-906-0000156193	GEORGIA DEPARTMENT OF BEHAVIORAL HEALTH	2020-2021 Fetal Alcohol and Drug Screening project: MSACD	83,323	70,083
44100-906-0000175615	GEORGIA DEPARTMENT OF BEHAVIORAL HEALTH	2021-2022 Fetal Alcohol and Drug Screening project: MSACD	208,333	191,384
44100-907-0000158746	GEORGIA DEPARTMENT OF BEHAVIORAL HEALTH	2020-2021 Emory Neuro Developmental Exposure Clinic (ENEC)	180,500	(11,511)
46900-620-V21EMU046	GEORGIA DEPARTMENT OF EARLY CARE AND LEARNING	Impact of Socio-emotional learning with Georgia Home Health Visiting Programs	60,181	82,840
5ARC-DHS AG2028.1	ATLANTA REGIONAL COMMISSION	Fuqua Center and Atlanta Regional Commission DHS Consultant Contract	1,292	13,956
GA-2022-F.A.S.T. 405	GOVERNORS OFFICE OF HIGHWAY SAFETY	2022 Statewide Seatbelt Use Survey	39,257	170,814
MSACD 44100-906-0000	GEORGIA DEPARTMENT OF BEHAVIORAL HEALTH	FETAL ALCOHOL AND DRUG SCREENING PROJECT: MATERNAL SUBSTANCE ABUSE	(9,820)	1,100
NU58DP006580	GEORGIA DEPT OF PUBLIC HEALTH	Evaluation of the REACH Grant	77,801	52,123
NU58DP006607	WISCONSIN DEPARTEMN OF HEALTH AND FAMIL	WI DHS DPP Advanced Learning	17,400	5,736
			<u>\$ 5,200,405</u>	<u>2,772,712</u>

See accompanying notes to Supplementary Schedule of Expenditures of Federal Awards and Schedule of Cash Receipts and Expenditures of State of Georgia Awards.

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Notes to Supplementary Schedules of Expenditures of Federal Awards and Cash Receipts and Expenditures of State of Georgia Awards

Year ended August 31, 2022

(1) Summary of Significant Accounting Policies

The accompanying supplementary schedule of expenditures of federal awards (the Schedule) includes the federal grant activity of Emory University and its subsidiaries (the University) and is presented on the accrual basis of accounting. The Schedule presents all grants, contracts, and similar agreements entered into directly between agencies and departments of the federal government and subawards to the University from nonfederal organizations pursuant to federal grants, contracts, and similar agreements. The Schedule also presents awards passed through from the University to other nonfederal subrecipient organizations. The information in the Schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Therefore, some amounts presented in the Schedule may differ from amounts presented in, or used in the preparation of, the consolidated financial statements.

The accompanying supplementary schedule of cash receipts and expenditures of State of Georgia awards includes expenditures incurred by the University and grant revenues received from State of Georgia agencies under various state contracts.

Negative balances represent programs with unfunded expenditures prior to normal closeout procedures, which were subsequently transferred to unrestricted cost centers.

(2) Basis of Accounting

Expenditures for federal student financial assistance programs are recognized as incurred and include grants to students under the Federal Pell Grant and Federal Supplemental Educational Opportunity Grant Programs, student earnings under the Federal Work Study Program, and administrative cost allowances, where applicable. Expenditures for loans related to the Federal Direct Student Loan Programs (FDSLPL) are reported in the Schedule when disbursed.

New loans made during the fiscal year and loans from previous fiscal years for which the University has continuing compliance requirements to adhere to related to the Federal Perkins Loan Program are reported in the Schedule. Expenditures for other federal awards are recognized as incurred using the cost accounting principles contained in Uniform Guidance. Under these cost principles, certain types of expenses are not allowable or are limited as to reimbursement.

COVID-19 Health Resources and Services Administration (HRSA) COVID-19 Claims Reimbursement for the Uninsured Program and the COVID-19 Coverage Assistance Fund (AL # 93.461) includes reimbursements for health care services rendered during the year ended August 31, 2022.

COVID-19 Provider Relief Fund (PRF) and American Rescue Plan (ARP) Rural Distribution (AL # 93.498) includes reimbursements for lost revenues during the period from July 1, 2020 to June 30, 2021, based upon the PRF report that is required to be submitted to the HRSA reporting portal.

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Notes to Supplementary Schedules of Expenditures of Federal Awards and
Cash Receipts and Expenditures of State of Georgia Awards

Year ended August 31, 2022

(3) Federal Loan Programs

Most federal financial assistance is in the form of cash awards. However, there are a number of federal programs that do not involve cash transactions with the University. These noncash transactions in which the University obtains other assistance are the FDSLP and revolving loan programs, such as the Federal Perkins Loan Program.

The loans advanced and related expenditures are as follows for the various student loan programs:

	<u>AL #</u>	<u>Amount</u>
Federal Direct Student Loan Programs:		
Student loans advanced:		
Subsidized Stafford Loan Program	84.268	\$ 6,182,201
Unsubsidized Stafford Loan Program	84.268	<u>85,677,252</u>
Total Direct Stafford Loan Program		91,859,453
Federal Direct PLUS Loan Program	84.268	<u>73,990,885</u>
Total Federal Direct Student Loan Programs		<u>\$ 165,850,338</u>

The Federal Perkins (Perkins) and Nurse Faculty and Student Loan Programs (Nursing) are administered directly by the University, and balances and transactions relating to these programs are included in the University's consolidated financial statements. The amounts presented on the Schedule include the Federal Perkins and Nurse Loans outstanding as of August 31, 2021. Perkins and Nursing loans outstanding at August 31, 2022 totaled \$2,940,607 and \$1,482,916, respectively. No Perkins loans were issued and \$281,477 Nursing loans were issued during the year ended August 31, 2022.

The University is responsible for the performance of certain administrative duties with respect to the FDSLP. It is not practicable to determine the balance of loans outstanding to students and former students of the University under this program as of August 31, 2022. These loans are not included in the University's consolidated financial statements.

(4) Matching

Under the Federal Supplemental Educational Opportunity Grant Program, the University matched \$428,761 in funds awarded to students for the year ended August 31, 2022 in addition to the federal share of expenditures included in the Schedule.

Under the Federal Work Study Program, the University matched \$502,812 in total compensation to students for the year ended August 31, 2022 in addition to the federal share of expenditures included in the Schedule.

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Notes to Supplementary Schedules of Expenditures of Federal Awards and
Cash Receipts and Expenditures of State of Georgia Awards

Year ended August 31, 2022

(5) Administrative Cost Allowance

The University recorded an administrative cost allowance of \$125,703 for the year ended August 31, 2022. This amount is included in the Schedule as federal expenditures under the Federal Work Study Program.

(6) Indirect Costs

For the year ended August 31, 2022, the University did not elect to use the 10% de minimis indirect cost rate permitted by the Uniform Guidance.

UNIFORM GUIDANCE REPORTS



KPMG LLP
Suite 2000
303 Peachtree Street, N.E.
Atlanta, GA 30308-3210

Independent Auditors' Report on Compliance for Each Major Federal Program; Report on Internal Control Over Compliance; and Report on Supplementary Schedules of Expenditures of Federal Awards Required by the Uniform Guidance and Cash Receipts and Expenditures of State of Georgia Awards

The Board of Trustees
Emory University:

Report on Compliance for Each Major Federal Program

Opinion on Each Major Federal Program

We have audited Emory University and its subsidiaries' (the University) compliance with the types of compliance requirements identified as subject to audit in the *OMB Compliance Supplement* that could have a direct and material effect on each of the University's major federal programs for the year ended August 31, 2022. The University's major federal programs are identified in the summary of auditors' results section of the accompanying schedule of findings and questioned costs.

In our opinion, the University complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended August 31, 2022.

Basis for Opinion on Each Major Federal Program

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America (GAAS); the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. Code of Federal Regulations Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Our responsibilities under those standards and the Uniform Guidance are further described in the Auditors' Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of the University and to meet our other ethical responsibilities, in accordance with relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on compliance for each major federal program. Our audit does not provide a legal determination of the University's compliance with the compliance requirements referred to above.

Responsibilities of Management for Compliance

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules and provisions of contracts or grant agreements applicable to the University's federal programs.



Auditors' Responsibilities for the Audit of Compliance

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on the University's compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about the University's compliance with the requirements of each major federal program as a whole.

In performing an audit in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material noncompliance, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the University's compliance with the compliance requirements referred to above and performing such other procedures as we considered necessary in the circumstances.
- Obtain an understanding of the University's internal control over compliance relevant to the audit in order to design audit procedures that are appropriate in the circumstances and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of the University's internal control over compliance. Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.

Report on Internal Control Over Compliance

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A material weakness in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A significant deficiency in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the Auditors' Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance. Given these limitations, during our audit we did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses, as defined above. However, material weaknesses or significant deficiencies in internal control over compliance may exist that were not identified.



Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

Report on Supplementary Schedules of Expenditures of Federal Awards Required by the Uniform Guidance and Cash Receipts and Expenditures of State of Georgia Awards

We have audited the consolidated financial statements of the University as of and for the year ended August 31, 2022, and have issued our report thereon dated December 19, 2022, which contained an unmodified opinion on those consolidated financial statements. Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying supplementary schedules of expenditures of federal awards and cash receipts and expenditures of State of Georgia awards are presented for purposes of additional analysis as required by the Uniform Guidance and the State of Georgia, respectively, and are not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with GAAS. In our opinion, the schedule of expenditures of federal awards and cash receipts and expenditures of State of Georgia awards are fairly stated, in all material respects, in relation to the consolidated financial statements as a whole.

KPMG LLP

Atlanta, Georgia
April 10, 2023

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Schedule of Findings and Questioned Costs

Year ended August 31, 2022

(1) Summary of Auditors' Results

- (a) The type of auditors' report issued on whether the consolidated financial statements were prepared in accordance with U.S. generally accepted accounting principles: **Unmodified**
- (b) Internal control deficiencies over financial reporting disclosed by the audit of the consolidated financial statements:
- Material weaknesses: **No**
 - Significant deficiencies: **None reported**
- (c) Noncompliance material to the consolidated financial statements: **No**
- (d) Internal control deficiencies over major program disclosed by the audit:
- Material weaknesses: **No**
 - Significant deficiencies: **None reported**
- (e) Type of auditors' report issued on compliance for major programs: **Unmodified**
- (f) Any audit findings, which are required to be reported under Section 2 CFR 200.516(a) of Uniform Guidance: **None reported**
- (g) Major programs:
- **Research and Development Cluster** – various AL numbers
 - **COVID-19 – Education Stabilization Fund – Higher Education Emergency Relief Fund (HEERF) Student Aid Portion AL# 84.425E and HEERF Institutional Portion AL# 84.425F**
 - **COVID-19 Provider Relief Fund (PRF) and American Rescue Plan (ARP) Rural Distribution – AL# 93.498**
 - **COVID-19 – HRSA COVID-19 Claims Reimbursement for the Uninsured Program and the COVID-19 Coverage Assistance Fund – AL# 93.461**
- (h) Dollar threshold used to distinguish between Type A and Type B programs: **\$3,000,000**
- (i) Auditee qualified as a low-risk auditee: **Yes**

(2) Findings Relating to the Consolidated Financial Statements Reported in Accordance with *Government Auditing Standards*

None

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Schedule of Findings and Questioned Costs

Year ended August 31, 2022

(3) Findings and Questioned Costs Relating to Federal Awards

None